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1 
Abstract 
 
Stilbene phytoalexins such as resveratrol, 1, and the arachidins, including arachidin-1, 
2, are naturally synthesised by peanut (Arachis hypogaea) plants1, 2. The peanut 
phytoalexins are polyphenolic compounds consisting of a stilbene backbone, with a 
number of derivatives also possessing a prenyl moiety 3. 
 
 
 
These distinctive phytoalexins have gained attention, as they exhibit various 
biological activities, for instance arachidin-1, 2, has been reported to be more potent 
than resveratrol, 1, in the inhibition of lipopolysaccharide-induced expression of 
cyclooxygenase-2 (COX-2) and COX-2 mRNA, in vitro at doses that were low in 
cytotoxicity3-5. Additionally the various arachidins have recently been shown to 
exhibit their anti-inflammatory properties, through the inhibition of a number of 
inflammatory mediator pathways 3.   
In this work, various routes into the synthesis of arachidin-1, 2, are described, via use 
of the Horner-Wadsworth-Emmons (HWE) reaction. Three different methodologies 
were explored, the first approach involving silyl ether (TIPS or TBDMS) protected 
benzaldehydes, proved unsuccessful due to cleavage of the silyl ether protecting 
groups, in basic and/or acidic conditions. This led to an alternative approach, whereby 
formation of the stilbene backbone proceeded via the regioselective demethylation of 
an acetal in the presence of sodium metal, subsequent electrophilic substitution using 
2 
iodomethane and finally acetal hydrolysis of the acetal, gave the isolated aldehyde in 
moderate yield (52 %). Coupling of the aldehyde with the substituted 
benzylphosphonate, via the HWE reaction gave the desired trans-stilbene in good 
yield (86 %), however incorporation of the prenyl side chain proved to be challenging 
via the Wohl-Ziegler bromination.   
Further adaptation of the aforementioned route, whereby alkylation using diethyl 
iodomethylphosphonate, enabled the incorporation of the prenyl moiety and the 
subsequent construction of the trans-stilbene backbone, gave the 4-(3-methyl-but-1-
enyl)-3,5,3’,4’-tetramethoxystilbene, 3, albeit in poor yield (47 %). The final step 
involving demethylation using BBr3 gave arachidin-1, 2, also in poor yield (30 %), 
nevertheless this approach has been proved to be a successful route for the total 
synthesis of arachidin-1, 2, however optimised studies are required in order to obtain 
the desired compound in quantitative yields. 
 
 
 
Synthetic analogues of resveratrol, 1, are also known for their biological activities, 
including anti-inflammatory and chemopreventative properties. Recently, the                    
anti-proliferative activity of a number of stilbenesulfonamides, against the National 
Cancer Institute’s 60 (NCI-60) human tumour cell line has been reported 6.  
Furthermore, the anti-inflammatory effects of novel heterocyclic methylsulfone and 
sulfonamide analogues, via inhibition of the COX-2 protein have also been 
published7, however both synthetic routes described require a total of six or seven 
3 
steps, from the sulfanilamide and are limited to the synthesis of primary sulfonamides 
(SO2NH2).  
In this work, an efficient three step synthesis has been designed and successfully 
implemented, proceeding via chlorosulfonation of diethyl benzylphosphonate, to form 
the sulfonyl chloride intermediate. Aminolysis of the sulfonyl chloride intermediate 
was then performed, using a range of primary, secondary and cyclic alkyl amines, as 
well as aromatic amines; including ammonia, dimethylamine, morpholine and 
diphenylamine. Finally, formation of the stilbene backbone with various substituted 
aldehydes, via the HWE reaction offered a short, versatile and alternative route to the 
synthesis of novel primary, secondary and tertiary trans-stilbene benzenesulfonamides 
and heterocyclic analogues, in yields of 42 – 100 %.  
The activity of a selection of the synthesised stilbene benzenesulfonamides was 
evaluated against the human lung adenocarcinoma epithelial cell line (A549). 
Amongst the compounds tested, analysis of the data showed that the novel analogue, 
4, was found to be the most potent compound, with a GI50 of 0.1 µM. Comparison 
with the previously published data found analogue, 4, to be approximately 500-fold 
more potent than the lead compound resveratrol, 1, (GI50 = 51.64 µM) and 
approximately twice as potent than 5-fluorouracil (GI50 = 0.189µM), a chemotherapy 
drug used to treat various forms of cancer 8. 
 
 
 
Overall, these results demonstrate that the total synthesis of trans-arachidin-1, 2, can 
be achieved via a five step methodology. A versatile route to the synthesis of novel 
4 
stilbene benzenesulfonamides has also been successfully achieved, amongst the 
compounds synthesised one appears to show promising anticancer activity, and 
warrants further investigation (i.e. in vitro studies using other cancer cell lines, and the 
synthesis of additional compounds using analogue, 4, as a lead compound). 
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Abbreviations 
 
δ   Chemical shift 
Ac   Acetyl 
AIBN                          Azobisisobutyronitrile 
Ar   Aromatic 
ArH   Aromatic proton 
ArC   Aromatic carbon 
ATR   Attenuated total reflectance 
b.p.   Boiling point 
CDCl3   Deuterochloroform (chloroform-d) 
ClSO3H  Chlorosulfonic acid 
CD3CN  Acetonitrile-d3 
COX   Cyclooxygenase 
D2O   Water-d2 
DMG   Dimethylglyoxime 
d   Doublet 
dd   Doublet of doublets 
dq   Doublet of quartets 
dsep   Doublet of septets 
DCM   Dichloromethane 
DMF   Dimethylformamide 
DMSO-d6  Dimethyl sulfoxide-d6 
EtOAc   Ethyl acetate 
7 
EtOH   Ethanol 
EtN(i-Pr)2  Diisopropylethylamine 
Equiv.   Equivalent 
FGI   Functional group interconversion 
GI50 The concentration of a compound required to inhibit cell 
growth by 50 %. 
IC50 The concentration of a compound required to achieve half 
maximal inhibition. 
IC100  The lowest concentration of a compound required to achieve 
complete inhibition of cell growth 
IR   Infrared 
J   Coupling constant 
Km Michaelis Menten constant; substrate concentration that gives 
half maximal velocity of an enzymatic reaction.  
lit.   Literature 
m   Multiplet 
mRNA messenger RNA  
MgSO4  Magnesium sulfate 
m.p.    Melting point 
MS   Mass spectrometry 
m/z   Mass to charge ratio 
NAD+   Nicotinamide adenine dinucleotide 
N2   Nitrogen  
NF-κB   Nuclear factor kappa b 
NMR   Nuclear magnetic resonance 
OMe   Methoxy  
Pd   palladium 
8 
PGE2   Prostaglandin E2 
ppm   Parts per million (chemical shift δ) 
Rf   Retention factor 
RT   Room temperature 
s   Singlet  
sep   Septet 
SI Selectivity index  
Str   Stretch 
t   Triplet 
tBuOK/KOtBu Potassium-tert-butoxide 
tBuOH   tert-butanol 
THF   Tetrahydrofuran 
TLC   Thin layer chromatography 
UV   Ultra violet 
ZnBr2   Zinc bromide 
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Chapter One 
 
 Introduction 
 
1.1 Stilbenes 
 
The stilbene (1,2-diphenylethylene) structure, comprises two phenyl rings linked 
together by an ethylene linkage (Figure 1.1). Stilbenes exist in two geometric forms; 
the stable trans-stilbene, 5, (E-stilbene) and the less stable cis-stilbene, 6, (Z-stilbene). 
The cis-isomer is considered less stable, due to steric interactions which force the 
aromatic rings out-of-plane, and as a result conjugation is lost 9. 
 
 
Figure 1.1 Stilbenes 
 
A number of stilbene derivatives, also known as stilbenoids are present in nature and 
act as phytoalexins. Phytoalexins are low molecular weight antimicrobial compounds 
that are synthesised and accumulate in plants, following exposure to fungal attack, 
excessive ultraviolet light or plant stress 10, 11. Although the mechanism of action to 
exogenous invasion is unclear, it has been suggested that these phytoalexins may 
display antimicrobial activity, by means of disrupting the cellular metabolism of the 
microorganism 10, 11. 
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1.2 Peanut stilbenes 
A number of stilbene phytoalexins are known to be produced by the peanut plant, 
Arachis hypogaea a species of the legume family (Legumino Sae). These 
phytoalexins, which have been characterised and reported within the literature, are 
predominately produced by fungally-challenged peanuts (Figure 1.2) and are present 
as trans-isomers 1-3, 12-14, with the majority possessing a prenyl moiety on the stilbene 
backbone, which is suggested to increase the compound’s bioactivity 15.  
 
 
 
Figure 1.2  Structure of known stilbene phytoalexins from peanut seed; trans-resveratrol 
(1), trans-arachidin-1 (2), trans-piceatannol (7), trans-arachidin-2 (8), trans-arachidin-3 (9), trans-
mucilagin A (10), trans-IPD (11) and trans-SB-1 (12) 
Chapter 1: General Introduction 
 
 
15 
Additionally, other novel phytoalexins (Figure 1.3) have been characterised by 
Sobolev et al., 1, 16 and by Liu and co-workers 17.  
 
 
 
Figure 1.3 Structures of known stilbene phytoalexins from peanut seeds: chiricanine A (13), 
arahypin-5 (14) and arahypin-6 (15). 
 
These distinctive phytoalexins are currently attracting considerable attention, due to 
the various biological and therapeutic properties including; antifungal 18, antibacterial 
19, cardioprotective14, neuroprotective20, phytoestrogenic21, anti-inflammatory22, 
antioxidative 3, and anticancer activity 3, 4, 23, as well as the benefit of being available 
from a dietary source.  
 
Stilbene phytoalexins are inexpensively extracted from plants, however they are 
seldom pure. Within the literature, mixtures of stilbenoids are commonly identified 
via spectral analysis (MS, NMR, and HPLC-MS), nonetheless despite the various 
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extraction methods which have been reported in the literature 1-3, 12-14, stilbenes are 
usually isolated in minute quantities (µg) 9, 24.  
Because of this, the synthesis of known prenylated peanut phytoalexins such as 
arachidin-1, 2, and SB-1, 12, are required, in order to obtain pure samples of these 
compounds, in sufficient yields to aid with their characterisation. Furthermore this 
will enable studies to be performed with regards to the biological and therapeutic 
properties displayed by these compounds. 
In this chapter, a brief overview into the biological properties displayed by 
peanut phytoalexins will be described, next coupling methods used in the formation of 
the carbon-carbon double bond (C=C), will be presented. Finally a background into 
benzenesulfonamides will be discussed later in this chapter, these compounds are 
analogues of resveratrol, 1, which have been reported to display promising biological 
activity. 
 
 
1.3 Biological activity of peanut stilbenoids 
1.3.1 Anti-inflammatory and cardioprotective activity 
 
Resveratrol, 1, exists in its two geometric isomers; cis- and trans-resveratrol, although 
the mechanism of action is still unclear, trans-resveratrol, 1, is suggested to be the 
isomer that exhibits the optimum bioactivity 13. 
The ability of both trans-resveratrol, 1, and trans-arachidin-1, 2, to exhibit 
anti-inflammatory activity, has been suggested to be linked to their capacity to supress 
cyclooxygenase-2 (COX-2) mRNA expression 4. This results in reduced levels of the 
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COX-2 enzyme, which are known to increase during an inflammatory process and 
consequently leads to an increase in pro-inflammatory prostaglandins (PG) 25, 26.  
The effect displayed by these peanut stilbenes on the synthesis of the COX 
isoenzymes (COX-1 and COX-2), have also been suggested to be linked with their 
cardioprotective effects27-29. In particular, both resveratrol, 1, 30 and piceatannol, 7, 31, 
32 appear to inihibit COX in the platelets, which leads to the blocking of thromboxane 
synthesis, and results in a reduced risk of thrombosis 33.  
In 1992, Siemann and Creasy 34 published their findings of resveratrol, 1, in 
wine (< 2.861 µmol/L), this discovery offered an explanation to the infamous “French 
Paradox”. The French Paradox was an observation made by the scientist Serge 
Renaud, his justification was that low rates of mortality caused by coronary heart 
disease in France, was due to the moderate consumption of red wine. Despite the 
relatively high levels of saturated fat and smoking, as part of the French lifestyle and 
so implying the consumption of wine may offer additional protection from 
cardiovascular disease35-37. 
 
1.3.2 Antioxidative activity 
 
 
Both resveratrol, 1, 38 and piceatannol, 7, 39, 40, are additionally known for their 
antioxidative activity, and it is suggested that the anti-inflammatory and antioxidative 
properties displayed by resveratrol, 1, may also assist in explaining the 
neuroprotective effects displayed by resveratrol, 1 41. Furthermore the prenyl 
stilbenes; arachidin-1, 2, arachidin-2, 8, and arachidin-3, 9, have been reported also 
exhibit potent antioxidative activity, and due to the presence of the 3’-OH moiety on 
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the stilbene backbone, arachidin-1, 2, was found to display greater activity compared 
to both arachidin-2, 8, and arachidin-3, 9 42.  
1.3.3 Anti-ageing activity 
 
 
Resveratrol has also been identified as one of the first small molecule activators of 
SIRT1, an enzyme reported to imitate the effects of calorie restriction in vivo, and an 
important factor in slowing down the rate of ageing, as well as preventing age-related 
diseases linked to causes of mortality; such as type 2 diabetes, heart disease, cancer 
and neurodegenerative diseases43-45. 
Howitz et al., 44 discovered resveratrol, 1, to be the most potent agent, in extending the 
lifespan of mammalian cells, when compared to other polyphenols including quercetin 
(3,5,7,3’,4’-pentahydroxyflavone), 16. This peanut phytoalexin was found to be 
effective in stimulating the activity of SIRT1 up to 10 fold, as a result of decreasing 
the Km of both nicotinamide adenine dinucleotide (NAD+) and peptide substrate                 
(Table 1.1).  
Moreover when the effects of resveratrol, 1, on the protein Sir2 was examined, in vivo 
using the single-celled baker’s yeast, S. cerevisiae, this stilbene was found to prolong 
the lifespan of the yeast by 70 % 44.  
The prolonging of lifespan following treatment with resveratrol, 1, has also been 
observed in a concentration dependent manner with Drosophila 46, in addition to 
multi-cellular organisms such as the short-lived vertebrate Nothobranchius furzeri, a 
fish which when in captivity is known to survive for a maximum period of 3 weeks. 
Nonetheless, despite the promising in vivo activity, the mechanism with regards to the 
longevity effect displayed by resveratrol, 1, in addition to its correlation with diet 
restriction is not known45, 47.  
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Table 1.1  Stimulation of SIRTI catalytic rate by plant polyphenols 44 
 
Compound 
(100 µM) 
Ratio to control 
(mean ± s.e) 
Structure 
 
Resveratrol 
  
 
13.4 ± 1.0 
 
 
 
 
Quercetin  
 
 
4.59 ± 0.47 
 
 
 
 
 
 
As a potent SIRT1 activator resveratrol, 1, has been coined to exhibit therapeutic 
potential in treating type 2 diabetes. An in vivo study on mouse models with type 2 
diabetes found resveratrol, 1, to increase mitochondrial activity and insulin sensitivity 
48, 49. However, due to some of the limitations displayed by resveratrol, 1, including; 
poor bioavailability and solubility, analogues of resveratrol which display efficacy in 
prolonging the lifespan eukaryotes are still required 50. 
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1.3.4 Antimicrobial activity 
 
Studies have also found resveratrol, 1, to display promising antifungal activity in 
spermatophytes 51, 52, however the fungicidal effects of this peanut phytoalexin in 
humans are still scarcely known 2, 3, 51, 53, 54. 
A recent report by Jung et al., compared the fungicidal effects of resveratrol, 1, 
against amphotericin B, an efficacious antifungal drug used in the treatment of 
systematic fungal infections, which is associated with severe adverse reactions, e.g. 
rupturing of red blood cells (haemolysis). When examined against known human 
infectious fungi; particularly Candida albicans, Saccharomyces cerevisiae and 
Trichosporon beigelii, resveratrol, 1, at doses of 10-20 µg/mL, was found to solely 
initiate antifungal activity. Additional in vitro studies found resveratrol, 1, to be as 
potent as amphotericin B, in inhibiting the growth of the fungus Candida albicans 
(Table 1.2).  
 
 
Table 1.2 Antifungal activities of resveratrol against various fungi 54 
 
 Minimum Inhibitory Concentration 
 (µg/mL) 
C. albicans S. cerevisiae T. beigelii 
Resveratrol 20 10-20 10 
Amphotericin B 5 10 5-10 
 
 
Furthermore, the study by Jung et al., 54 into the effects of resveratrol, 1, on human 
erythrocytes demonstrated the non-haemolytic activity displayed by resveratrol, 1, 
against red blood cells. This means that the treatment of systematic fungal infections 
with resveratrol, 1, could offer an advantage (over existing antifungal drugs, i.e. 
Chapter 1: General Introduction 
 
 
21 
amphotericin B) of reducing the chances of dangerous side effect, thus improving 
patient compliance.  
 
The administration of current antiviral drugs including; acyclovir, famciclovir and 
valaciclovir in the treatment of viral infections, are often administered with a 
corticosteroid 55, which acts as both an anti-inflammatory agent and analgesic to treat 
the symptoms of pain and inflammation 56, 57, however this may be unnecessary with 
the application of resveratrol, 1.  
A number of in vitro and in vivo studies 65 – 67 have detailed the antiviral properties 
displayed by resveratrol, 1, frequently reporting this natural stilbene, to be as potent as 
the various antiviral drugs currently on the market. Furthermore due to the anti-
inflammatory effects displayed by resveratrol, 1, the addition of corticosteroids would 
no longer be required. 
As an antiviral agent, resveratrol, 1, has been reported to display activity against the 
herpes simplex virus (Herpesviridae) family 58, 59, including the herpes simplex virus-
1 (HSV-1), herpes simplex virus 2 (HSV-2) 58, 59, varicella zoster virus (VZV) 57 and  
human cytomegalovirus (HCMV) 60.  
The herpes simplex virus is known to affect an estimated 95 million of the population 
worldwide 61, although a cure has not been found, medication can be applied in order 
to reduce the event of spreading. The anti-HSV activity of resveratrol, 1, by means of 
in vitro and in vivo models, have been extensively studied by Docherty et al.,59, 62. For 
instance resveratrol, 1, was found to reduce the cellular growth of mice cells at S-G2-
M phases and inhibit the production of the infected cell protein (ICP-47), an early 
protein of HSV. When compared to piceatannol, 7, this stilbenoid was ineffective, 
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which suggests that in stilbene derived compounds, a specific chemical structure is 
crucial in the inhibition of HSV replication 58. 
Other studies have demonstrated the effectiveness of resveratrol, 1, as an anti-HSV 
drug by means of an in vivo model. The comparison of the dose dependent resveratrol 
cream (12.5 % or 25 %) with 5 % acyclovir ointment (Zovirax™) and 10 % docosanol 
cream (Abreva™) on hairless SKH1 mice, infected with HSV-1 found this natural 
stilbene to significantly inhibit the development of HSV-1 induced skin lesions, 
particularly when compared to 5 % acyclovir ointment Zovirax™ (p = 0.0001), with 
no signs of dermal toxicity after the application of five times a day for 5 days 59. 
Furthermore, when evaluating the route of drug administration, the topical 
administration of resveratrol, 1, was found to be an effective route in inhibiting viral 
replication 63.  
Chicken pox (varicella) and shingles (herpes zoster) are signs of primary infection by 
the varicella-zoster virus (VZV). This virus is transmitted among humans via 
respiratory droplets and direct skin contact, with sufferers often showing signs of a 
fever and vesicular rash. Subsequent to an infection, the VZV is known to lay dormant 
within the dorsal root, cranial and autonomic ganglia, with recurring viral infections 
resulting in shingles. An in vitro study by Docherty and co-workers in 2006, 
examining the effects of non-toxic doses of resveratrol, 1, (219 µM) on human diploid 
lung cells    (MRC-5) infected with VZV cells, reported resveratrol, 1, to inhibit the 
replication of the varicella-zoster virus via a dose-dependent, time dependent and 
reversible approach, when applied 30 h after the viral infection. Resveratrol, 1, was 
also reported to operate by not averting the VZV attachment or causing inactivation of 
the virus, but in a reversible manner, when observed via western blot and real-time 
PCR analysis. The analysis found resveratrol, 1, to play a significant role in limiting 
Chapter 1: General Introduction 
 
 
23 
the synthesis of the IE62 protein, an essential immediate early gene transactivating 
protein, by reducing the levels of mRNA 57.  
Resveratrol, 1, has also been reported to display potent and selective antiviral 
activity against HCMV, by inhibiting viral replication when examined on human 
embryonic lung fibroblasts, limiting the appearance of the immediate-early and late 
HCMV proteins. With the suggested mode of action proceeding via inhibiting the 
virus-induced activation of the epidermal growth factor receptor (EGFR), and as a 
result preventing entry into the HCMV virus. As well as inhibiting 
phosphatidylinositol-3-kinase signal transduction, in addition to the NF-κB and Sp1 
transcription factor activation, following an infection 60.  
Several antiviral drugs have also been designed to treat the influenza virus, 
nonetheless many have been found to be ineffective. Resveratrol, 1, has been reported 
to effectively inhibit the reproduction of the influenza virus in vitro, this stilbene was 
found to effectively increase the survival of the influenza infected mice, by decreasing 
pulmonary viral titres 64.  
Furthermore resveratrol, 1, has been shown as non-toxic, in addition to displaying 
antiviral and anti-inflammatory activity, albeit dependent on the nature of the virus, 
time of administration, concentration and frequency of treatments per day, therefore 
this compound encompasses the pharmacological properties desired in a novel drug 
for the treatment of viral infections. Although the mechanism of action displayed by 
resveratrol, 1, is not fully understood, this stilbenoid is known to have an effect on a 
spectrum of viruses. Reports have also suggested resveratrol, 1, to selectively target 
the cell instead of acting directly on the virus, as part of its mechanism to prevent viral 
replication57, 64, 65, however this warrants further investigation. 
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Likewise, the search for an antimicrobial drug of which combines as an anti-
inflammatory agent, has attracted great interest. The antifungal and antiviral activity 
of resveratrol, 1, 18, 62 as well as the desirable anti-inflammatory property has led to the 
evaluation of this compound as a potential antibacterial agent, in the treatment of 
human skin conditions. Initial microbiology studies have identified resveratrol, 1, as 
an antimicrobial agent, albeit with selective activity towards Gram negative bacteria.  
In 2001, an in vitro model examining the antimicrobial activity of resveratrol, 1, 
against Neisseria meningitidis (meningitis) and Neisseria gonorrhoeae (gonorrhoea) 
was performed by Docherty et al., whereby the administration of resveratrol, 1, was 
found to selectively inhibit the activity of the Gram-negative bacteria (Table 1.3), 
however resveratrol, 1, did not show efficacy against the Gram-positive bacteria 
examined 66. The results from other in vitro studies, investigating the growth of Gram-
positive and -negative bacteria in the presence of resveratrol, 1, were found to also be 
consistent with the study performed by Docherty and co-workers 67. 
 
 
Table 1.3 ICs of resveratrol against various bacteria 66 
 
Microorganism IC50  
(mg/L) 
IC100 
 (mg/L) 
N. gonorrhoeae 25 75 
N. meningitidis 100 125 
E. coli > 200 > 200 
S. aureus > 200 > 200 
S. pyogenes > 200 > 200 
P. aeruginosa > 200 > 200 
C. albicans > 200 > 200 
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Conversely, the study by Chan et al., in 2002 68, reported the antibacterial effect of 
resveratrol, 1, on a number of Gram-positive bacteria, commonly known to cause 
various human skin conditions; including S. aureus and Streptococcus group D, 
known to cause pimples, folliculitis and boils (furuncles), as well as the examination 
of Gram-negative bacteria; Pseudomonas aeruginosa commonly found in water, skin 
flora and soil and common dermatophytes including tinea pedis (athlete's foot) and 
tinea corporis (ringworm). In the study by Chan and co-workers, the use of trypticase 
soy agar (TSA) plates was reported, a basic medium suitable for culturing various 
microorganisms. Resveratrol, 1, at a dose of 171 µg/mL in 1.7 % DMSO, was 
reported to display efficacy in inhibiting the growth of the Gram-positive bacterium, 
S. aureus, by up to 90 %. However, the application of resveratrol, 1, at higher doses 
342 µg/mL in 3.3 % DMSO was found to show similar results against the Gram-
negative bacterium P. aeruginosa, with inhibition of up to 50 % against 
dermatophytes in the presence of 5 % DMSO.  
With regards to the activity displayed by resveratrol, 1, compared to benzoyl peroxide 
and erythromycin, compounds both commonly used in the formulation of treatments 
for skin diseases, the performance of this stilbene remains promising 69. 
The antimicrobial activity of resveratrol, 1, is not solely seen with trans-
resveratrol, 1, both geometric isomers of resveratrol have been reported to exhibit 
antimicrobial activity against E. coli, Sarcina lutea, Bacillus subtilis and 
Staphylococcus sp. However, the trans-isomer was found to display greater 
antimicrobial activity in comparison to the cis isomer (Table 1.4).  
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Table 1.4 Diameters of inhibition zone for the resveratrol extracts 
Bacterium Ethanolic extract of  
trans-resveratrol  
 
(mm) 
Ethanolic extract of  
cis-resveratrol  
 
(mm) 
 
Escherichia coli 13.7 ± 1.86 11.6 ± 1.90 
Bacillus subtilis 15.0 ± 2.37 10.4 ± 1.77 
Staphylococcus sp. 15.8 ± 1.40 11.2 ± 0.9 
Sarcina lutea 16.2 ± 1.40 10.0 ± 1.22 
 
 
In this study trans-resveratrol, 1, was reported to demonstrate significant efficacy 
against Gram-positive bacteria and limited activity against Gram-negative bacteria. 
The observations reported may have been as a result of the variation in cell wall 
structure between the microorganisms examined, as the structure of the cell wall of a 
Gram-negative bacterium comprises of liposaccharide chains, therefore providing 
structure and protection from xenobiotics 70.  
Studies into the mode of action by which resveratrol, 1, displays its 
antibacterial activity against bacterial pathogens is not fully understood, although it 
has been suggested that the selectivity displayed by resveratrol, 1, is possibly due to 
the microorganisms possessing a binding site, which the stilbene compound can easily 
bind to. Furthermore it is also thought that the antimicrobial activity displayed by 
resveratrol, 1, is due to the compound’s solubility resveratrol, 1, being lipophilic is 
insoluble in water therefore when dissolved in DMSO, instead of ethanol has been 
shown to improve the compounds performance.  
The selection of agar in the study is also crucial in obtaining optimum results 
with the stilbene, therefore what may be required is an evaluation of the inhibitory 
activity displayed by resveratrol, 1, using a medium which is not selective towards the 
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growth of one colony of organisms. For instance, the use of the Luria-Bertani (LB) 
agar, although not suitable for organisms such as Neisseria, it is a common medium 
used in microbiology studies and does not favour the growth of one microorganism 
over another. 
 
1.3.5 Anti-cancer activity 
 
The anti-cancer properties of resveratrol, 1, including the inhibition of cell 
proliferation as well as the ability to induce apoptosis, has been demonstrated in vitro, 
against various human cancer cell lines such as; colon, breast, glioma and prostate 
cancers23, 71. Additionally, the arachidins have been reported to exhibit anti-cancer 
activity, by inducing apoptosis in human leukaemia (HL-60) cancer cells 72, although 
arachidin-1, 2, has been found to exhibit greater activity compared to its analogues (8 
and 9). 
Furthermore when examined using mouse macrophages arachidin-1, 2, was found to 
display similar or even lower levels of toxicity than resveratrol 1, which suggests that 
the reduced levels of toxicity displayed by arachidin-1, 2, could give it a greater 
advantage over resveratrol, 1, as a drug. As one of the clinical challenges with using 
resveratrol, 1, was its ability to reduce the growth of cycling normal human peripheral 
blood lymphocytes, at concentrations similar to that required to inhibit most 
leukaemia cells 4, 5. 
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1.4 Pharmacokinetics of resveratrol 
Although the therapeutic properties displayed by resveratrol, 1, are promising, the 
quantity required to exert these therapeutic effects can often be higher than the amount 
of resveratrol, 1, actually measured in human plasma, following oral administration. 
This is due to the rapid metabolism of resveratrol, 1, in the liver into its glucuronide 
and sulphate conjugates, which consequently reduces its bioavailability and as a drug, 
prevents this natural stilbene from being effective. However, the potential of 
increasing the bioavailability of resveratrol, 1, has been reported by De Santi and co-
workers, with the use of quercetin, 16, a flavonoid found in wine, fruits and 
vegetables, and a potent inhibitor of important drug-metabolising enzymes including 
Cytochrome P450 3A4 (CYP3A4) and Cytochrome P450 2C9 (CYP2C9)73. 
Previous studies have examined the bioavailability of trans-resveratrol, 1, and the 
determination of its levels in blood plasma, however very little is known about its 
distribution, mainly due to the limited availability of validated in vitro and in vivo 
methods, which are needed to correctly determine the concentrations of resveratrol, 1, 
and its conjugates distributed within the body 23.  
An in vivo study carried out by Emilia Juan et al., detailed the development of 
a selective extraction process, used for the determination and quantification of trans-
resveratrol, 1, and its conjugates in rat kidney, lung, liver, testis and brain tissues. 
When administered with 15 mg/kg of pure resveratrol, 1, the natural compound was 
detected in the kidneys, liver and lungs, generally organs of which large volumes of 
blood are applied to. However lower concentrations of resveratrol, 1, and its 
metabolites were found in organs with specific barriers naturally designed to prevent 
xenobiotics from entering. The kidneys were reported to contain considerable 
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concentrations of pure resveratrol, 1, and its glucuronide conjugate compared to the 
other organs. The hydrophilic nature of the sulphate conjugate, meant that it was 
easily removed from the kidneys, which suggest the possible elimination of trans-
resveratrol, 1, via renal excretion 74.  
As seen from a number of in vivo metabolic studies, both Phase I and Phase II 
reactions on resveratrol, 1, affect its ability to act as a potential drug, despite it being 
highly absorbed75, 76. It is therefore unclear whether the effects of resveratrol, 1, 
observed in cell culture and animal model studies will be replicated in clinical human 
studies. Despite this, cytotoxicity testing on animal models has shown                                   
trans-resveratrol, 1, as a drug to be safe 77, a study in which Sprague-Dawley rats were 
administered with 20 mg/kg of resveratrol, 1, for 28 days, a level 1000 times over the 
amount that may be consumed by a person, drinking one glass of red wine a day 
verified the compound’s non-toxicity 13.  
Resveratrol, 1, is now available within the commercial market as a dietary 
supplement, sold in capsule, pill and powder form. Although within the literature, the 
biological and therapeutic properties displayed by resveratrol, 1, are well known, very 
little is known about the remaining novel peanut phytoalexins, due to the quantities 
obtained (µg) when extracted from peanut plants. Therefore strategies towards the 
total synthesis of these novel compounds are still required, in order to determine if 
these natural compounds display similar or increased activity compared to resveratrol 
1.  
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1.5 Structure-Activity-Relationship 
 
 
The Structure-Activity Relationship (SAR) of a lead compound is examined, in order 
to determine the relationship between its molecular structure, and the biological 
activity it exhibits as drug. Knowledge based on the SAR can then be used to perform 
modifications on the lead compound, in order to improve the pharmacological 
activity.  
Characteristics that influence the SAR of a drug include; size, shape, the presence of 
functional groups, stereochemistry, reactivity, resonance, electronic effects and so on. 
Additionally Quantitative Structure Activity Relationship models (QSAR) are often 
applied, to mathematically characterise the correlation between a lead compound and 
its biological activity 78, 79.   
Resveratrol, 1, is known as an antioxidant, antimicrobial and cancer 
chemopreventative agent, however the relationship between its structure and 
biological activity has not been extensively explored. Although studies have 
highlighted characteristics, including the stereoisomerism, stilbene skeleton and the 
positioning of hydroxyl groups, to play an important role in pharmacological activity 
observed3, 9.  
 
Lipid peroxidation is a quintessential mechanism which leads to cell and tissue 
damage, and as a result causes a range of diseases. The potent antioxidative activity 
displayed by resveratrol, 1, has been reported to reduce lipid peroxidation, by the 
scavenging of free radicals in vitro. The 4’-OH group is believed to be crucial for the 
radical scavenging activities displayed by resveratrol, 1, furthermore the presence of 
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the 3-OH and 5-OH groups were also found to be equally important, as they offered 
additional resonance stability for the stilbene 80.  
With regards to the role of resveratrol, 1, in activating the protein SIRT1 and 
prolonging of lifespan, the hydroxyl moieties at the 3- and 5- positions of the aromatic 
ring, coupled with the trans-geometry have been reported to be necessary for its 
activity 50, with resveratrol, 1, displaying potent activity towards the SIRT1 protein up 
to 12 fold, compared to other substituted analogues 44. Additionally, both the stilbene 
backbone and the trans-configuration have been suggested to be essential for the 
antiproliferative and DNA polymerase activity displayed by resveratrol, 1 38.  
 
 
1.6 Synthesis of stilbenes  
1.6.1 Non-catalytic coupling reactions 
 
Various synthetic routes have been reported for the synthesis of peanut phytoalexins 
and stilbene derivatives, however the most common coupling methods used in the 
formation of the carbon-carbon double bond (C=C), include the Wittig-Horner 81, 82 
and Horner-Wadsworth-Emmons (HWE) reaction83, 84. In addition to palladium (Pd) 
catalysed coupling reactions such as the Heck 85 and Suzuki 86 reaction. However, 
other commonly known alkene forming reactions; such as the Julia olefination87, 88, 
Ramberg-Bäcklund89, 90, McMurry 91 and Negishi-Stille reaction 92, 93 have not been 
fully explored for the synthesis of natural stilbenes. Additionally some reactions 
including the Peterson reaction, to date have not been reported in the construction of 
stilbene systems, nevertheless with the majority of the aforementioned reactions, the 
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percentage yields obtained are often quite poor due to the number synthetic steps 
required.  
Another challenge with regards to the construction of the C=C bond, is 
controlling the regio- and stereoselectivity of the reaction, to give the desired trans-
isomer. The Wittig, also known as the Wittig-Horner type reaction 81, offers a solution 
to this matter, this traditional coupling approach has been reported in the synthesis of 
peanut stilbenes including trans-resveratrol, 1, and piceatannol, 7, in addition to other 
synthetic analogues 82, 95-102.  
This approach has many benefits, due to it being simple, efficient, whilst offering a 
stereoselective approach to the synthesis of alkenes103. Additionally the Wittig is an 
attractive route compared to other elimination reactions, such as the Julia or Peterson 
reaction, due to it proceeding in one step88, 104. The widespread use of this reaction in 
organic synthesis has also been attributed to the mild reaction conditions and the 
ability to proceed without the need of an inert atmosphere or expensive catalysts9, 81, 
103, 105.  
Although the Wittig reaction to date is still the primary approach for the formation of 
stilbenes, this reaction often results in low yields of the desired trans-alkene, due to 
the formation of both E/Z-alkenes106. Additionally, this reaction is limited to 
substrates possessing a carbonyl moiety and requires a stoichiometric ratio of the 
reactants used107.  
In 2009 Alonso and co-workers98, reported a one-pot type Wittig olefination of 
substituted benzyl alcohols, 19, and ylide, 18, in the presence of nickel(0) 
nanoparticles (NiNPs), in order to synthesise trans-resveratrol, 1, in good yield (70 %) 
(Scheme 1.1). This study proved that stilbenes could be formed, via the Wittig 
reaction, without the need of a carbonyl substrate.  
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Scheme 1.1 Synthesis of resveratrol via Wittig-type olefination in the presence of nickel 
nanoparticles 
 
Other variations of the Wittig reaction have been reported for the synthesis of both 
meta- and para-substituted stilbene derivatives (51 – 93 %), using crown ether, 18-
crown-6, potassium hydroxide and a solid-liquid biphasic system (K2CO3/PhMe) 
(Table 1.5). However the stereoselectivity observed in this approach, was found to be 
comparable with the traditional Wittig reaction, as the selectivity for the trans-isomer 
was believed to be highly dependent on both the substituent present on the 
phosphonium halide and the reaction condition used. Notably, the solid-liquid 
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biphasic system comprising of benzyldiphenylchlorophosphonium bromides displayed 
almost complete trans-stereospecificity (Z/E < 2:98)108.  
 
Table 1.5 Coupling via the Wittig reaction 
 
 
Compound R1 X R2 Temperature 
(°C) 
Z : Ea 
 
23 
 
p-OMe 
 
Cl 
 
H 
 
-70  
 
85 : 15 
24 H Br p-OMe -70 
 
70 : 30 
25 p-Me Cl H -70 
 
85 : 15 
26 p-CF3 Br p-CF3 -70 
 
82 : 18 
27 p-CN Br p-CN -70 
 
>98 : <2 
28 H Br p-CF3 25 4 : 96 
 
29 
 
H 
 
Br 
 
p-NO2 
 
25 
 
1 : 99 
 
a Determined by HPLC 
 
 
Following the discovery of the Wittig reaction in 1954 81, an alternative and attractive 
alkene-forming reaction, was first reported by Horner et al., in 1958 109 and further 
developed by Wadsworth and Emmons 110.  
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The HWE reaction is generally limited to the coupling between substituted aldehydes 
(or ketones) with stabilised phosphonate carbanions. This coupling reaction has 
proved to be a reliable and versatile route for the synthesis of stilbenes, including 
many peanut phytoalexins such as resveratrol, 1, (Scheme 1.2) with high selectivity 
for the trans-isomer 22, 106, 111, 112. The high selectivity is thought to be due to the 
phosphonate stabilised carbanions used in the reaction, which thermodynamically 
favours the construction of the trans-isomer over the cis-isomer and as a result, 
affords only the trans-alkene 105, 110, 113. 
 
 
Scheme 1.2 Synthesis of resveratrol and resveratrol analogues via the HWE reaction 
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This reaction has additional advantages, which include the use of mild reaction 
conditions, and the isolation of the desired trans-alkene can be performed by aqueous 
work up, which enables the easy removal of the product from the water-soluble 
phosphorus by-product. This gives the HWE reaction a great advantage over the 
Wittig reaction, as the triphenylphosphine by-product in the Wittig requires separation 
via chromatographic purification 9, 82, 99, 102, 103.  
Furthermore, although only limited to compounds possessing a carbonyl moiety, the 
HWE reaction has been reported to be a reasonable and adaptable method for the 
coupling of sensitive functional groups, such as furan-2-carboxaldehyde 114, 115.  
Within the literature, the reported synthesis of natural prenylated peanut 
phytoalexins is limited, however the HWE reaction is currently the only coupling 
reaction, reported in the synthesis of prenylated peanut stilbenes.  
Park and et al.,84 in 2011, reported the synthesis of trans-arachidin-2, 8, and trans-
arachidin-3, 9, in good yields, via the HWE reaction, whilst using a combination of 
triisopropylsilyl (TIPS) and methoxymethyl (MOM) protecting groups (Scheme 1.3).  
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Scheme 1.3 Synthesis of trans-arachidin-2 and trans-arachidin-3 
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Recently, Hartung and co-workers, in 2014 attempted to synthesise the natural 
prenylated stilbene Pawhuskins, isolated from purple prairie clovers (Dalea purpurea) 
and at the same time reported an alternative and efficient approach towards the total 
synthesis of trans-arachidin-2, 8, in quantitative yields, via the HWE condensation, 
with the use of MOM protecting groups (Scheme 1.4) 116. 
The HWE coupling has been proved to be an effective route to the synthesis of other 
peanut phytoalexins, however attempts towards the total synthesis of                                           
trans-arachidin-1, 2, to date has not been reported in the literature, therefore it would 
be of interest to attempt the synthesis of arachidin-1, 2, via this approach. 
 
 
 
Scheme 1.4 Synthesis of trans-arachidin-2, via HWE coupling 
 
 
Besides the Wittig and HWE coupling reactions, the Julia olefination 88, is an 
alternative non-catalysed coupling reaction, which has been frequently used for the 
regioselective synthesis of alkenes. This coupling reaction occurs between a phenyl 
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sulfone (PhSO2) with either an aldehyde or ketone, in the presence of a powerful 
reducing agent, such as sodium amalgam 88. Due to its chemoselectivity towards the 
sulfone moiety, the reducing agent samarium(II) iodide is suggested to be most 
favourable for this elimination reaction 117. This reaction also has its benefits, 
particularly with regards to the simple preparation of the starting materials, and as a 
result various substrates, of which poses a PhSO2 moiety, next to the leaving group 
(carboxylate) can be used.  
Although the Julia olefination offers good selectivity for the trans-isomer, this 
reaction is only stereoselective and not stereospecific, furthermore the selectivity has 
been reported successful, when minimal substitution is present on the coupling 
substrates 104. 
A variation of this coupling reaction by means of the one-pot Julia Olefination, also 
known as the Julia-Kocienski reaction 118, 119 has been reported, for the synthesis of 
resveratrol, 1, and resveratrol analogues (Figure 1.4), with good yields and excellent 
selectivity (Z/E = 1 : 99), when  unsubstituted aromatic substrates were used 87. 
 
 
 
Figure 1.4 Synthesis of resveratrol analogues, via Julia Olefination 
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The Ramberg-Bäcklund reaction, discovered by Ludwig Ramberg and Birger 
Bäcklund in 1940, involves the transformation of α-halosulfones into alkenes, in the 
presence of a strong base, which is known to favour the formation of trans-alkenes 89, 
120. Foot and co-workers, in 2007 121 reported the use of this coupling reaction, in the 
synthesis of stilbene analogues, with moderate yields (Scheme 1.5).  
 
 
 
Scheme 1.5 Synthesis of stilbene analogues via the Ramberg-Bäcklund reaction 
 
 
This approach has also been reported recently in the literature, as a strategy towards 
the synthesis of resveratrol, 1 90. An advantage of this approach is the use of various 
substituted α-halosulfones of which are commercially available, although the 
syntheses of the sulfones are known to be challenging. 
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A number of modified one-pot syntheses via the Ramberg-Bäcklund reaction have 
been reported, such as the work by Meyers and co-workers, whereby a sulfone is 
transformed into the trans-stilbene, 57, in quantitative yield, in the presence of carbon 
tetrachloride and potassium hydroxide  (Figure 1.5) 122. Additionally by Chan et al., 
whereby the use of potassium hydroxide absorbed unto an aluminium support and 
dibromodifluoromethane as the halogen source, was reported. This approach, has been 
shown to allow the transformation of sulfones directly into alkenes (54 – 96 %) 123. 
 
 
 
Figure 1.5 Modified one-pot syntheses via the Ramberg-Bäcklund reaction 
 
 
Furthermore, this one-pot Ramberg-Bäcklund approach has been applied towards the 
total synthesis of trans-resveratrol, 1 (Scheme 1.6) 124. 
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Scheme 1.6 Synthesis of trans-resveratrol via the Ramberg-Bäcklund coupling reaction 
 
 
The construction of the C=C double bond in stilbenes has also been reported via the 
condensation of an aromatic aldehyde, with a methylarene or phenylacetic acid, this 
approach is known as the aldol-type condensation 9.  
A novel approach to the synthesis of trans-resveratrol, 1, via an aldol-type coupling 
reaction was published studied by Poulnin (Scheme 1.7). The reaction involved the 
facilitated benzylic deprotonation of an η6-benzene-Cr(CO)3 analogue, followed by 
condensation with para-anisaldehyde, 65, in fair yields (56 %) 125. 
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Scheme 1.7 Synthesis of resveratrol via Aldol-type condensation  
 
 
The Perkin reaction 126 is commonly used to form α,β-unsaturated carboxylic acids, by 
the condensation of an aromatic aldehyde and acid anhydride, in the presence of an 
alkali salt of the acid, however modifications of the Perkin condensation have enabled 
the synthesis of stilbenes, via the coupling of benzaldehydes and phenylacetic acids, to 
afford stilbenoids, including resveratrol, 1, 102, 127-130, piceatannol, 7, 102, 131 and other 
stilbene analogues, with selectivity for the trans-isomer 132, 134. 
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In 2003 Solladié and co-workers 128 reported the synthesis of resveratrol, 1, via the 
condensation of 3,5-diisopropoxybenzaldehyde, 67, with 4-(tert-butoxyphenyl)acetic 
acid, 68, in the presence of acetic anhydride and triethylamine. The reaction 
proceeded via the subsequent decarboxylation of the acid intermediate, 69, in the 
presence of copper chromite, followed by isomerization of the product via reflux, 
using phenyl disulfide in THF, to afford the trans-isomer, 71, in excellent yield. 
Cleavage of the protecting group in the presence of BCl3 gave trans-resveratrol, 1, in 
good yield (85 %) (Scheme 1.8).  
 
 
 
Scheme 1.8 Synthesis of trans-resveratrol by the Perkin reaction 
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Other research groups have published similar work to this, including the coupling of                     
3,5-dimethoxyphenylacetic acid with the commercially available                                          
3,5-dihydroxyacetophenone, in the presence of acetic anhydride and triethylamine, to 
afford stilbenes in good yield 102. Additionally the work by Sinha et al., 127 offered 
both a benign and convenient route to the synthesis of resveratrol, 1, and various 
stilbenoids, in fair to good yields (41 – 71 %), using the modified Perkin reaction. 
This reaction involves a one-pot condensation of substituted hydroxybenzaldehydes, 
72, and phenylacetic acids, 73, in the presence of piperidine-methylimidazole and 
polyethylene glycol under microwave heating (Figure 1.6). Which in turn prevents the 
use of toxic quinoline-copper salt reagents in the decarboxylation step of the reaction. 
 
 
 
Figure 1.6 Coupling of substituted hydroxybenzaldehydes, using the modified Perkin 
reaction 127 
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1.6.2 Palladium catalysed coupling reactions 
 
The Heck reaction, also known as Mizoroki-Heck reaction is said to be an ineffective 
reaction, without the presence of a metal catalyst. This reaction mechanistically 
involves the coupling of a halide (R-X) via nucleophilic addition to an alkene, in the 
presence of mild bases, such as triethylamine, potassium carbonate or sodium acetate, 
in addition to a Pd catalyst to form an alkene.    
The use of the Heck cross-coupling reaction, in the synthesis of the natural stilbene 
resveratrol, 1, is well known. Guiso et al., have demonstrated an efficient synthetic 
route into the synthesis of resveratrol, 1, by the coupling of 3,5-diacetoxystyrene, 75, 
with the p-iodoarene derivative, 76. The reaction performed in the presence of 
palladium(II) acetate (Pd(OAc)2), 1 mol % and triphenylphosphine ligands gave solely 
the trans-isomer of resveratrol in excellent yields (99 %) (Scheme 1.9) 135. 
Additionally the syntheses of resveratrol, 1, and other stilbenoids have been reported 
by the coupling of an aryl halide with a styrene, in good yields 85, 136. 
 
 
 
Scheme 1.9 Synthesis of trans-resveratrol via the Heck coupling reaction in the presence of 
Pd(OAc)2 catalyst 
AcO
AcO
75
OAcI+
76
Pd(OAc)2, Ph3P, Et3N
CH3CN, 65 oC
AcO
AcO
77
OAc
NaOMe cat.
THF, MeOH
HO
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1
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Another study has reported the one-vessel synthesis of resveratrol, 1, (Scheme 1.10) 
via a two sequential Heck-type reaction 137. The synthesis of resveratrol, 1, in the 
presence of palladium(0) bis(dibenzylideneacetone) (Pd(dba)2) involved the coupling 
of the aryl halide (4-methoxyiodobenzene), 78, with vinyltrimethylsilane, 79, as the 
alkene equivalent, to give 4-methoxystyrene, under arylation-desilyation conditions. 
Subsequent removal of excess vinyl trimethylsilane and arylation of 4-methoxystyrene 
by 3,5-dimethoxyiodobenzene, 80, followed by demethylation of trans-3,5,4’-
trimethoxyresveratrol, 62, in the presence of boron tribromide / tetra-n-
butylammonium iodide gave resveratrol, 1, in good yield (85 %). This synthetic route 
performed in one-vessel, is efficient and extremely stereo-, regio- and chemo- 
selective yielding solely the trans-isomer. 
 
 
Scheme 1.10 Synthesis of trans-resveratrol, via the Heck cross coupling reaction, in the 
presence of Pd(dba)2 catalyst 
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Berthiol et al., 138 have also reported the highly chemo-, regio- and stereoselective 
synthesis of trans-stilbene analogues, via the coupling of simple linear alkenes to aryl 
halides in the presence of a newly developed Pd metal catalyst coordinated to the 
tedicyp ligand, 81, (Figure 1.7). This stable catalyst consisting of tetraphosphine 
ligands was believed to increase catalyst stability due to the ligands close proximity to 
the metal centre. An increased selectivity for the trans-alkenes has been reported to be 
influenced by a number of factors, first of all by chain length, the longer the alkyl 
chain, the greater the percentage of the E-isomer over the Z-isomer. In addition to the 
choice of halides, as reactions with aryl bromides were reported to be highly selective 
towards the trans-isomer, compared to other halides used 138. 
 
 
 
                                                               
 
Figure 1.7 Structure of cis, cis, cis-1,2,3,4-tetrakis(diphenylphospinomethyl) cyclopentane 
(tedicyp) 138 
 
Although some limitations of the Heck reaction include the oxidative degradation and 
side reactions that occur as a result of the phosphine. Furthermore the increased 
reactivity, selectivity of the reaction and percentage yield are known to be influenced 
by the type of electrophile used (ArI > ArBr >> ArCl). However studies have found 
the use of specific catalytic systems, such as palladium(II) acetate, 
tetraphenylphosphonium chloride (Ph4PCl/Pd), to increase the activity of these aryl 
halides (Table 1.6) 139, 140. 
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Table 1.6 Synthesis of resveratrol analogues via the Heck reaction 
 
 
Compound R1 Catalytic system 
(2 mol %) 
DMG 
(mol %) 
Conversion 
(%) 
Selectivity 
(trans:cis:1,1-
regioisomer) 
 
 
84 
 
 
H 
 
 
[Pd(MeCN)2Cl2] . 6 
Ph4PCl 
 
12 
 
96 
 
96 : 1 : 3 
 
85 
 
 
CHO 
 
Pd(MeCN)2Cl2] . 6 
Ph4PCla 
 
 
0.6  
 
96 
 
98 : < 1 : 3 
 
86 
 
H 
 
Pd(OAc)2 . 6 Ph4PCl 
 
 
12 
 
97 
 
97:  1 : 2 
87 H [Pd(MeCN)2Cl2].6 
Ph4PCl 
- 96 95:  1 : 4 
 
88 
 
H 
 
[Pd(MeCN)2Cl2] . 6 
Ph4PCl 
 
12 80 
 
97:  1 : 2 
a 0.1mol % 
 
 
The Heck reaction is considered to be an important reaction in chemistry, with the 
advantage of being versatile, very efficient and extremely stereoselective, whereby 
favouring the trans-geometric isomer. Palladium is the most popular and widely used 
metal in homogenous catalysis, as it enables the use of various functional groups in 
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the starting materials and results in high regio-and chemoselectivity, as a result of 
selecting the optimum reaction conditions. 
Palladium complexes such as Pd(0) and Pd(II), commonly coordinated to 
triphenylphosphine ligands are frequently used in Heck reactions, however these 
phosphine ligands in the Pd complexes have been suggested to affect the rate of 
catalysed reactions 104, 138.  
 
The Heck-Matsuda reactions can be performed using arenediazonium salts, in place of 
phosphine ligands and a base, though a catalytic loading of the palladium catalyst              
(1-2 mol %) is required 107. Nonetheless, the synthetic benefits of using 
arenediazonium salts have resulted in an increased interest, due the reaction offering 
high stereo- and regioselectivity. An example of this can be seen with the synthesis of 
the resveratrol analogue, DMU-212 (3,4,5,4'-tetramethoxystilbene), 63, in the 
presence of arenediazonium salt and the catalyst Pd2(dba)2 141. Additionally the use of 
an arenediazonium salt, with a catalytic loading of 2 mol % Pd2(dba)2·dba, gave 
DMU-212, 63, in quantitative yield after 20 minutes (Scheme 1.11). However, a lower 
catalytic loading resulted in longer reaction times, although gave the stilbene in 
excellent yield (> 90 %).  
In contrast, the synthesis of resveratrol, 1, was found to afford moderate yields                   
(< 57 %), in addition to a number of by-products under the same reaction conditions, 
using 4-methoxystyrene, 89, and the palladium catalyst (Pd2(dba)2·dba). There are 
many advantages with the use of arenediazonium salts as electrophiles in the Heck 
reaction, these salts are fast, cost effective, benign, stereoselective and easier to use 
compared to other traditional protocols.  
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Scheme 1.11 Synthesis of DMU-212 via the Heck-Matsuda coupling reaction 
 
 
Furthermore, the decarbonylative Heck reactions are proven to be effective in the 
synthesis of natural stilbenes, although the success of the reaction is also believed to 
be dependent on the type of base added; where amines including n-ethylmorpholine 
(NEM) and N,N-dimethylbenzylamine (BnNMe2), have been reported to be the most 
effective 142. Moreover, the versatility of this reaction enables the use of various 
substituted cyclic alkenes, aryl halides in the formation of trans-stilbenes 138, 143. 
Alternatively, decarbonylative Heck reactions using chlorides are becoming 
increasingly popular for the synthesis of stilbenes, specifically resveratrol analogues. 
This approach has many advantages, such as the reaction being relatively fast, in 
addition to the various aromatic carboxylic acids which can be used as precursors       
(Table 1.7) 142. 
 
 
 
 
 
 
 
 
89
N2BF4MeO+
90
Pd(dba)2 . dba (2 mol %)
NaOAc (3 eq.), PhCN
80 - 90 oC, 5h
63
OMe
MeO
OMe
OMe
MeO
MeO
+MeO
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Table 1.7 Decarbonylative Heck coupling 
 
 
Compound R Mol % Pd 
 
Ligand Base Time 
 (h) 
 
Yield  
(%) 
 
93 
 
Me 
 
5 
 
- 
 
NEM 
 
18 
 
75 
 
94  
 
95 
Me 
 
Me 
5 
 
5 
 
- 
 
-  
BnNMe2 
 
EtN(i-Pr)2 
18 
 
18 
52 
 
35 
 
96 
 
Ac 
 
1 
 
 
- Et3N 
 
3.5 
 
57 
97 Ac 1 - NEM 3.5 63 
 
98 
 
Ac 
 
1 
 
5 
 
Et3N 
 
3.5 
 
57 
 
 
Other reactions such as the Suzuki coupling reaction 86, 144 is an alternative Pd 
catalysed reaction, which also offers versatility, high selectivity and efficiency. This 
reaction involves the coupling of a halide with an organoboronic acid (aryl, alkyl, 
alkenyl or alkynyl) or alternatively with an organoborane or boronate ester or 
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potassium trifluoroborate substrate, in the presence of a palladium catalyst and a base, 
such as sodium ethoxide 145, 146. 
This reaction has its advantages such as giving both high regio- and stereospecificity, 
in addition to the easy synthesis of reagents and mild reaction conditions. The Suzuki 
coupling, as well as the modified Hunsdiecker-Suzuki approach have been reported in 
the synthesis of resveratrol derivatives147-149. However this strategy, to date, has not 
yet been applied to the synthesis of other peanut stilbenes.  
 
Conversely, the Stille reaction involves the palladium catalysed cross-coupling of 
organotin compounds (organostannanes) and aryl halide or alkenyl halide or triflate 
reagents. This approach has its benefits, besides being stereospecific and 
regioselective, as a variety of electrophiles can be used in this reaction. Furthermore 
this reaction is known to proceed without the need of a base, which gives the Stille a 
greater advantage over the Suzuki coupling. Additionally the organostannanes have 
been suggested to be suitable for use, in the presence of a wide range of functional 
groups, under mild conditions 92. However, to date the synthesis of natural peanut 
stilbenes via the Stille reaction has not been reported in the literature, possibly due to 
the toxicity of the organostannanes 150. Nonetheless with the hope of forming 
resveratrol analogues, Kang and co-workers, recently reported the synthesis of the 
stilbene, 2,3,6,2′,3′,6′-hexamethyl-4,4′-dihydroxy-trans-stilbene, 99, (Figure 1.8) via a 
one-pot Stille–Heck tandem reaction 151. 
 
 
Figure 1.8 2,3,6,2′,3′,6′-hexamethyl-4,4′-dihydroxy-trans-stilbene 
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Similarly only the synthesis of novel trans-stilbenes has been reported via the Negishi 
coupling reaction 152, 153. This reaction involves the cross-coupling of an organozinc 
reagent and an aryl halide or alkenyl halide or triflate, in the presence of a palladium 
catalyst. This route is considered stereoselective, versatile with regards to the 
functional groups present on the organohalide 152, 153, additionally this route is not 
limited to the formation of biaryls 93.  
Kabir et al., in 2007 154, reported the synthesis of stilbene derivatives, by the coupling 
of aryl or vinyl iodides with arylzinc reagents, 101, (Figure 1.9). This versatile 
approach was found to be advantageous, as various functional groups specifically 
heteroaromatic compounds could be used, with low catalytic loading, in the absence 
of a ligand. 
 
 
Figure 1.9 Synthesis of stilbene analogues in the presence of arylzinc reagents 
 
 
1.6.3 Non-palladium catalysed coupling reactions 
Other well-known alkene forming reactions such as the highly efficient olefin 
metathesis in the presence of a ruthenium catalyst, 103, 155 or molybdenum catalyst, 
104, (Figure 1.10) 156, to date have not been fully explored in the synthesis of natural 
stilbenes.  
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Figure 1.10 Structure of ruthenium and molybdenum catalyst 
 
 
This is primarily due to the complexity in controlling the selectivity and in particular 
the stereochemistry of the newly formed alkene bond, which often produces a mixture 
of geometric isomers, as a result of the direct cross coupling of two styrenes, and/or 
homo-dimerization 157. Nevertheless, studies reporting the synthesis of stilbenoids via 
olefin cross-metathesis are still somewhat limited 107, 158.  
In 2004, Grubbs and co-workers reported their study into the synthesis of 
stilbenoids, via cross metathesis, in the presence of a second generation Grubbs 
catalyst, 105, (Figure 1.11), with the use of a range of substituted styrenes 157. 
 
 
Figure 1.11 Structure of second generation Grubbs catalyst 
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Resveratrol, 1, was synthesised with high selectivity for the trans-isomer (95 %), via 
the cross-metathesis coupling of 3,5-dihydroxystyrene, 107, with excess                                        
4-hydroxystyrene, 106, in the presence of the ruthenium-carbene catalytic complex, 
105. Notably, the reaction also gave two other isomers; trans-3,3’,5,5’-
tetrahydroxystilbene, 110, and trans-4,4’,dihydroxystilbene, 109, (Scheme 1.12). 
 
 
 
Scheme 1.12 Synthesis of resveratrol via cross-metathesis 
 
 
Additionally Chang and co-workers in 2002, reported the solid-phase cross metathesis 
using supported styrenyl ethers with styrene derivatives in the presence of the 
ruthenium carbene catalytic complex (SIMes)(PCy3)Cl2Ru=CHPh, 111, (Figure 1.12). 
This approach efficiently produced resveratrol, 1, and other stilbenoid analogues, in 
good to excellent yields (77 – 98 %), whilst providing 100 % stereoselectivity for the                       
trans-isomer. The study demonstrated a benefit of using a solid-phase system for the 
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cross metathesis for the synthesis of alkenes, as when a solution-phase metathesis was 
used instead, stereoselectivity was not observed. 
 
 
 
 
Figure 1.12 Structure of ruthenium carbene catalytic complex 
 
 
Although scarcely reported for the synthesis of natural stilbenes, the solid phase cross 
metathesis offers a benefit, with regards to easy separation of the product, from the 
reaction mixture upon completion 159, though the presence of a solid-phase system has 
been reported to result in slightly slower reaction rates. 
According to Chang and co-workers, the Merrifield resin was found to be most 
suitable in supporting various styrenyl derivatives in a solution of benzene. The 
subsequent cleavage and filtration of the resin with trifluoroacetic acid (TFA) in 
dichloromethane, gave stilbene analogues with complete trans-selectivity (Scheme 
1.13) 158.  
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Scheme 1.13 Synthesis of stilbene analogues via solid phase cross metathesis 
 
Conversely, the McMurry coupling reaction offers an alternative approach to the 
synthesis of the C=C bond, via the reductive dimerization of two aldehydes or 
ketones, in the presence of a low-valent titanium catalyst (TiCl4) 91. This reaction has 
its disadvantages, as it known to produce geometric isomers, and is limited to the use 
of molecules possessing a carbonyl (C=O) moiety. Nonetheless the McMurry reaction 
has been shown to be successful in the synthesis of a number of stilbene derivatives 
160-162, in moderate yields (Table 1.8) 163. However, this approach has not yet been 
reported in the synthsis of peanut stilbenoids. 
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Table 1.8 Synthesis of synthetic polyalkoxy- and polysilyoxystilbenes  
 
 
 
Compound Benzaldehyde 
 
(R1) 
Stilbene 
 
(R1) 
Yield  
 
(%) 
 
119 
 
2-Methoxy 
 
2,2’-Dimethoxy 
 
71 
 
120 
 
3-Methoxy 
 
3,3’-Dimethoxy 
 
57 
 
121 
 
3,5-Dimethoxy 3,3’, 5,5’-Tetramethoxy
 
 
42 
 
122 
 
4-t-Butyldimethylsilyloxy 
 
4,4’-di-t-Butyldimethylsilyloxy 52 
 
123 
 
3,5-di-t-
Butyldimethylsilyloxy 
 
3,3’,5,5’-Tetra-t-
butyldimethylsilyloxy 
 
79 
 
 
 
1.7 Resveratrol Analogues 
Recently within the literature, various resveratrol derivatives have been designed and 
developed (Pan et al., 2009), in the hope of identifying an efficacious anticancer 
agent. Compounds possessing methoxy moieties around the stilbene scaffold, such as 
the analogue MR-5, 124 (Figure 1.13), have been extensively researched and found to 
display increased chemopreventative and/or chemotherapeutic properties, in vitro. 
Moreover these stilbene analogues have been reported to display greater potency 
compared to resveratrol, 1164-167. 
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Figure 1.13 Structure of resveratrol analogue MR5 
 
 
Several novel sulfonamides have also been reported to exhibit antitumour activity via 
a number of mechanisms, including acting on polo-like kinase (PLK) enzymes; which 
are involved in mitotic events 168, mitotic cell cycle arrest, apoptosis in the M-phase of 
cell growth, inhibition of microtubule assembly 169, as well as targeting the G1 phase 
of the cell cycle in cancer cells 170.  
Recently, stilbene benzenesulfonamides, 125, possessing a primary sulfonamide 
moiety (SO2NH2), have been reported to display promising cancer chemopreventative 
164, 171, 172 and anti-inflammatory activity 173. As a number of studies have reported a 
link between compounds possessing a sulfonamide moiety and antitumour properties, 
it has led to the synthesis and study of other novel benzenesulfonamide analogues169, 
170, 174. 
 
 
1.7.1 Benzenesulfonamides 
 
In 2002, stilbene benzenesulfonamide analogues, 125, derived from trans-resveratrol, 
1, (Figure 1.14) were designed by Yang and co-workers in order to study their activity 
against the NCI-60 human tumour cell line 6.   
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Figure 1.14 trans-stilbene benzenesulfonamide analogues 
 
 
Albeit lengthy and requiring a total of 6-7 synthetic steps, the approach developed by 
Yang et al., enabled the synthesis of seven novel stilbene benzenesulfonamide 
analogues, 125a – 125g, (Figure 1.15), possessing a primary sulfonamide moiety 
(SO2NH2).  
 
 
 
Figure 1.15 Structure of novel stilbene sulphonamide analogues 
 
 
The initial step towards the synthesis of these compounds involved diazotization of 
the sulphanilamide, 126, to generate the diazonium salt, 127, followed by the 
Sandmeyer reaction in the presence of potassium cyanide/copper sulfate pentahydrate, 
to generate the benzonitrile, 128, (53 %). Subsequent Stephen reduction of the 
benzonitrile with Raney nickel in acid formed benzaldehyde, 129, (86 %), and 
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reduction of the aldehyde in the presence of sodium borohydride gave the alcohol, 
130, in good yield (92 %). Treatment with phosphorous tribromide followed by 
triethyl phosphite formed phosphonate 132, next Wittig-Horner coupling using the 
diethyl phosphonium salt with a range of benzaldehydes gave the desired trans-
stilbene benzenesulfonamides, 125a – 125g (Scheme 1.14).  
 
 
Scheme 1.14 Synthesis of stilbene benzenesulfonamides, via the Wittig-Horner coupling 
reaction 
 
The in vitro studies, from the work published by Yang and co-workers, noted that 
benzenesulfonamides possessing a 4-fluoro, 125a, or 3-methoxy, 125d, moiety were 
found to exhibit significant selective activity against breast; BT-549 (GI50 0.205 µM), 
and colon; HT-29 (GI50 0.554 µM) tumour cell lines, respectively 6. Although the 
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activity of these novel compounds were not compared to the control, the stilbene 
benzenesulfonamide analogues show promising activity, however their mechanism of 
action still needs to be understood.   
The synthesis of stilbene benzenesulfone and benzenesulfonamide derivatives 
in the form of styrylheterocycles has also been achieved. The synthetic method 
reported by Lim et al., details the Wittig reaction to couple the 4-
(methylthio)benzaldehyde, 133, with various phosphonium bromides, 134a – 134d. 
This approach proceeds via the oxidation of the 4-methylthio moiety with an aqueous 
Oxone® solution, to provide the methylsulfone analogues, 136a – 136d, which can 
then be converted to the corresponding sulfonamides, 138a – 138d, in two subsequent 
steps (Scheme 1.15) 7. 
 
 
 
Scheme 1.15 Synthesis of benzenesulfone and benzenesulfonamides analogues, via the Wittig 
reaction 
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When the benzenesulfone analogues were evaluated for their inhibitory activity 
against lipopolysaccharide (LPS) stimulated RAW 264.7 murine macrophage cells, 
these novel compounds were found to result in up to five times reduced potency, 
compared to the lead compounds, 139(a-d), possessing a para-OMe moiety (Figure 
1.16) 175. 
 
 
 
Figure 1.16 Structure of styrylheterocyclic analogues 
 
 
Alternatively the benzenesulfonamide analogues, possessing the thiophene 
functionality, 138c and 138d, were reported to be either as equipotent (138d), or 
found to exhibit a 40-fold greater potency (138c), compared to the furan derivatives, 
139c and 139d, with IC50 values of 0.013 µM and 0.44 µM, respectively. Furthermore, 
benzenesulfonamides possessing a furan moiety, 139a and 139b, were found to either 
display decreased potency (IC50  1.18 µM) or were ineffective (IC50  > 50 µM) 173. 
In relation to SAR, the presence of a sulfonamide (p-SO2NH2) or a 
methylsulfone (p-SO2Me) moiety and the aromatic ring in stilbene 
benzenesulfonamide analogues, were suggested to be essential in providing the 
highest efficacy, with regards to selectivity, potency towards COX-2 inhibition, as 
these pharmacophores have been said to interact with the COX-2 side pocket through 
tight-binding kinetics 173, 176. When molecular modelling studies were performed, in 
order to determine the interaction of the most potent benzenesulfonamide, 138c, with 
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the COX-2 protein. The docking study found that the spatial location of the p-SO2NH2 
moiety in compound, 138c, and the celecoxib analogue (SC-558), 140, partially 
overlapped (Figure 1.17). Additionally, the benzenesulfonamide moieties in both 
groups were superimposed, and were reported to interact with the amino acid residues 
lining the COX-2 binding site. Furthermore hydrogen bonding was observed between 
the two oxygen atoms within the SO2NH2 moiety and the backbone (N-H) of both 
His90 and Arg513 (distance = 2.87 Å). 
 
 
Figure 1.17 Structure of benzenesulfonamide analogue (138c) and SC-558 
 
Additional hydrogen bonding was also observed between the nitrogen atom in the 
SO2NH2 group and the backbone carbonyl in Gln192 (3.72 Å), Phe518 (3.84 Å) / 
Leu352 (4.12 Å) (Figure 1.18) 7. 
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Figure 1.18 Docking model of compound 138c, (shown in purple) and SC-558, 140, (shown in 
grey) overlaid within the active site of COX-2 (Protein Data Bank code 1CX2). Hydrogen bonds 
and possible hydrogen bonds indicated by red dashed and orange solid lines, respectively. The 
key amino acid residues are shown in green 7. 
 
 
1.7.2 Phenylazobenzenesulfonamides & derivatives 
 
 
Further studies have discovered a range of phenylazobenzenesulfonamide derivatives, 
141, to display increased potency and selectivity towards the COX-2 protein177-179. 
In order to increase the potency and selectivity, other novel analogues were designed 
based on the lead compound resveratrol, 1. These benzenesulfonamides, 141, 
comprised of a para-sulfonamide functionality, in-place of the para-hydroxyl moiety, 
and the bioisosteric substitution of the central ethylenic linkage with an azo N,N-
double (N=N) bond (Figure 1.19). 
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Figure 1.19 Structure of resveratrol and the general structure of 
phenylazobenzenesulfonamides 
 
The synthesis of these benzenesulfonamide analogues, via the coupling of an aryl 
diazonium salt and various substituted phenols has been reported 180. However Lin 
and co-workers, in 2008 successfully developed the synthesis of 
phenylazobenzenesulfonamides in accordance with the work by Yang et al., 6 via 
diazotization of the sulfanilamide and subsequent coupling of the aryl diazonium salt 
with various substituted aromatic substrates (Scheme 1.16). 
 
 
Scheme 1.16 Synthesis of phenylazobenzenesulfonamide analogues 
Catechol	
and
phenyl	isocyanate
or
4-isopropylphenyl	isocyanate
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Two years later, the synthesis of 4-benzylideneamino- , 146, and 4-
phenyliminomethyl-benzenesulfonamides, 147, (Figure 1.20), constructed by the 
bioisosteric replacement of the central ethylenic –C=C– bond with a –N=C– or –
C=N– double bond were reported 177. 
 
 
 
 
Figure 1.20 Generic structure of 4-benzylideneamino- and 4-phenyliminomethyl-
benzenesulfonamides 
 
 
The various trans-4-benzylideneamino benzenesulfonamide derivatives, 146,                  
(15 – 88 %) were formed by the coupling of a sulfanilamide, 126, with a substituted or 
protected benzaldehyde (Scheme 1.17). When these novel benzenesulfonamide 
analogues were evaluated for their selectivity and potency towards COX-2 inhibition, 
using a human whole blood (HWB) assay. The electron withdrawing groups (F, NO2 
and CO2Me), particularly when monosubstituted at the para-position to the 
sulfonamide moiety, were found to display both increased inhibitory activity and 
selectivity towards the COX-2 enzyme. For instance, benzenesulfonamides; 
possessing carboxylic (3-CO2H), 146d, and hydroxyl (4-OH), 146c, moieties were 
reported to exhibit a significant increase in both potency (IC50 = 0.74 µM) and 
increased selective COX-2 inhibitory activity (SI = 114.5), compared to resveratrol, 1, 
(SI = 0.1) as well as the nonsteroidal anti-inflammatory drug (NSAID) celecoxib (SI = 
78), furthermore compounds comprising of either 3,4,5-trimethoxy or 4-hydroxy-3,5-
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dimethoxy moieties were found display increased selective COX-2 inhibitory activity 
181.   
 
 
Scheme 1.17 Synthesis 4-benzylideneamino benzenesulfonamide derivatives 
 
Conversely, analogues possessing an electron donating groups; such as 4-methyl and 
4-methoxy moieties, as well as with the electron withdrawing 4-trifluoromethyl group 
displayed reduced COX-2 selectivity. Overall, the COX-2 selectivity displayed by 
these compounds proceeded in the following hierarchy, when the functional groups 
were position on ring ‘B’; 4-F > 4-CO2Me > 4-NMe2 > 4-NO2 > 4-OH > unselective 
3-NO2. 
Alternatively the design of 4-phenyliminomethyl-benzenesulfonamide analogues, 147, 
proceeded via the modified method reported by Yang et al., (Scheme 1.18) 6, in the 
presence of methanol 177 and the potency and selective inhibitory activities of this 
series of 4-phenyliminomethyl compounds, 147a – 147j, were evaluated against both 
COX-1 and COX-2 isozymes. A reduced selectivity was observed overall, especially 
with the benzenesulfonamide possessing a 4-N,N-dimethylamino, 147e, moiety (SI = 
33.0).  
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Scheme 1.18 Synthesis of 4-phenyliminomethyl-benzenesulfonamide analogues 
 
 
Additionally, the recently synthesised novel pyridine acyl sulfonamide analogues, 
have been found to display enhanced inhibitory activity (IC50 = 0.8 µM), when 
examined in vitro on murine macrophage RAW 264.8 cell lines, a number of the 
analogues exhibited good inhibitory activities against PGE2 production, with IC50 
values ranging between 0.15 – 2.8 µM. Furthermore, these benzenesulfonamides were 
reported to be more potent than celecoxib in inhibiting the growth of melanoma (B-
16-F10), liver (HepG2) and breast (MCF-7) cancer cell lines, with no toxicity as a 
drug compound 179. 
  Although, the current studies show promising activity, the mechanisms into 
how these novel benzenesulfonamides exhibit their activity, remains to be reported. 
However, potential lead parent compounds, of which display increased selectivity 
towards cancer cell lines, compared to current therapeutic medicines, have been 
highlighted as either potential drug candidates or lead compounds for further study 138. 
 
 
 
Chapter 1: General Introduction 
 
 
71 
Peanut phytoalexins are of great interest due peanuts being a dietary source, of which 
these bioactive compounds can be administered into the body 182. Apart from 
resveratrol, 1, these natural compounds are currently unavailable within the 
commercial market and because of this, the use of these natural polyphenols within 
the pharmaceutical industry remains limited.  
Although, the biological properties of trans-resveratrol, 1, has been predominately 
explored 192 – 194, the biological effects of other prenylated stilbenoids, specifically 
arachidin-1, 2, to date has not been extensively explored, especially with regards to 
the pharmacokinetic properties of this natural compound. Therefore the design and 
synthesis of natural peanut phytoalexins as well as their analogues are of interest and 
are essential for further in vitro and in vivo studies.  
The aim of this work was therefore to investigate routes towards the synthesis 
of arachidin-1, 2, in order to synthesise an authentic sample of arachidin-1, 2. An 
additional aim was to investigate and develop methods towards the synthesis of novel 
resveratrol analogues, possessing various substituents groups around the aryl rings.  
Palladium catalysed reactions have been shown to be efficient in the formation of the 
stilbene backbone, however with less regioselectivity. Although the literature has 
proved that the regioselectivity of these catalysed reactions can be controlled, other 
issues (as discussed in Section 1.6.2) still remain. The formation of the ethylene-
linkage via traditional methods such the HWE reaction has proved, within the 
literature to be a favoured and successful approach for the synthesis of natural 
stilbenes and their derivatives, therefore the use of the HWE reaction will be explored 
in this research. 
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1.8 Summary 
 
Stilbene phytoalexins isolated and characterised from the peanut, Arachis hypogaea, 
plant; in particular trans-resveratrol, 1, and trans-arachidin-1, 2, have been found to 
display an array of promising biological and therapeutic properties. The analogues of 
resveratrol, in particular stilbene benzenesulfonamides, possessing a primary 
sulfonamide moiety have been reported to exhibit promising cancer 
chemopreventative and anti-inflammatory activity compared to resveratrol, 1. 
Methodologies into the synthesis of various peanut stilbenoids, specifically  
resveratrol, 1, have been established and developed. However, the need for a reliable 
and stereoselective approach for the synthesis of trans-arachidin-1, 2, and other novel 
peanut phytoalexins still remains. 
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Chapter Two 
 Synthesis of Arachidin-1: Part I 
 
2.1 Strategy for the synthesis of arachidin-1 
 
The first stage of this study was to examine a suitable coupling reaction, which would 
allow the construction of the trans-stilbene backbone. The volume of literature detailing 
methods for the synthesis of stilbenes and the formation of the C=C double bond is vast 9, 
91, 98, 103, 105, 107, however the Horner-Wadsworth-Emmons (HWE) reaction has been 
shown to be an effective and reliable route for the synthesis of resveratrol, 1, and its 
derivatives 9, 22, 106, 111. As well as natural products, including palmerolide A; a cytotoxin 
isolated from the antarctic marine tunicate Synoicum adareanum 183, with high selectivity 
for the trans-isomer 184. 
Additionally, the recent reported synthesis of the naturally occurring peanut prenylated 
stilbenes, trans-arachidin-2, 8, and trans-arachidin-3, 9, by Park and co-workers 84 has 
further demonstrated the use of this ‘traditional’ approach, to be an adaptable method.   
Once the reaction conditions for the formation of the stilbene skeleton have been 
established, it would then enable the study of strategies towards the synthesis of                 
arachidin-1, 2, to be performed, and give scope to investigate other routes towards the 
synthesis of novel resveratrol analogues. 
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In this chapter the synthetic strategy towards the synthesis of arachidin-1, 2, is 
described, the first proposed approach which was adapted from the work reported by Park 
et al., 84 is outlined, whereby selected silyl ethers were used for the hydroxyl protection of 
3,4-dihydroxybenzaldehyde, 150. The silyl ether selected for this reaction was of 
importance, as it was necessary for the protecting group to be able to withstand the 
various basic and/or acidic reactions, the aldehyde would be involved in. Next coupling 
via the HWE reaction with the protected benzaldehyde, 151(a-b), and diethyl 3,5-
dimethoxybenzylphosphonate, 153, which was synthesised from the substituted benzyl 
bromide, 152, via the Michaelis Arbuzov reaction 185 would afford the stilbene backbone. 
Once the stilbene skeleton was formed, the next step would be demethylation using a 
strong acid such as boron tribromide, this would then allow for the introduction of the 
side chain and finally cleavage of the silyl ether protecting groups, to give the target 
compound, as shown in Scheme 2.1. 
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Scheme 2.1 Synthetic strategy into the synthesis of trans-arachidin-1 
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2.2 Synthesis of branched and un-branched trans-alkenes 
The majority of this work involved coupling to form the trans-stilbene backbone, 
therefore initial studies into the synthesis of trans-arachidin-1, 2, began by performing 
model reactions in order to examine, with regards to the boundaries of this research, if 
the HWE reaction, under the chosen reaction conditions would be effective in forming 
the trans-alkene. The study began by exploring the synthesis of branched, 157, and 
unbranched, 158, trans-alkenes (Figure 2.1).  
 
 
Figure 2.1 Structure of branched and unbranched trans-alkenes 
 
 
The first model reaction investigated was the coupling of the commercially available        
3,5-dimethoxybenzaldehyde, 159, with diethyl propylphosphonate, 160, in the 
presence of sodium methoxide (Scheme 2.2). It was anticipated that the use of this 
base, would be sufficient to drive the formation of the phosphonate carbanion and the 
subsequent nucleophilic addition of the carbanion to the aldehyde 103. Nevertheless, 
the reaction did not go to completion and failed to result in the desired product, 
despite the addition of extra sodium methoxide. 
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Scheme 2.2 Attempted coupling via the Horner-Wadsworth-Emmons reaction 
 
Analysis of the reaction mixture (1H NMR) indicated the presence of both starting 
materials, and it was likely that the lack of stability displayed by the aliphatic 
phosphonate carbanion, may have been the cause of this unsuccessful reaction 110, 113.  
The use of stabilised phosphonate carbanions are known to be essential for the HWE 
reaction, therefore coupling using diethyl benzylphosphonate, 162, was attempted 
(Scheme 2.3). The benzylphosphonate carbanion is known to be stabilised by 
delocalisation from the aromatic ring, therefore when coupled with 2-methylpropanal, 
163, in the presence of sodium methoxide, this reaction gave a mixture of compounds; 
the desired compound (E)-(3-methylbut-1-en-1-yl)benzene, 157, (25 %), phosphonate, 
162, (55 %) and aldehyde, 163, (20 %). Although the reaction did not go to 
completion, it is possible that longer reaction times may be required in order to obtain 
higher yields of the alkene. 
 
 
Scheme 2.3 Coupling via the Horner-Wadsworth-Emmons reaction using 2-methylpropanal 
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Nevertheless, formation of the desired C=C bond was evident by characterisation of 
the 1H NMR spectrum, whereby two doublets at δ 6.00 ppm and δ 6.18 ppm, were 
observed. Furthermore, the calculated J couplings of the two doublets (JAB = 16 Hz 
and JAB = 15.9 Hz), confirmed the formation of the desired trans-alkene, 157. This 
therefore proved the traditional HWE reaction, with the use of a stabilised 
phosphonate, to be a good approach not only for the synthesis of the trans-stilbene 
backbone, but also potentially for the incorporation of the prenyl side-chain.  
 
 
2.3 Preparation of starting materials 
 
2.3.1 Arbuzov reaction 
Several alternative methodologies for the synthesis of diethyl benzylphosphonate 
(Scheme 2.4), are detailed in the literature, however the traditional and most 
commonly used method is the Michaelis-Arbuzov reaction 185, 186.  
 
 
Scheme 2.4 Synthesis of benzylphosphonates 
 
 
The first method, reported by Michaelis and further developed by Arbuzov, involves 
nucleophilic attack of the phosphorus atom towards an halide, followed by 
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dealkylation of the intermediate, via a second SN2 nucleophilic attack to afford the 
phosphonate ester187, this substrate is commonly used for coupling reactions such as 
the HWE reaction 110, 112.  
Variations of this rearrangement, are also known; including the Lewis acid-mediated 
Michaelis-Arbuzov reaction 188, reductive coupling 189, palladium-(0)-catalysed cross-
coupling reaction 190, 191, and the conversion of benzyl alcohol to benzylphosphonate, 
via zinc mediated reactions 192. However the Michaelis-Arbuzov reaction is known to 
be the most favoured approach due to the excellent yields obtained and the use of 
inexpensive reagents 185, 186. 
In this study, the Arbuzov reaction between 3,5-dimethoxybenzyl bromide, 152, and 
triethyl phosphonate (1 equiv.), was performed and gave the desired compound, 153, 
in excellent yield (98 %) (Scheme 2.5). Based on optimised reaction conditions 
performed, this reaction proceeded smoothly when stirring at >130 °C for 24 h. The 
formation of the new CH2-P bond was confirmed by 1H NMR, whereby a doublet at δ 
3.06 ppm, integrating to two protons (CH2) was observed on the spectrum.  
 
 
 
Scheme 2.5 Michaelis-Arbuzov reaction with triethyl phosphite 
 
Additionally a large 2JPH value was calculated (J = 21.6 Hz), which was characteristic 
of the geminal coupling between 31P and 1H, therefore confirming the phosphonate, 
153, had been formed.  
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2.3.2 Hydroxyl group protection 
The next step of this methodology was to perform hydroxyl protection on the 
aldehyde, 150. Within the literature there were a number of strategies for the 
protection of the hydroxyl moieties, one approach considered was the conversion of 
the OH functional groups into their corresponding ethers; for example alkyl, allyl or 
benzyl ethers. However, allyl ethers and trityl ethers, although stable under basic 
conditions were very acid-labile, therefore were not an option.  
The use of alkyl and benzyl ethers at first were an attractive approach, however as 
both functional groups were known to be relatively unstable in basic, acidic, and harsh 
conditions 193, it was likely that cleavage of these protecting groups would occur 
during the demethylation stage of this methodology (as detailed in Scheme 2.1), in the 
presence of boron tribromide 194, 195, based on this the alkyl and benzyl ether 
protecting groups were no longer a viable option 
Another option, in relation to the protection of the hydroxyl groups, would be 
to convert the groups into acetals, such as methoxymethyl ether 194 or 
benzyloxymethyl ether derivatives. These groups are commonly known to be stable 
under basic conditions, moreover they are relatively stable under mild acidic 
conditions. Additionally, as shown by Park and co-workers 84, in the synthesis of 
peanut prenylated stilbenes, 8-9, these protecting groups were easy to cleave when 
incorporated as part of phenols. However, these protecting groups were not selected in 
this study as they are also known to be unstable during purification via column 
chromatography193. Furthermore some acetal reagents are recognized carcinogens, 
such as methoxymethyl chloride (MOMCl), although an alternative route to the 
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formation methoxymethyl esters, has been suggested via the use of dimethoxymethane 
195 and is suggested to be less harmful. 
Nevertheless, the conversion of the alcohol, 150, into silyl ethers, tert-
butyldimethylsilyl (TBDMS) or triisopropylsilyl (TIPS) group 84, 196, was both 
attractive and plausible protecting groups to use in this approach, due to the silyl 
ethers displaying stability in both basic and mild acid conditions, in addition to their 
selectivity towards primary (1°) alcohols and facile cleavage, in the presence of a 
fluoride ion or aqueous acid. Furthermore, these inexpensive protective groups have 
been frequently used as hydroxyl protecting group in the literature193, 197, 198.  
It was therefore decided that protection of 3,4-dihydroxybenzaldehyde, 150, would be 
explored using two different silyl ethers (TBDMSCl and TIPSCl) as both protecting 
groups offered different stabilities in acidic and basic media (Figure 2.2).  
 
 
 
 
Figure 2.2 Stability of common silyl ethers toward acidic/basic media 193 
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2.3.2.1 Hydroxyl protection using tert-butyldimethylsilyl chloride 
 
The first hydroxyl group protection was attempted using TBDMSCl (2.2 equiv.), 
under basic conditions (Scheme 2.6). In accordance with the literature 203, the 
optimised reaction conditions performed in this work identified the addition of the 
base DMAP, in excess to be essential in order to accelerate the reaction. Purification 
via flash chromatography, following aqueous work up of the reaction mixture gave the 
desired TBDMS protected aldehyde, 151a, in almost quantitative yield 97 %.  
 
 
Scheme 2.6 Hydroxyl protection of 3,4-dihydroxybenzaldehyde with TBDMSCl 
 
Characterisation of the silyl protected aldehyde, 151a, was performed by NMR and 
MS, from the 1H NMR spectrum singlets at δ 0.00 ppm, integrating to 12 protons (Si-
Me) and at δ 0.82 ppm, integrating to 18 protons (6 x Me) were observed, therefore 
confirming hydroxyl protection with TBDMSCl was successful. Furthermore from the 
13C NMR spectrum the carbon nuclei, present within the silyl ether moieties were 
observed at; δ -3.63 ppm (Si-Me), δ 17.9 ppm (C-t-butyl) and δ 25.6 ppm (Me), 
respectively. Additionally the mass spectral data additionally confirmed the success of 
the reaction, with a molecular ion peak of m/z = 369. 
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2.3.2.2 Hydroxyl protection using triisopropylsilyl chloride 
 
Following the same procedure used for the TBDMSCl reaction, protection of 3,4-
dihydroxybenzaldehyde, 150, was attempted using TIPSCl (Scheme 2.7). 
 
 
 
Scheme 2.7 Hydroxyl protection of 3,4-dihydroxybenzaldehyde with TIPSCl 
 
 
Characterisation of the product suggested that a mixture of compounds had been 
made, in this mixture the desired compound, 151b, with a purity of 86 % was 
identified, and compound, 168, which appeared to have only one protected silyl ether 
moiety (14 %) was also observed via 1H NMR analysis (Scheme 2.8). Additionally, 
formation of the two compounds were observed by mass spectral analysis, whereby 
molecular ion peaks at m/z = 293 (C16H26O3Si) and m/z = 450 (C25H46O3Si2), 
respectively were seen, therefore indicating the reaction did not to go to completion, 
and as a result purification proved to be challenging and was repeated a number of 
times.  
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Scheme 2.8 Attempted synthesis of 3,4-bis((triisopropylsilyl)oxy)benzaldehyde 
 
 
2.4 Horner-Wadsworth Emmons coupling reaction 
 
 
The construction of the stilbene was first attempted via the HWE reaction, using the 
TIPS protected aldehyde, 151b, and the phosphonate, 153, in the presence of NaOMe 
(5 equiv) (Scheme 2.9). However the reaction was not successful, this was evident 
when characterised by both 1H and 13C NMR, as the spectra did not show the presence 
of the ethylenic linkage. However what was observed were the two starting materials, 
with the presence of the phosphonate distinctly present in the 13C NMR spectrum. 
 
 
 
Scheme 2.9   Attempted synthesis of (E)-((4-(3,5-dimethoxystyryl)-1,2-
phenylene)bis(oxy))bis(triisopropylsilane) 
 
Next coupling via the HWE reaction was attempted again, however this time with the 
use of potassium tert-butoxide (3-4 equiv) and THF, as alternative reagents. Upon 
immediate addition of the aldehyde, 151a, to the phosphonate, 153, a colour change 
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from white to yellow was observed, along with the release of heat energy from the 
flask, which was indicative that nucleophilic addition as well as the subsequent 
elimination was occurring. The removal of the phosphate by-product, via solvent 
extraction, gave the trans-stilbene in a yield of 79 %, which was similar to the yields 
reported by Park et al., when MOM (82 %) and TIPS (80 %) protected stilbenes were 
synthesised in the literature 84. Although in this work, the results also showed the 
presence of another stilbene, 169, when characterised by 1H NMR, and the presence of 
the two compounds, were additionally confirmed by both mass spectral and TLC 
analyses, whereby multiple spots were observed. From the mass spectral data the 
molecular ion peak (m/z = 589) of the desired compound, 154b, was observed, 
additionally the molecular ion peak of                m/z = 427 was also identified, which 
suggests that a stilbene, 169, possessing the molecular formula of C25H35O4Si was also 
formed (Scheme 2.10). 
 
 
Scheme 2.10   Synthesis of (E)-((4-(3,5-dimethoxystyryl)-1,2-
phenylene)bis(oxy))bis(triisopropylsilane) 
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Based on the molecular ion peak value observed, it was possible that cleavage of one 
TIPS protecting group had occurred. A suggestion as to why one TIPS groups was 
observed, could be due to the protecting group being unstable in the acidic silica 
stationary phase, during purification via column chromatography. If the acidic 
stationary phase was the cause of the TIPS protecting group cleaving, an alternative 
option could be to use a non-silica based stationary phase, however these stationary 
phases are known to be more expensive.  
Next, it was decided upon to investigate and determine, if the TDBMS 
protected aldehyde would be stable under both basic reaction conditions (HWE 
coupling) and acidic conditions (purification via column chromatography). Following 
the same procedure as above, coupling of the aldehyde, 151a, with the diethyl 
benzylphosphonate, 153, was examined (Scheme 2.11), the reaction was found to be 
successful in producing solely the trans-alkene. The 1H NMR analysis indicated the 
presence of two doublets at δ 7.10 and δ 7.23 ppm, respectively, integrating to 2 
protons (HC=CH), with J-coupling values of 16.5 Hz and 16.8 Hz, respectively, 
thereby confirming the formation of the ethylene linkage. 
 
 
 
 
Scheme 2.11 Attempted synthesis of stilbene derivative 
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However, characterisation of the spectrum also suggested that the silyl protecting 
group had been cleaved, to afford compound, 170 (87 %), attempts were made to 
separate the mixtures, however due to similar Rf values, this proved to be challenging. 
Interestingly, cleavage of the TBDMS protecting groups have also been reported in 
the literature, via the Wittig reaction 135.  
The successful construction of the stilbene backbone, as suggested by Wadsworth and 
co-workers 110, involves the phosphoryl-stabilised carbanion attacking the carbonyl, 
via nucleophilic addition, to give the betaine intermediate, which is suggested to be 
the rate limiting step in the formation of the alkene (Figure 2.3). 
 
 
 
 
Figure 2.3 Mechanistic approach for the Horner-Wadsworth-Emmons reaction 
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The carbonyl is thought to approach the C-P bond at a 90° angle, this antiperiplanar 
approach in relation to steric effect is said to be most favoured (Figure 2.4) 104, 110. 
Both the cis- and trans-oxaphosphetane intermediates are said to lead to stereospecific 
syn-elimination, and result in the formation of both cis- and trans-alkenes, 
respectively. 
 
 
 
 
Figure 2.4 Steric approach between the phosphoryl stabilised carbanion and the carbonyl  
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Although this is not fully understood, it is suggested that under kinetic conditions, the 
product initially formed is the cis-oxaphosphetane diastereoisomer, 177, which 
consequently affords the cis-isomer, 178(a-b). However the reversibility of the 
intermediate affords predominately the trans-isomer, 154(a-b), under thermodynamic 
conditions, due to the trans-oxaphosphetane, 175, being more stable. This theory has 
been supported by both kinetic and spectroscopic studies, of which have shown that 
the stereochemistry in the HWE reaction can be explained by stereoselectivity in the 
initial C-C bond formation step, in addition to the reversibility of the two 
intermediates. It is also suggested that the thermodynamically stable isomer, which 
leads to the formation of the trans-alkene, is due to the bulky aromatic rings of which 
are positioned on either side of the carbon-carbon bond within the ring (Figure 2.5) 
103.  
 
 
 
 
 
 
 
 
 
Figure 2.5 3D configurations of trans- and cis-oxaphosphetane intermediates  
(Calculated from Cambridgesoft ChemBioDraw Ultra software v.14.0.0.117) 
 
trans-oxaphosphetane intermediate 
 
cis-oxaphosphetane intermediate 
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2.5 Summary 
The silyl ether protected benzaldehydes, 151a and 151b, were synthesized, using 
either TBDMS or TIPS groups, as hydroxyl-protecting moieties.                                                                 
The 3,4-dihydroxybenzaldehyde, 150, was most conveniently transformed into the 
TBDMS or TIPS ether in the presence of DMAP in excess. Furthermore formation of 
the stilbene skeleton was found to be successful via the HWE coupling reaction, 
however only by coupling of the TIPS protected aldehyde, 151b, with diethyl 
benzylphosphonate, 153, in the presence of t-BuOK and THF. According to the 
literature, the increased steric bulk of the TBDMS group is known to enhance the 
stability of the protecting group 199, furthermore the chemistry of the HWE reaction 
has been reported to be suited with this base resistant protecting group 200. In this 
study the base used in the HWE coupling reaction, appeared have had an effect on the 
reactivity of the silyl ether protecting group, TBDMS. Upon purification using silica, 
the TIPS moiety was found to be susceptible to decomposition during column 
chromatography and resulted in cleavage from the stilbene scaffold. However, there is 
a possibility the use of a non-silica based stationary phase, may overcome this issue. 
Characterization by 1H NMR and mass spectral analysis indicated the presence of the 
stilbene skeleton, 169, (21 %), which was found to have one TIPS protecting group. 
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Chapter Three 
 
 Synthesis of Arachidin-1: Part II  
 
3.1 Retrosynthetic strategy 
 
Having attempted the synthesis of arachidin-1, 2, via silyl ether protection, it was decided 
that an alternative approach, would be to construct the trans-stilbene backbone, by the 
synthesising the substrates; 3,5-dimethoxy-4-methylbenzaldehyde, 183, and diethyl (3,4-
dimethoxybenzyl)phosphonate, 185, 201, 202 and then coupling the two compounds via the 
Horner-Wadsworth-Emmons (HWE) reaction 103, 110. 
The retrosynthetic strategy of this approach is outlined in Scheme 3.1, the starting 
material 3,4,5-trimethoxybenzaldehyde dimethyl acetal, 184, was chosen as this 
compound has been reported to successfully undergo regioselective demethylation, in the 
presence of an alkali metal. Next subsequent electrophilic substitution of the acetal, 184, 
using iodomethane and finally acetal hydrolysis, would give the desired aldehyde, 183, 
201, 202. The acetal, 184, used in the study, would also enable the masking of the hydroxyl 
groups by means of methyl ethers, which are of interest in this approach as these 
protecting groups have the advantage of being extremely stable in various reaction 
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conditions, with the option of cleaving via a demethylation reaction, in the presence of a 
strong Lewis acid, at the penultimate stage of the synthetic route 203.  
Furthermore, by adapting the procedure described by Azzena and co-workers 201, 202, it 
would allow for the exploration of electrophilic substitution reactions, using selected 
alkyl halides, following regioselective demethylation.  
Once the stilbene backbone had been formed, it was envisaged that                                 
N-bromosuccinimide (NBS) could then be used as a brominating agent in the Wohl-
Ziegler reaction204, 205, and the subsequent Michaelis-Arbuzov rearrangement185, 186 on the 
brominated stilbene, would afford the phosphonate. Next HWE coupling with                                 
2-methylpropanal, 163, would allow us to incorporate the side-chain, and finally the 
demethylation reaction could then be performed, in order to afford arachidin-1, 2.
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Scheme 3.1   Retrosynthetic strategy for the synthesis of trans-arachidin-1 
181
MeO
OMe
OMe
MeO
Br
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3.2 Regioselective demethoxylation 
The initial step of this approach involved the synthesis of the aldehyde, 183, (Scheme 
3.2), first the 4-methoxy moiety in 3,4,5-trimethoxybenzaldehyde dimethyl acetal, 184, 
was regioselectively removed, upon the addition of sodium metal (3 equiv.), this 
methodology was performed according to the procedure published by Azzena et al., 202. 
Following the addition of sodium metal, a colour change from yellow to purple was 
observed in the reaction mixture, therefore indicating the progress of the radical 
demethoxylation step.  
Next, decanting of the reaction mixture, to remove the excess sodium metal was 
performed, before the reductive alkylation step with iodomethane in excess (~ 1.5 equiv.), 
which proceeded smoothly. Finally acidic hydrolysis of the crude reaction material, gave 
the desired benzaldehyde, 183, with an excellent yield of 92 %. When compared to the 
literature, the yield obtained was similar to that reported in the literature (> 90 %) 202.  
 
 
Scheme 3.2 Regioselective demethoxylation of 3,4,5-trimethoxybenzaldehyde dimethyl acetal 
 
 
Chapter 3: Synthesis of Arachidin-1: Part II 
  
 
95 
 
The reaction was repeated, however in the second attempt sodium metal, 30-35 wt. % 
dispersion in wax, was used instead of the freshly cut sodium, it was envisioned that the 
increase in surface area of the metal would minimise the challenge of decanting the 
residual metal from the reaction mixture, prior to the addition of iodomethane. This 
approach was found to proceed smoothly, without the need of decanting the reaction 
mixture and gave a high yield of the aldehyde, 183 (82 %). Although the yield obtained 
with this approach was lower than that reported in the literature, it is possible that the loss 
of yield may have occurred during the filtration stage of the recrystallization process, as 
from the analysis (1H NMR) of the precipitate extracted from the mother liquor, the 
presence of the aldehyde, 183, along with the what was believed to be an acetal 
intermediate was observed in the spectrum. When the crude product from the mother 
liquor was purified again, an additional 6 % yield of the pure product, 183, was obtained. 
 
The substitution of the methoxy moiety with a hydrogen atom (reductive demethylation) 
is known to proceed via a two-electron-transfer (reductive) process, whereby cleavage of 
the aryl-oxygen (C-O) bond, present in aryl ethers takes place at the 4-OMe group 206. 
Mechanistically two reaction routes have been reported within the literature, and both 
mechanistic pathways (Equation 3.1), according to Azzena and co-workers 207 are 
suggested to begin with the formation a radical anion (Equation 3.1; (1)).  
The reaction is said to occur via cleavage of the radical anion, resulting in the aryl radical 
being formed (Equation 3.1; (2)), which consequently can be reduced into an aryl anion 
(Equation 3.1; (3)). Alternatively, a hydrogen atom could be abstracted from the reaction 
medium (Equation 3.1; (4)) leading to aryl radical decay. The hydrogen atom donors are 
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suggested to be least likely with the use of THF as the solvent, however, the source of the 
hydrogen atom is suggested to be from the methoxide ion formed during the reductive 
cleavage.  
The decay of the aryl radical (Equation 3.1; (4)) is thought to compete with the reduction 
into aryl anions (Equation 3.1; (3)), this is considered to be the stage needed to form the 
intermediate species, ready for the subsequent electrophilic attack. On the other hand, it is 
reported that the radical anion is additionally reduced to the dianion, via 
disproportionation (Equation 3.1; (5)), and subsequent cleavage of the aforementioned 
stage is said to afford the aryl anion (Equation 3.1; (6)). Furthermore studies into the 
mechanism of reductive demethylation have also found that the nature of the aldehyde 
protective group, provides a crucial role in the demethylation step of the synthesis 208.  
 
  
Equation 3.1   The reaction pathway proposed for the cleavage of aryl-O bonds of aryl ethers, via 
reductive electron transfer. 208 
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Furthermore, reduction in the presence of an alkali metal in low polarity solvents, such as 
THF, have been found to result in 100 % regioselective demethoxylation in almost 
quantitative yields. However, other solvents of lower polarity were found to reduce the 
reactivity of the substrates, additionally the presence of the dimethyl acetal moiety, para 
to the leaving methoxy group, has been reported to influence the mechanism(s) of the C-
O bond cleavage 208. Azzena et al., have suggested that the regioselective cleavage of the 
aryl-oxygen bond occurs due to the 4-methoxy group, twisting out of plane on the 
aromatic ring, this twisting is thought to be caused by the two adjacent ortho-methoxy 
groups. Moreover, the reaction is also believed to be influenced, electronically by the two 
ortho-substituents207, 209.  
Under similar conditions to that shown in Scheme 3.2, the regioselective demethoxylation 
has been previously reported in the literature, using potassium metal as the alkali metal, 
however for compounds such as 3,4,5-trimethoxybenzaldehye dimethyl acetal 184, the 
use of finely cut sodium metal (3 equiv.), was found to be highly successful, with THF 
being the most suited solvent for the reaction. Moreover the use of potassium metal (3 
equiv.) was found to give lower yields, due to the incomplete complete conversion of the 
acetal. Furthermore, at lower temperatures (-20 °C), the use of the potassium metal gave 
higher yields, in addition to by-products which according to Azzena et al., are believed to 
be from the Wittig rearrangement of the acetal group, which is induced by reductive 
electron transfer. The use of lithium metal was also found to result in slow conversion (50 
% over 7 days) 169, however the alkylation of the demethoxylated intermediate, with 
secondary alkyl halides, such as 2-iodopropane has been reported to be unsuccessful, 
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regardless of extended reaction times 207, based on these findings optimisation studies 
were not performed for this step of the methodology. 
  
3.3 Formation of the benzylphosphonate 
 
The next step in the synthetic methodology was the nucleophilic substitution (SN2) 
reaction of 3,4-dimethoxybenzyl alcohol, using 1.2 equiv. of phosphorus tribromide, in 
the presence of diethyl ether (Scheme 3.3). The bromo-compound, 187, was prepared 
according to the procedure reported by Charlton and co-workers 210 and gave an excellent 
yield of 93 %, as determined by 1H NMR. Furthermore 1H NMR confirmed the success of 
the reaction, as a broad singlet which is characteristic of the hydroxyl (O-H) proton 
environment was no longer observed in the spectrum.  
 
 
Scheme 3.3 Synthesis of Diethyl (3,4-dimethoxybenzyl)phosphonate 
 
Additionally, the melting product of the crystalline product, 187, was determined                
(m.p. 48 ºC - 51 ºC), notably the narrow melting point range obtained was similar to that 
of the literature 47 - 50 °C 97, therefore indicating that the product was pure. According to 
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the literature 218, this bromo compound has been reported to be unstable, therefore triethyl 
phosphite was subsequently added to the crude benzyl bromide, 187, following full 
characterisation. The Arbuzov reaction in the presence of triethyl phosphite in excess 
gave inconsistent yields compared to other Arbuzov reactions performed in this work, 
with the formation of the desired benzylphosphonate, 185, obtained in moderate yield  
(53 %). A possible explanation of the low yield obtained, could be due to the large scale 
of the reaction (71 g scale), the reaction may have not been given enough time to reach 
completion, as the presence of the starting material was also observed by 1H NMR. 
Nevertheless, the formation of the desired phosphonate was confirmed by 1H NMR 
analysis, with a doublet observed at δ 2.94 ppm, integrating to 2 protons (CH2-P). 
 
 
3.4 Coupling via HWE 
Next the stilbene, 182, was constructed via the HWE reaction, yielding the trans-alkene 
in good yield (86 %), the use of the base (NaOMe) in excess (> 8 equiv) provided the best 
yields (Scheme 3.4). The synthesis of the stilbene skeleton was performed in a one-pot 
reaction to reduce the loss of yield, furthermore as suggested by Wadsworth et al., 110, 113, 
preparation of the phosphonate carbanion was carried out, by the addition of the base in 
DMF at room temperature, to ensure deprotonation of the acidic proton, on the α-carbon 
adjacent to the phosphorus atom proceeded smoothly.  
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Scheme 3.4 Synthesis of (E)-5-(3,4-dimethoxystyryl)-1,3-dimethoxy-2-methylbenzene 
 
Characterisation by 1H NMR confirmed the formation of the trans-isomer, whereby a 
doublet and a multiplet were observed at δ 6.93 and δ 7.02 ppm, respectively, each 
integrating to 1 H, with a J-coupling value of JAB = 16.2 Hz, which is characteristic of the 
trans-ethylenic linkage (HC=CH). Additionally, from the mass spectral data the 
molecular ion peak of m/z = 315, was observed which confirmed the formation of the 
stilbene, 182. The next stage was bromination of the 4-Me moiety, in order to incorporate 
the prenyl moiety. 
 
3.5 Wohl-Ziegler Bromination 
 
α-Bromination of alkyl, allylic and benzylic compounds, have been reported to proceed 
using a brominating agent, such as bromine 211, 212, N-bromosuccinimide (NBS) 213 or 
bromotrichloromethane (CBrCl3) 214, in the presence of halogenated solvents such as 
carbon tetrachloride (CCl4), dichloromethane (CH2Cl2), chloroform (CHCl3) or 1,2-
dichloroethane (CH2ClCH2Cl), with the reaction proceeding under the irradiation of light 
and/or with heat. 
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The Wohl-Ziegler bromination reaction 204, 205, is a benzylic or allylic bromination 
reaction, commonly performed in the presence a stoichiometric quantity of NBS, as a 
bromine (Br2) source, which is generated in situ, via a rapid reaction. A radical initiator, 
such as UV or AIBN in minute quantities, is required for the homolytic bond cleavage of 
Br2, in addition to a halogenated solvent. Carbon tetrachloride is commonly selected as 
the halogenated solvent of choice, for use at high temperatures as yields of 30 - 87 % 
have been reported in the presence of CCl4, due to the halogenated solvent being inert and 
having very little capability of undertaking free-radical reactions 213. 
Furthermore, though NBS is known to be poorly soluble in CCl4, the progress of the 
reaction can be visibly identified by the insoluble succinimide product (Figure 3.1) 
floating at the surface of the solvent 204. 
 
 
 
Figure 3.1  Wohl Ziegler Bromination 
 
 
Although this traditional approach is said to be obsolete 215, the successful preparation of 
stilbenes via the Wohl-Ziegler bromination 204, 205, 213 has been previously reported within 
the literature 216, 217.  
In this study, the radical-initiated bromination of compound, 182, was performed based 
on the reaction conditions detailed by Soomro et al., 217; the equivalents of reagents, 
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effects of irradiation with light, solvent, and temperature effects, were examined         
(Table 3.1).  
First, the Wohl-Ziegler reaction was performed on the stilbene, 182, in the presence of 
NBS (Table 3.1; Entry 1), carbon tetrachloride, with the addition of the radical initiators, 
AIBN and an incandescent light, these conditions gave a very low yield (8 %). However, 
characterisation by mass spectrometry indicated the presence of the molecular ion peak of 
m/z = 392, and characterisation by 1H NMR, showed the presence of the newly formed 
CH2-Br bond, with a peak at δ 4.60 ppm, integrating to 2 H, which is characteristic of the 
methylene protons, therefore confirming the successful bromination of the 4-Me moiety, 
within the stilbene skeleton. 
Next, the radical initiated reaction between the stilbene, 182, NBS, AIBN and carbon 
tetrachloride, was attempted and in this investigation AIBN was used as the only source 
of the radical initiator (Table 3.1; Entry 2). This reaction showed an improvement and 
gave the best yield, albeit still relatively low (19 %), analysis by 1H NMR, indicated the 
disappearance of the methyl protons at δ 2.10 ppm and the presence of a quartet at δ 4.53 
ppm (J = 3.2 Hz), which is characteristic of the protons present in a methylene group 
(CH2-Br). The presence of the 12 protons present in the four methoxy moieties positioned 
around the stilbene scaffold, were also observed in their two different proton 
environments at δ 3.75 ppm and 3.96 ppm, respectively. Although characterisation of the 
protons within the aromatic region of the spectrum proved exceptionally difficult to 
perform, due to the noisy baseline, the success of the reaction was confirmed by mass 
spectrometry, which indicated the presence of a molecular ion peak of m/z = 393. In 
contrast with the literature 229, this reaction indicates the use of an incandescent light is 
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not required, as the 1H NMR spectrum indicated that the methyl group (Me) had been 
successfully converted into CH2-Br, in the presence of the radical initiator (AIBN). 
However, it is possible that side reactions or decomposition may have occurred, which 
could offer an explanation to the low yields obtained in this study. 
The use of pure water, in the presence of NBS and an incandescent light bulb, has 
been found to be a benign approach to radical bromination of substituted toluene 
derivatives218 and aromatic compounds 219. The bromination of toluene and xylenes in the 
presence of bromine and water, under the irradiation of a mercury lamp as the source of 
light, was additionally reported successful, by Shaw and co-workers 220, furthermore 
water has been seen to be a suitable alternative solvent, for use radical reactions, 
compared to the carcinogenic CCl4 221. 
Unfortunately, the model NBS bromination model reaction, using pure water as an 
alternative solvent was found to be unsuccessful, with the presence of starting material, 
182, observed by 1H NMR (Table 3.1; Entry 3). It was thought that the temperature the 
reaction was conducted at 30 ° C, moreover the solubility of NBS in water may be the 
cause of this reaction been unsuccessful. Nevertheless, as the study had so far shown that 
the radical initiated NBS bromination, in the presence of CCl4 was successful, it was 
decided that the phosphonate could be synthesised via the Arbuzov reaction. 
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Table 3.1 Summary of N-Bromosuccinimide bromination reaction conditions 
 
 
Entry Compound Solvent Ratio  
[stilbene : NBS] 
Conditions % Puritya 
1 181a CCl4 1 : 6 78 °C, 24 h, incandescent light, AIBN 19 
2 181b CCl4 1 : 4 78 °C, reflux, 24 h, AIBN 8  
3 - H2O 1 : 1.05 30 °C, 72 h, incandescent light, AIBN - 
a Determined by HPLC
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3.6 Arbuzov Reaction 
Attempts incorporating the phosphonate moiety into the trans-stilbene backbone were 
not successful. The Arbuzov reaction was attempted with the stilbene, 181b, at a 
lower temperature (89 °C), in order to avoid decomposition of the product, due to the 
melting point of the stilbene (98 - 110 ºC) (Scheme 3.5), however characterisation by 
1H NMR confirmed the reaction did not go to completion as the presence of both 
starting materials were detected. 
 
 
Scheme 3.5 Attempted synthesis of diethyl (E)-(4-(3,4-dimethoxystyryl)-2,6-
dimethoxybenzyl)phosphonate 
 
 
Within the stilbene skeleton, the presence of the methylene (CH2-Br) protons (δ 4.59 
ppm) were observed, moreover the CH2-P bond usually observed at ~ δ 3.00 ppm and 
large J-coupling value (JP-H ~ 21 Hz) was not detected. Characterisation by mass 
spectrometry indicated the presence of molecular ion peaks of m/z = 393 (79Br) and           
m/z = 394 (80Br), respectively, which are characteristic of the brominated stilbene, 
181b. Therefore suggesting the temperature used in the reaction was not high enough 
to activate the reaction. 
Since the traditional Michaelis–Arbuzov rearrangement was unsuccessful, an adapted 
Arbuzov reaction reported by Rajeshwaran et al., 188, was attempted whereby the 
Lewis acid zinc bromide (ZnBr2), was used as a catalyst in order to lower the 
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temperature needed for the reaction (Scheme 3.6). Characterisation by 1H NMR 
indicated only the presence of the starting material, 181a, furthermore the molecular 
ion peak of the desired product was not observed following analysis by mass 
spectrometry. 
 
 
 
Scheme 3.6  Attempted synthesis of diethyl (E)-(4-(3,4-dimethoxystyryl)-2,6-
dimethoxybenzyl)phosphonate in the presence of the Lewis acid catalyst, zinc bromide 
 
 
It can be argued that an increased equivalent of the Lewis acid could have been used 
in the reaction, however the failure of the reaction could also be due to the approach 
of the large triethyl phosphite group, therefore contributing to steric effects and 
preventing the reaction from proceeding.  
 
 
3.7 Strategy for the synthesis of arachidin-1: Part III  
 
Having unsuccessfully attempted the synthesis of arachidin-1, 2, via the classical 
Wohl Ziegler bromination reaction 205, 213, it was thought that the scope of the 
regioselective demethoxylation of 3,4,5-trimethoxybenzaldehyde dimethyl acetal, 184, 
could be investigated further. Therefore with this assumption, an alternative strategy 
towards the total synthesis of arachidin-1, 2, was devised, as shown in Scheme 3.7 
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which additionally provided the advantage of avoiding the previously required NBS 
brominating step. 
 
 
 
Scheme 3.7 Synthetic strategy for the total synthesis of trans-arachidin-1  
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3.7.1 Regioselective reductive electrophilic substitution with 
diethyl(iodomethyl)phosphonate 
 
The studies by Azzena et al.,202, 222 have shown the approach, via the regioselective 
demethoxylation of 3,4,5-trimethoxybenzaldehyde dimethyl acetal, 184, to be an 
advantageous route to incorporate various alkyl moieties, including methyl, ethyl and 
butyl groups, into the 4-position of a substituted benzaldehyde using primary alkyl 
halides 202.  
Although it has not been previously reported in the literature, it was envisaged that 
alkylation with diethyl iodomethylphosphonate, as the electrophilic reagent could 
conveniently introduce a diethyl phosphonate moiety at the 4-position of the acetal, 
184, (Scheme 3.8). 
 
 
Scheme 3.8 Regioselective reductive alkylation of 3,4,5-trimethoxybenzaldehyde 
dimethylacetal using diethyl(iodomethyl)phosphonate 
 
 
This reaction was attempted in a small scale, with the aim of optimising the reaction 
once the methodology had been proven successful. Following the regioselective 
demethylation of the acetal, 184, in the presence of sodium metal, via a two-electron-
transfer step of the 4-OMe group, alkylation of the intermediate proceeded by the 
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addition of the primary alkyl halide diethyl, iodomethylphosphonate (1.5 equiv.) at a 
low temperature (0 °C), work up gave the alkylated crude acetal product, 190, in good 
yield (86 %). Characterisation by the mass spectral analysis, was found to be valuable, 
as the mass corresponding to the molecular ion (m/z = 361) of the desired compound, 
190, was observed. Furthermore, formation of the phosphonate, 190, was also 
confirmed by 1H NMR, although the presence of the acetal, 184, (14 %), was also 
detected, it is possible that longer reaction times may be required, or optimisation of 
the reagents may be needed, in order to obtain higher yields. 
 
 
3.7.2 Prenylation via HWE coupling 
 
Once the phosphonate, 190, was formed, two possible routes were considered for the 
next step in the methodology, the first option was deprotection of the acetal, 190, to 
afford the aldehyde, and subsequent HWE coupling to first form the 3-methylbut-1-
enyl side construct the stilbene backbone. 
Alternatively, the second option was to incorporate the side chain first, followed by 
the deprotection of the acetal, 191, to give the aldehyde, 192. However it was assumed 
that should the aldehyde be formed first, isomerisation would occur in the presence of 
the base during the HWE coupling reaction. Since acetals are known to be stable in 
the presence of nucleophiles and bases at room temperature 203, it was decided the 
next step of this methodology would be to incorporate the 3-methylbut-1-enyl moiety               
(Scheme 3.9).  
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Scheme 3.9 Coupling of diethyl (4-(dimethoxymethyl)-2,6-dimethoxybenzyl)phosphonate 
with 2-methylpropanal 
 
 
Treatment of the acetal, 190, with 2-methylpropanal, 163, in the presence of t-BuOK 
and THF as the solvent, proceed smoothly to give the desired prenylated acetal, 191, 
in good yield (71 %). Formation of the trans-alkene moiety was confirmed by 1H 
NMR, following the success of the reaction, acetal hydrolysis was immediately 
performed. 
 
 
3.7.3 Acetal hydrolysis 
There were various methods reported for the deprotection of acetals 223, 224, however 
cleavage of the acetal, 191, was performed according to the work published by 
Azzena and co-workers 202, via acid catalysed hydrolysis 203. The acetal hydrolysis 
proceed by stirring the acetal, 191, with a solvent system comprising of aqueous 
hydrochloric acid and tetrahydrofuran in a 1:1 ratio (Scheme 3.10). This approach 
gave the desired (E)-3,5-dimethoxy-4-(3-methylbut-1-en-1-yl)benzaldehyde, 192, in 
moderate yield (52 %). Characteristic bands arising from the aldehyde, carbonyl 
stretch (C=O) were observed from the IR spectrum, with the C=O bands located at 
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1706 cm-1, furthermore characterisation by mass spectrometry indicated the desired 
product, 192, (MW = 234 gmol-1), was successfully made as the presence of a 
molecular ion peak of m/z 233 was also observed. 
 
 
 
Scheme 3.10 Acid catalysed hydrolysis of the dimethyl acetal 
 
 
The acetal hydrolysis is known to proceed first by protonation of a methoxy (OMe) 
moiety, with the acid (HCl), leading to the subsequent loss of methanol, and affording 
the oxonium ion as the cationic intermediate. Next, the nucleophilic attack towards the 
electrophilic cation, via 1,2-addition results in the formation of the protonated 
hemiacetal, followed by proton transfer to the adjacent OMe group, leading to the loss 
of a second alcohol, via 1,2-elimination. Lastly deprotonation of the protonated 
aldehyde to affords the aldehyde (Figure 3.2) 225.  
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Figure 3.2  Acid catalysed hydrolysis mechanism of (E)-5-(dimethoxymethyl)-1,3-
dimethoxy-2-(3-methylbut-1-en-1-yl)benzene 
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3.7.4 Formation of the stilbene via HWE coupling 
 
Coupling using 1 equiv. of the previously synthesised 3,4-dimethoxy 
benzylphosphonate, 185, with the newly formed aldehyde, 192, (1 equiv.), in the 
presence of t-BuOK and THF, successfully formed the crude trans-alkene in moderate 
yield (30 %) (Scheme 3.11). Characterisation by mass spectrometry indicated the 
reaction did not go to entire completion, as the presence of benzylphosphonate, 185, 
was also observed on the spectrum (m/z = 287), in addition to the molecular ion peak 
of the desired product, 3, (m/z = 367), however optimised studies are still required in 
order to obtain higher yields. 
 
 
Scheme 3.11 Horner-Wadsworth-Emmons condensation of 3,4-dimethoxy benzylphosphonate 
and substituted benzaldehyde. 
 
 
3.7.5 Demethylation model reactions 
The use of ethers as protective groups for phenols, have the advantage of being 
extremely stable in various reaction conditions, with the option of facile cleavage via 
demethylation 203. This type of reaction is known to proceed using harsh reagents 
and/or reaction conditions, such as the use of the reagent boron tribromide (BBr3), in 
the presence of dichloromethane, at extremely low temperatures 226. Additionally the 
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use of pyridine hydrochloride (Py.HCl) at high temperatures 227, 228, is a well-known 
approach. Alternatively, milder reaction conditions using an aluminium halide-thiol 
system, have been reported in the literature for the demethylation of methyl ethers of 
alcohols and phenols 229. Furthermore methyl ethers are also known to be cleaved in 
the presence of iodotrimethylsilane (TMSI) 230-232, AlCl3 233 and BeCl2 234. 
Additionally, sodium thioethoxide in the presence of N,N-dimethylformamide has also 
been reported by Feutrill and Mirrington as a powerful reagent, for the cleaving of 
aryl methyl ethers235.  
With a number of the possible demethylation reagents being expensive to purchase, it 
was decided to perform model demethylation studies, using the readily available and 
inexpensive Py.HCl, in addition to boron tribromide (BBr3), and TMSI. A pure sample 
of the stilbene, trans-3,4-dimethoxy-4'-methylstilbene, 199, as shown in Figure 3.3, 
was used, as this stilbene being similar in structure to our target product, 2, was simple 
to construct on a large scale. These studies were considered advantageous as it would 
enable us to determine the most suited reaction conditions and reagent(s), needed for 
the cleavage of the aryl ethers present around compound, 199, to be performed. 
 
 
Figure 3.3 Structure of trans-3,4-dimethoxy-4'-methylstilbene 
 
 
Demethylation reactions using the Lewis acid BBr3 is a reliable and commonly used 
method within the literature 226, for the cleavage of OMe moieties.  
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In this work, the established cleavage of methyl aryl ethers using the Lewis acid, 
boron tribromide was attempted first, this approach led to C-O bond cleavage, to give 
an alkyl bromide in addition to an alkoxyborane, which affords an alcohol following 
aqueous workup (Figure 3.4). As a result of this complexation, it is suggested that one 
mole of BBr3 should be used for each heteroatom present within the molecule. Within 
the stilbene backbone, 199, there were two ethereal oxygens, therefore the use of 4 
equiv. of BBr3 was decided upon.   
 
 
Figure 3.4   Demethylation mechanism using boron tribromide 
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Within the literature, demethylation reactions using BBr3 have been reported to 
proceed at temperatures at or below room temperature, with the use solid CO2             
(-70 °C) or liquid nitrogen (-196 °C), to achieve the temperatures required for the 
reaction 226. However, due to the resources available, examining the reaction at 
temperatures lower than -20 °C was not possible. Nevertheless, when stirring at a 
temperature of -20 °C, the crude product was obtained after 4 h, following solvent 
extraction and trituration the desired product, 202a, was isolated in low yield (44 %). 
 
Table 3.2 Summary of model demethylation reaction conditions 
 
 
Entry Compound reagent Ratio  
[stilbene : reagent] 
Conditions % Puritya 
1 202a BBr3 1 : 4 -20 °C / 4 h 44 
2 - Py.HCl 1 : (>10) > 180 °C / 3 h - 
3 202b Py.HCl 1 : (>10) 141 °C / 1 h 38 
4 - TMSI 1 : 2.5 30 °C / 72 h / DCM - 
a Determined by 1H NMR 
 
 
Characterisation by IR analysis indicated a broad peak at υ 3344 cm-1, which is 
characteristic of the hydroxyl moiety (OH). Furthermore, the protons from the 
methoxy moieties (OMe) were not observed on the 1H NMR spectrum, therefore 
signifying the success of the reaction. However, what was observed was a broad 
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singlet integrating to 2 protons at δ 5.32 ppm, which is characteristic of the OH proton 
environment. The disappearance of the broad singlet was also observed when a D2O 
exchange was performed on the NMR sample. The molecular ion peak of the desired 
product (m/z = 225) was also observed by mass spectrometry, therefore confirming 
OMe cleavage. 
 
Alternative demethylation methods were additionally explored (Table 3.2), next in 
the presence of molten pyridine hydrochloride at elevated temperatures of 141 – 200 
°C236. This reagent has also been reported in the literature, for the demethylation of 
methyl aryl ethers under solvent free conditions, via microwave heating 227. However, 
in this study the small scale model demethylation reactions with Py.HCl in excess  (> 
180 oC) were unsuccessful, as characterisation by 1H NMR showed that 
decomposition had occurred, therefore suggesting the high temperature required to 
keep the reagent molten could have disrupted the integrity of the structure. 
Furthermore due to the raised temperature, the reaction mixture turned into a dark tar-
like solid, therefore making it challenging to extract. As a result, the reaction was 
heated for no longer than 1 h at    141 °C, with intermittent monitoring by TLC 
(Table 3.2; Entry 3).  
Characterisation of the product, by 1H NMR data suggested cleavage of the methyl 
moieties had been successful, as the proton environments characteristic of the 
phenolic (OH) protons at δ 5.12 ppm (2 H) were observed. Furthermore 
characterisation by mass spectrometry also confirmed cleavage, as a molecular ion 
peak of m/z = 226 was observed. Although demethylation using pyridine 
hydrochloride was successful in the model reaction, the 1H NMR also confirmed the 
presence of a mixture of compounds; the desired product, 202c, (38 %), but also the 
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presence of the starting material, 199, (18 %), and residual solvent ethyl acetate 
(44%). Furthermore the issues with regards to using elevated temperatures, and 
maintaining the temperature within the reaction flask, in order to prevent the salt from 
returning back to its crystalline state, made this method an unattractive one to use. 
Next, the demethylation was explored using TMSI (2.5 equiv.), this specific 
molar equivalent was chosen as according to the work by Tamura and co-workers 
(245), the cleavage of aryl ethers was found to be successful when this ratio was used. 
This model study therefore proceeded with 1 equiv. of the stilbene, 199, and TMS-
iodide (2.5 equiv.), dissolved in DCM (Table 3.2; Entry 4). In accordance with the 
literature the demethylation reaction using TMSI was found to proceed slowly 232, 237, 
as monitoring by TLC over 72 h did show the slow progress of the reaction. 
Characterisation of the dark brown oil, by 1H NMR indicated the presence of a 
mixture of compounds comprising of both OH and OMe groups, around the stilbene 
backbone, as the proton environments at δ 3.89 ppm and 3.93 ppm, which are 
characteristic of the methoxy moieties were observed, therefore suggesting the 
compounds present were those shown in Figure 3.5. The mixture of products also 
resulted in difficulties in separating the desired product. 
 
 
 
 
Figure 3.5 Structure of (E)-2-methoxy-4-(4-methylstyryl)phenol and (E)-2-methoxy-5-(4-
methylstyryl)phenol 
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Although TMSI is known to be an effective reagent in the regioselective mono ortho-
demethylation of less accessible methoxy moieties, the failure of the reaction was 
likely due to TMSI being a less reactive reagent, compared to alternative 
demethylating reactions using reagents such as BBr3 232, it was therefore decided to 
explore the use of the reagent BBr3 in our next stage of study. 
 
 
3.7.6  Demethylation of 5-((E)-3,4-dimethoxystyryl)-1,3-dimethoxy-2-((E)-3-
methylbut-1-en-1-yl)benzene 
 
The demethylation reaction, in the presence of milder reagents such as BBr3 has been 
reported to react faster compared to alternative reagents such as TMSI 232, 237. Based 
on this model study the Lewis acid, BBr3 was the only reagent to successfully cleave 
the aryl methyl ethers with good yield, compared to the other two reagents examined. 
The choice of using BBr3 was also decided on, based on the rationale that the reaction 
conditions could be controlled easily, in comparison to demethylation reactions using 
Py.HCl.  
Using identical reaction conditions as the model study, whereby 5 equiv. of 
BBr3 and the stilbene, 3, (1 equiv.) were stirred at -20 °C, gave the crude in low yield 
(47 %) (Scheme 3.12). Analysis by mass spectrometry indicated the desired 
compound, 2, had been successfully synthesised, as a molecular ion peak of (m/z = 
312) was observed, however optimised studies are still required in order to obtain 
arachidin-1, 2, in quantitative yields. 
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Scheme 3.12 Demethylation using boron tribromide 
 
 
3.8 Summary 
The synthesis of arachidin-1, 2, was explored first via the Wohl Ziegler bromination 
of the synthesised stilbene (E)-5-(3,4-dimethoxystyryl)-1,3-dimethoxy-2-
methylbenzene, 182, using NBS as the brominating source. A range of conditions 
were attempted, including the use of the benign solvent, water which was found to be 
unsuccessful. In order to synthesise the target compound, an alternative route was 
envisaged, by means of the regioselective demethoxylation of 3,4,5-
trimethoxybenzaldehyde dimethyl acetal, 184, and subsequent alkylation with diethyl 
iodomethylphosphonate. This reaction proved successful, which enabled the 
incorporation of the side chain via the classic HWE reaction, in the presence of 2-
methylpropanal, 163. Following acetal hydrolysis of the dimethyl acetal, 191, the 
stilbene backbone was successfully constructed, once again using the HWE coupling 
reaction between the aldehyde, 192, and 3,4-dimethoxy benzylphosphonate, 185. The 
small scale model demethylation reactions found boron tribromide to be the most 
suited reagent for the cleavage of the methyl ethers, and when demethylation was 
performed on the stilbene, 3, analysis by mass spectrometry indicated that the reaction 
was successful, and confirmed the formation of the target compound, arachidin-1, 2.  
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Chapter Four 
 
 Synthesis of resveratrol analogues: Part I 
 
4.1 Strategies to the synthesis of resveratrol analogues – Part I 
An additional aim of this work, was to investigate and develop methods towards the 
synthesis of novel resveratrol analogues. Although various potential analogues could 
have been made, derivatives possessing methoxy or sulfonamide moieties were of 
interest, as according to the literature the presence of these functional groups have 
been found in vitro, to display comparable or increased chemopreventative and/or 
chemotherapeutic properties, compared to resveratrol, 1, 164-167.   
Notably, the polymethoxy analogues of resveratrol whereby the hydroxyl groups have 
been replaced with polymethoxy moieties around the stilbene scaffold, are of interest 
as these compounds have been reported to offer increased lipophilicity in addition to 
exhibiting anticancer activity. For instance, both natural and synthetic analogues of 
resveratrol; including MR-3, 205, MR-5, 124, DMU-212, 63, and Combretastatin A-4, 
206, (Figure 4.1) have been reported to prevent cancer growth in several cancer cell 
lines167, 238-243. 
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Figure 4.1 Chemical structure of methoxy analogues of resveratrol 
 
 
The stilbene, MR-5, 124, has been found to display increased anti-proliferative 
effects, compared to both resveratrol, 1, and its methoxy derivatives 166. Further 
studies have suggested that not only does the presence of additional methoxy moieties 
increase the compound’s activity towards apoptosis, but importantly the presence of 
the 3,4,5- trimethoxy substitutions, the trans-stilbene backbone, and the presence of a 
4’-OMe moiety on the stilbene backbone have been suggested to be essential for 
retaining the anticancer activity of these analogues 166, 244.  
The construction of synthetic polymethoxy stilbenes in the form of MR-5, 124, 245-247 
and related analogues 240 have been described in the literature, however the synthesis 
of polymethoxy analogues of resveratrol, possessing either an aliphatic side chain or a 
prenyl moiety, to our knowledge has not yet been explored. 
In this chapter, the aim of this phase of work was to synthesise resveratrol analogues, 
by incorporating a side chain into the polymethoxy-stilbene backbone, with the aim of 
improving the anti-cancer properties. The Horner-Wadsworth-Emmons (HWE) 
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reaction has been proved to be a simple and versatile reaction in the formation of the 
stilbene backbone, therefore this coupling reaction was used to construct the trans-
stilbene backbone, using diethyl 3,4,5-trimethoxybenzylphosphonate, 209, and 3,5-
dimethoxybenzaldehyde 211. Next the regioselective formylation using the Lewis acid 
(TiCl4), as detailed by Garcia et al., 248, would allow the addition of a formyl moiety 
unto the stilbene skeleton and finally enable the incorporation of the side chain via a 
non-catalytic coupling reaction, would afford the target compound. 
 
 
4.2 Synthesis of diethyl 3,4,5-trimethoxybenzylphosphonate 
The first stage of the synthesis was the formation of 5-(bromomethyl)-1,2,3-
trimethoxybenzene, 208, the synthetic procedures available for the preparation of 
alkyl halides from alcohols are vast. However most methods detailed in the literature 
involve the conversion of an alcohol into the corresponding halide, in the presence of 
reagents; such as phosphorus halides 210, 249, triphenylphosphine 250, 251, 2,4,6-
trichloro[1,3,5]triazine in N,N-dimethyl formamide, 252, or thionyl chloride 253. Other 
examples within the literature report the use of thiols, as possible alternative 
precursors to alcohols 254, although these reagents facilitate the direct conversion of 
alcohols to alkyl halides, the reaction conditions employed for some of these methods 
can be quite extreme. It was therefore decided that the substituted benzyl bromide 
would be prepared using phosphorus tribromide, to convert the primary alcohol, 3,4,5-
trimethoxybenzyl alcohol, 205, into 5-(bromomethyl)-1,2,3-trimethoxybenzene, 208. 
Under the reaction conditions, shown in Scheme 4.1, the formation of the phosphorus 
ester and subsequent nucleophilic substitution (SN2) proceeded smoothly, to afford the 
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desired compound, 208, with an isolated yield of 97 %. Due to the lack of stability 
displayed by the benzyl bromide, 208, 210 the product was immediately used for the 
subsequent Michaelis-Arbuzov reaction, following full characterisation.  
 
 
Scheme 4.1 Synthesis of 5-(bromomethyl)-1,2,3-trimethoxybenzene  
 
 
Having formed the benzyl bromide, 208, the conversion into the phosphonate was 
attempted, using the traditional Michaelis-Arbuzov reaction (198, 201). The 
preparation of the benzylphosphonate, 209, from 5-(bromomethyl)-1,2,3-
trimethoxybenzene, 208, (Scheme 4.2) also proceeded smoothly with a high % purity 
obtained (90 %). However, it is thought that due to the large scale of the reaction (39 
g), had sufficient time been given to the reaction, quantitative yields would have been 
obtained from the reaction, as the presence of triethyl phosphite (10 %) was also 
detected by 1H NMR. 
 
 
Scheme 4.2 Synthesis of diethyl 3,4,5-trimethoxybenzylphosphonate 
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The formation of the new CH2-P bond was confirmed by 1H NMR, whereby a doublet 
was observed at δ 2.70 ppm, integrating to two protons (CH2). Additionally a large 
2JPH value was calculated (J = 21.4 Hz), which was characteristic of the geminal 
coupling between 31P and 1H. Furthermore, based on the mass spectral data the 
molecular ion peak (m/z = 319) of the desired compound, 209, was also observed. As 
the results proved the formation of the phosphonate, 209, was successful, the next step 
of the methodology was to synthesise the aldehyde, 210, which would also be used for 
the HWE coupling.  
 
 
4.3  Synthesis of 3,5-dimethoxybenzaldehyde 
 
Next the benzaldehyde, 210, was synthesised from 3,4,5-trimethoxybenzaldehyde 
dimethyl acetal, 184. The previous work by Azzena and co-workers 202, offered a 
route to the highly regioselective demethoxylation of the acetal, 184, via cleavage of 
the aromatic C-O bond present in the methoxy group, by electron transfer in the 
presence of sodium metal 222. As detailed in Section 3.2, amendments to the procedure 
were made, these included the type of sodium used, for instance sodium metal pellets 
were replaced by sodium, 30-35 wt % dispersion in wax, in order to increase the 
surface area of the metal, therefore avoiding the problems of residual metal within the 
reaction mixture, due to the metal being used in excess and the need to decant the 
mixture into a clean vessel, before performing acetal hydrolysis (Scheme 4.3).  
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Scheme 4.3 Synthesis of 3,5-dimethoxybenzaldehyde 
 
 
Characterisation of the isolated product (100 %), were consistent with the literature 
202, and formation of the aldehyde, 210, was confirmed by 1H NMR, whereby a singlet 
at    δ 9.80 ppm, integrating to one proton was observed, which was characteristic of 
the aldehyde (CHO) moiety. Additionally, two identical singlets at δ 3.74 ppm and δ 
3.75 ppm, were observed each peak integrating to three protons, therefore confirming 
the presence of the two OMe moieties. More importantly multiplets at δ 6.60 ppm, 
integrating to one proton and at δ 6.91 ppm, of which integrated to two protons were 
also observed, indicating the presence of three protons around the aromatic ring, and 
confirming that the regioselective demethoxylation of the 4-OMe group had 
successfully taken place. 
 
 
4.4 Coupling of aldehyde with diethyl benzylphosphonate 
 
Next coupling of the aldehyde with the phosphonate to form the desired trans-
stilbene, 124, the HWE reaction conditions, previously employed in Chapter 2 were 
used in this methodology to give the crude product, 124, in a high yield (72 %), 
however following recrystallization and characterisation by 1H NMR the yield of the 
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trans-stilbene, 124, was reduced to 39 % (Scheme 4.4). When compared to the 
literature 149, the yield of the pure product obtained in this work was considerably 
lower than that reported in the literature (88 %), although the methodology described 
in the literature was different. However, the reduction in yield was possibly due to the 
less polar solvent (ethanol) used in the purification process, it can therefore be 
concluded that the use of a more polar solvent, namely methanol would have given a 
higher % yield. 
 
 
Scheme 4.4 Synthesis of 3’,5’,3,4,5-pentamethoxy stilbene 
 
Nonetheless, subsequent optimisation of reactions were performed, whereby the 
inexpensive 3,5-dimethoxybenzaldehyde, 210, was purchased and used for the HWE 
reaction, on a large scale. Recrystallization of the isolated product using methanol 
gave the trans-stilbene, 124, in excellent yield (89 %), the pure product was found to 
have a similar melting point value (132 – 136 °C) to that of the literature  (135 ºC) 249, 
301.   
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4.5 Formylation of substituted trans-stilbene 
In order to incorporate a side-chain into the stilbene scaffold, it was envisaged that a 
formylation reaction would allow us to introduce a formyl group (-CHO) into the 
pentamethoxy-stilbene backbone, 124, (Figure 4.2). The literature provides a number 
of ways to perform aromatic formylation reactions, via electrophilic aromatic 
substitution; these include Rieche formylation, in the presence of dichloromethyl 
methyl ether 255, Vilsmeier-Haack reaction using the electrophilic chloroiminium salt 
256, 257, the Reimer-Tiemann reaction 258, 259, using the electrophilic chloroiminium salt 
and the use of hexamethylenetetramine in the Duff reaction 260, 261. The formylation of 
aromatic compounds has also been reported via the Sommelet reaction 262 the 
Gattermann 263-265 and Gattermann-Koch approach 266, however, these methods are 
known to afford low yields, and often require harsh reaction conditions. On the other 
hand, the Rieche formylation presented itself as an attractive route, as within the 
literature it is commonly used with sterically hindered compounds 248, 267, and 
therefore was considered to be an plausible reaction to use with the sterically hindered 
polymethoxy-stilbene substrate, 212.  
 
 
Figure 4.2 Proposed formylation of 3’,5’,3,4,5-pentamethoxy stilbene 
 
 
Formylation 
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The reaction was performed using dichloromethyl methyl ether (1.4 equiv.), in the 
presence of 6 equiv. of the Lewis acid, titanium(IV) chloride (Scheme 4.5). The 
reaction temperature was kept as low as possible during the addition, as studies have 
indicated at higher temperatures (> 0 °C), the yield obtained can often be low, as a 
result of side reactions occurring simultaneously with the formylation reaction, 
whereby the dichloromethyl methyl ether is decomposed 268.  
 
 
Scheme 4.5 Attempted formylation of 3’,5’,3,4,5-pentamethoxy stilbene 
 
 
Characterisation by 1H NMR indicated the desired product was not obtained, 
surprisingly analysis of the 1H NMR spectrum suggested that whilst formylation at the 
ortho position (between the 3’, 5’-dimethoxy groups) did not occur, di-formylation 
however had taken place. Additionally, the mass spectral analysis indicated the 
presence of a molecular ion peak of m/z = 387, which suggests that the compound 
made was a 3,4,5,3’,5’-pentamethoxystilbene, 213, possessing two aldehyde moieties 
within its structure, and had a molecular weight of 386 gmol-1.  
On the 1H NMR spectrum two singlets; at δ 10.43 ppm and 10.52 ppm, were  also 
observed which were characteristic of aldehyde protons, thereby indicating the 
presence of two CHO groups on the aryl ring. The shielded peak (δ 10.43 ppm), due to 
the three OMe moieties, indicated that the aldehyde may be positioned on ring ‘A’ of 
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the stilbene skeleton (Figure 4.3). Once one formyl group had substituted in the 
aromatic ring, it was unlikely that further substitution would occur on the same ring as 
electronically, it would be deactivated, therefore not allowing further substitutions in 
that ring 267. 
 
 
Figure 4.3  Annotated structure of 3’,5’,3,4,5-pentamethoxy stilbene 
 
 
Looking at the OMe peaks on the 1H NMR spectrum, five singlets within the region of 
δ 3.89 ppm - δ 4.03 ppm, were observed therefore suggesting the five methoxy groups 
around the stilbene skeleton were in different environments. Similarly, this was also 
observed on the 13C NMR spectrum, whereby three peaks at δ ~ 55 ppm and two 
peaks at ~ 61 ppm, respectively were identified. If formylation had occurred at the 
desired position (position 4’), as electronically the meta-methoxy groups adjacent to 
the 4’-position is believed to activate the 4’-H (Figure 4.3), making it more reactive 
for electrophilic aromatic substitution to occur, we would therefore have seen the 
symmetry within the molecule remain, with the three peaks on the spectrum 
representing the methoxy groups.  
The two protons present in the alkene linkage between the two aromatic rings, are 
characteristically observed in the 1H NMR spectrum as two doublets, however what 
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was observed was one peak, integrated to two protons which appeared to be coupling, 
thereby suggesting the alkene protons were possibly in indistinguishable chemical 
environments. Following an expansion of the spectrum, doublet of doublets with a          
J-coupling of J = 16.0 Hz, were observed which are characteristic of coupling 
constant for trans-alkenes. This peak was observed downfield at δ 7.9 ppm, therefore 
suggesting that the product synthesised was likely to be 2,2’-diformyl-3,4,5,3’,5’-
pentamethoxystilbene, 213, (Figure 4.4). However, further structure determination 
techniques by 2D NMR (NOESY), in the future will be performed in order to 
determine the positions of the formyl groups within the stilbene backbone.  
 
 
 
Figure 4.4 Chemical structure of di-formyl stilbene 
 
 
Cresp and co-workers reported the formation of two products, when titanium(IV) 
chloride (TiCl4) and dichloromethyl methyl ether were reacted with phenols, resulting 
in a major and minor product, in the presence of both hydroxyl- and methoxy-rich 
aromatic compounds 269. Similarly, Yakubov and co-workers also reported the 
occurrence of di-formylation, via the Rieche formylation, when using Lewis acids 
including TiCl4 and AlCl3, respectively, with dichloromethyl methyl ether, in the 
presence of sterically hindered arenes, such as mesitylene and durene 267.  
 
 
Chapter 4: Synthesis of resveratrol analogues: Part I 
  
 
132 
 
Further studies were performed in order to optimise the reaction conditions and the 
equivalent of TiCl4 used, in order to successfully incorporate an aldehyde moiety into 
the stilbene backbone (Table 4.1). Notably, the Lewis acid in excess (6 equiv.), in 
addition to the reaction proceeding at very a low temperatures (-10 to -15 °C) for a 
duration of 2 h, gave the desired formyl compound, 212a, in moderate yield                      
(50 %). The Lewis acid, TiCl4 was chosen in excess of 6 equivalents, so that the metal 
halide could coordinate with the neighbouring methoxy groups positioned at 3,4,5- of 
the stilbene, 124, and the reaction time was kept to a minimum to prevent other side 
reactions from occurring. This approach was found to be ideal, however further work 
towards optimising the formylation reaction is required, in order to improve the % 
yield.  
 
Table 4.1 The formylation reaction of trans-pentamethoxy stilbene with titanium 
tetrachloride 
 
 
Entry Compound Equivalents of 
TiCl4 
Temperature 
(ºC) 
Time 
(h) 
 
Yield a 
(%) 
1 212a 6 -15 to -10 2 50 
2 - 6 -10 to RT 8 -  
3 - 5 -10 to -5 3 -  
a Determined by 1H NMR 
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On the other hand when 6 equiv. of the Lewis acid was used at a temperature range of 
-10 to RT, the reaction was unsuccessful. It is possible that the length of the reaction 
time (8 h) and the temperature of the reaction mixture for that length of time, may 
have led to decomposition (Table 4.1), as the product obtained could not be identified 
by NMR, nor by mass spectral analysis. Additionally, when 5 equiv. of TiCl4 was 
used, only the presence of the starting material, 124, was detected by 1H NMR, 
therefore suggesting that more than 5 equiv. of the Lewis acid is required in the 
formylation reaction with the stilbene, 124. 
The findings from the optimisation studies, are in line with the work developed 
by Garcia et al., whereby it has been reported that the ortho-formylation of 
polysubstituted aromatic compounds, in the presence of dichloromethyl methyl ether 
and TiCl4 can regioselectively occur, affording high yields and most importantly 
without the event of di-formylation taking place 248. According to Garcia et al., the 
high regioselectively of this reaction is suggested to be due to the metal halide 
coordinating with each heteroatom present on the stilbene skeleton. A number of 
studies have also supported the rationale behind the use of the Lewis acid in excess, in 
order to ensure the coordination with the heteroatom. This would therefore hinder 
substitution at ring ‘A’ (Figure 4.5) and increase the electrophilicity of the 
dichloromethyl methyl ether, as well as allow electrophilic aromatic substitution to 
take place, resulting in the formation of the formyl moiety at the vacant ortho-position 
on ring ‘B’ 248.  
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Figure 4.5 Structure of 3’,5’,3,4,5-pentamethoxy stilbene 
 
This same theory could offer an explanation, to why addition of the formyl group did 
not occur, at position 4’- on the stilbene backbone. It is possible, that because of the 
excess TiCl4 (6 equiv) used, there was an increased chance of TiCl4 binding to more 
than one methoxy functional group, therefore hindering substitution. This is illustrated 
in Figure 4.6, which shows the structure of compound, 214, and the binding of TiCl4 
to more than one methoxy moiety, thereby hindering electrophilic aromatic 
substitution on position 4’ 270. 
 
 
Figure 4.6 Coordination of the Lewis acid, TiCl4, with methoxy moiety 
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4.6 Coupling reaction 
 
The formation of compound, 213, presented an opportunity to perform a coupling 
reaction, in order to determine if a side chain could be incorporated unto the stilbene 
backbone (Scheme 4.6).  
 
 
Scheme 4.6 Attempted synthesis of stilbene derivative via the Wittig reaction 
 
As detailed in Chapter 2, the HWE reaction with an aliphatic phosphonate was found 
to be unsuccessful, therefore the Wittig reaction was chosen as an alternative method 
for the formation of the carbon-carbon double (C=C) bond. The utilisation of a 
phosphonium ylide was considered to be favourable, although it has been reported that 
the use non-stabilised ylides, kinetically would result in the formation of the less 
stable cis-alkene, Maryanoff et al., additionally stated that the use of aromatic 
aldehydes in the presence of non-stabilised ylides, may result in the formation of 
trans-alkenes, in the presence of a strong base 103.  
The first step in the reaction was to form a phosphonium salt, which could then be 
deprotonated to form the ylide. Treatment of triphenylphosphine with the alkyl halide, 
1-bromopentane, under reflux in the presence of toluene, gave the desired 
alkyltriphenylphosphonium salt (Scheme 4.7), albeit in low yield (26 %). Nonetheless, 
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formation of the desired product, 215, was confirmed by mass spectral analysis, as the 
presence of a molecular ion peak of m/z = 332 was observed.  
 
 
Scheme 4.7 Synthesis of pentyltriphenylphosphonium salt 
 
Next, coupling with the diformylstilbene, 217, was attempted in the presence of 
sodium methoxide, in order to form the phosphonium ylide, via deprotonation of the 
α-carbon in the alkyltriphenylphosphonium salt. However, the desired product was not 
detected by 1H NMR, what was observed were the starting materials. It is possible the 
ylide may have been too bulky to couple with the aldehyde moieties, on the other hand 
the base used may have also played a crucial part in the unsuccessful deprotonation of 
the α-carbon positioned on the phosphonium salt.  
After searching the literature, the work by McNulty and Das 96, offers an alternative 
and benign approach to the synthesis of trans-alkenes, with high stereocontrol via the 
Wittig reaction. The use of these reported semi-stabilised ylides, derived from trialkyl 
benzylphosphonium salts and sodium hydroxide, in the presence of water, albeit with 
limited applicability as only small alkyl functionalities (trimethyl and 
triethylphosphosphine oxides) are highly soluble in water. This alternative route is an 
approach to explore, as the synthesis of trans-stilbenes, including DMU-212, 63, have 
already been successfully attempted via this approach. 
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4.7 Summary 
The polymethoxy stilbene backbone, 124, was synthesized using diethyl 3,4,5-
trimethoxybenzylphosphonate, 209, and the commercially available                                           
3,5-dimethoxybenzaldehyde, 211, via the HWE reaction, under mild reaction 
conditions. Formation of the substituted benzylphosphonate, 209, proceeded smoothly 
via the SN2 reaction between triethyl phosphite and 3,4,5-trimethoxybenzyl bromide, 
208. Coupling of the phosphonate, 209, with the benzaldehyde, 211, gave the desired 
stilbene in excellent yield (89%), when the commercially available aldehyde, 211, was 
used. Attempts of the formylation reaction with the substituted stilbene, using 
dichloromethyl methyl ether and various molar equivalents of titanium(IV) chloride 
and reaction temperatures were unsuccessful, as di-formylation on the stilbene 
skeleton was believed to have occurred, in accordance with the observations by 
Yakubov et al., 267 and Cresp et al., 269. 
Attempts to incorporate a side chain into the diformylstilbene, 213, via the HWE 
reaction, under mild conditions were made however the use of an unstabilized 
phosphonate appeared to be unsuccessful under these reaction conditions. The Wittig 
reaction was subsequently attempted using a triphenyl-derived phosphonium ylide, 
which was prepared by heating 1-bromopentane, 217, with triphenylphosphine, 218, 
under reflux, albeit in poor yield (26 %). Coupling of the alkyltriphenylphosphonium 
salt, 215, with the aldehyde, 213, via the Wittig reaction was also found to be 
unsuccessful.   
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Chapter Five 
 
 Synthesis of resveratrol analogues: Part II 
 
5.1 Strategies to the synthesis of resveratrol analogues – Part II 
Resveratrol, 1, has been reported to induce apoptosis in a number of cancer cell lines, 
including the human pancreatic 271, and lung cancer cell lines 165. Furthermore, as detailed 
in Chapter 1, various resveratrol analogues have been extensively studied within the 
literature, in order to find a potential cancer chemopreventative and/or cancer 
chemotherapeutic agent 166. In 2002, Yang and co-workers 6 reported the synthesis of 
novel stilbenesulfonamide analogues possessing a primary sulfonamide (SO2NH2) 
moiety, in place of the 4’-OH moiety in trans-resveratrol, 1, (Figure 5.1), even though the 
published methodology towards the synthesis of stilbene benzenesulfonamides was long 
(7-8 steps), and limited to the synthesis of primary sulfonamides, these compounds were 
found to display both increased activity against several cancer cell lines, when compared 
to resveratrol, 1. 
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Figure 5.1 Structure of resveratrol and trans-stilbene benzenesulfonamides 
 
 
The sulfonamide functional group (SO2NH2) has been widely reported in the literature, 
and suggested to be implicated in the potent antitumour activity of a number of anticancer 
drugs such as the compound E7010, which is currently in clinical trials as an anticancer 
drug 164, 169-171, 174. 
The discoveries from these studies indicates a need for further examination of novel 
stilbenesulfonamides, in order to enhance their selectivity and activity towards various 
cancer cell lines. In this chapter, the aim of this phase of work was to design and develop 
a versatile methodology, which would enable the synthesis of novel trans-resveratrol 
analogues, in the form of stilbene benzenesulfonamides, 125. 
A three step methodology towards the synthesis of stilbenesulfonamides, via the HWE 
reaction has been designed, it was believed that this approach would enable the synthesis 
of stilbene benzenesulfonamide analogues of which comprised of primary, secondary and 
tertiary sulfonamide moieties. 
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5.2 Strategy towards stilbenesulfonamide synthesis 
A number of routes into the synthesis stilbenesulfonamides were explored, within the 
literature, however the possibility of forming various sulfonamides, by reacting a sulfonyl 
chloride moiety with an amine 272 was of great interest. For this reason chlorosulfonic 
acid was identified as a suitable sulfonating species, which could be used to synthesise an 
arylsulfonyl chloride intermediate. 
According to the literature, the chlorosulfonation of trans-stilbene (1,2-diphenylethene), 
5, was considered unsuccessful, and would not afford identifiable products, due to the 
stability of the substrate 272. After searching the literature, it was discovered that 
Hoffmann and co-workers 273 reported that an aryl sulfonyl chloride intermediate could be 
formed prior to coupling, by reacting excess chlorosulfonic acid, 219, with diethyl 
benzylphosphonate, 162, (Scheme 5.1).  
 
 
 
Scheme 5.1 Chlorosulfonation of diethyl benzylphosphonate 
 
The preparation of the sulfonyl chloride intermediate, 220, would then allow for the 
subsequent aminolysis reaction to proceed, as it was expected that via this approach the 
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sulfonamide moiety, at the 4’-position of the stilbene skeleton could be varied using a 
wide range of amines. Finally, coupling via the HWE reaction would form the stilbene 
backbone (Figure 5.2), therefore providing an alternative and concise route for the 
synthesis of stilbene benzenesulfonamides, 222. 
 
  
 
Figure 5.2 Approach to the synthesis of stilbene sulfonamides 
 
 
The use of this methodology, as detailed in Figure 5.2, would first of all allow the use of 
various substituted benzaldehydes; possessing electron-withdrawing or electron-donating 
groups. Second of all, it would enable the use of various amines, to produce a range of 
sulfonamide moieties. Additionally in developing this work, the methodology would 
enable an inexpensive, direct and versatile route towards the synthesis trans-stilbene 
benzenesulfonamide analogues, in addition to other novel analogues, reported in the 
literature 164, 173.  
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The choice of analogues synthesised in this study were primarily limited to aldehydes 
possessing the most attractive functionalities, based on previous literature 164, 173, as it was 
envisioned that additional analogues would be made, following the biological studies 
which would be performed on these compounds. 
 
 
5.2.1 Synthesis of diethyl benzylphosphonate 
The first step, was the synthesis of the diethyl benzylphosphonate, 162, via the Michaelis 
Arbuzov reaction 187, with the use of benzyl bromide, 223, and triethyl phosphite, 166, 
(Scheme 5.2). This SN2 reaction proceeded smoothly for 48 h, to give the diethyl 
benzylphosphonate, 162, in moderate yield (48 %). No further purification was 
performed, as a high % purity (96 %), was calculated via 1H NMR analysis.  
 
 
Scheme 5.2 Synthesis of diethyl benzylphosphonate via the Michaelis-Arbuzov reaction 
 
IR characterisation indicated the important P=O peak at approximately υ 1250 cm-1, 
furthermore characterisation  by 1H NMR displayed a doublet with a large two-bond 
coupling constant at δ 3.09 ppm (2JP-H = 21.9 Hz), which was indicative of the 
phosphorus coupling with a proton nuclei positioned on the α-carbon. The protons present 
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in the P-CH2 bond, on a 1H NMR spectrum should show as a doublet in a ratio of 1:1 274, 
however a roofing effect was observed in the spectrum obtained. An explanation may be 
due to the presence of low level impurities underneath the peaks located at δ 3.09 ppm, 
because of this a deuterium oxide (D2O) shake was performed on the sample, to see if the 
effect of a different solvent would alter the nature of the peak, nevertheless the data 
showed minimal changes at this particular chemical shift. Additionally, doublet of 
quartets 275, which appear to overlap on the 1H NMR spectrum were observed, and were 
believed to be attributed to the protons present in the O-CH2 moiety of compound, 162, 
being diastereotopic. As a result, the protons were observed in inequivalent chemical 
environments on the proton NMR spectrum 274.  
Although the phosphonate, 162, was synthesised in moderate yields, it was decided that 
the synthesis of the phosphonate, 162, was not necessary as the substrate could be 
inexpensively purchased. Furthermore, by starting the synthetic methodology from the 
commercially available diethyl benzylphosphonate, 162, it would enable the total reaction 
sequence to be reduced to three steps. 
 
 
5.2.2 Synthesis of diethyl 4-(chlorosulfonyl)benzylphosphonate  
 
The next step was to prepare the aryl sulfonyl chloride, the formation of this synthetic 
intermediate has been reported, via various methodologies including chlorosulfonation 
using chlorosulfonic acid, 219 276, alternatively by direct oxidation of thiol analogues, in 
the presence of hydrogen peroxide (H2O2) and the Lewis acid titanium tetrachloride 277, 
278, or with sulfonic acids in the presence of the chlorinating agent; 2,4,6-trichloro-1,3,5-
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triazine 279. Within the literature, chlorosulfonic acid, 219, has been shown to be a 
versatile reagent in the chlorosulfonation of various organic compounds 273, therefore this 
acid was chosen as the sulfonating species. Furthermore, the formation of the sulfonyl 
chloride, when involving aromatic and hetero-aromatic substrates, was suggested to be 
successful with chlorosulfonic acid, 219, in excess 280, which was of great advantage, as a 
substituted aromatic substrate would be used in this methodology. 
According to the literature, it has been suggested that the presence of the 
chlorosulfonic acid, 219, in excess drives the reaction to completion, thereby converting 
the sulfonic acid reaction intermediate into the sulfonyl chloride, 220 276. Chlorosulfonic 
acid reactions, between the substrate and acid, have also been reported to be successful in 
the presence of a solvent, such as dichloromethane and thionyl chloride 273.  
Therefore, the first attempt in forming the sulfonyl chloride intermediate, 220, proceeded 
by reacting diethyl benzylphosphonate, 162, with chlorosulfonic acid, 219, in excess 281, 
this approach was found to be successful and gave the sulfonyl chloride, 220, in good 
yield (82 %) (Scheme 5.3).  
 
P(OEt)2
P(OEt)2
O
ClSO3H
162 220
O
SO2Cl
 
Scheme 5.3 Chlorosulfonation of diethyl benzylphosphonate 
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The structural assignment by IR spectral analysis featured two distinguishable peaks, 
characteristic of the sulfonyl chloride (S=O) bond present at υ = 1173 cm-1 and            
1369 cm-1, respectively. Additionally, the presence of the phosphonate moiety was also 
observed at υ = 1246 cm-1 (P=O str). Formation of the sulfonyl chloride intermediate was 
also confirmed by 1H NMR, whereby of the presence of two doublets, with chemical 
shifts at δ 7.49 ppm and δ 7.90 ppm, were observed indicating the presence of a 1,4-
disubstituted aromatic system. 
As the chlorination step in the chlorosulfonation reaction was a reversible step          
(Equation 5.1) 276, the optimised reaction conditions, with chlorosulfonic acid : substrate 
in a ratio of (10 : 1) was used in order to ensure the completion of the reaction in high 
yields. Furthermore, the initial slow addition of the substrate, 162, to the excess 
chlorosulfonic acid, 219, at temperatures of less than 0 °C was found to be successful in 
order to minimise unwanted side reactions, such as di-sulfonation as well as the 
production of arylsulfonic acid. 
 
 
 
Equation 5.1   Two-step process of chlorosulfonation with an aromatic substrate   
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5.2.3 Synthesis of diethyl 4-sulfamoylbenzylphosphonate 
Having successfully formed the sulfonyl chloride intermediate, 220, the aminolysis 
reaction using various amines was explored. One of the most important aspects to 
demonstrate, was that the primary sulfonamide moiety (SO2NH2) could be formed with 
this approach. Therefore the aminolysis reaction was initially attempted using excess 
ammonia solution (in 2 M ethanol), as the source of ammonia, with diethyl 4-
(chlorosulfonyl)benzylphosphonate, 220, (Scheme 5.4). This reaction was found to 
proceed smoothly, affording the desired primary sulfonamide, 221a, in excellent yield (90 
%).  
 
 
Scheme 5.4 Synthesis of sulfonamide via, aminolysis using ammonia 
 
 
Formation of the desired sulfonamide was confirmed by IR analysis, whereby the 
characteristic bands arising from the primary sulfonamide stretch were observed, with the 
S=O bands located at υ 1156 cm-1 and 1337 cm-1, respectively. More importantly                  
N-H bands were identified in the form of two broad peaks (υ 3200 cm-1 and 3298 cm-1), 
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which are characteristic of primary amines. Furthermore, the presence of the phosphonate 
ester was also observed, with peaks characteristic of the P=O bond at approximately                     
υ 1234 cm-1 identified, thereby confirming the phosphonate moiety was still present.  
Additionally, following characterisation by 1H NMR, the presence of the sulfonamide 
moiety was confirmed at δ 4.99 ppm, and to identify the exchangeable protons present in 
the sulfonamide moiety, a D2O exchange was performed whereby the disappearance of 
the N-H signal, with the appearance of a DOH peak was observed as expected. As the 
rapid proton exchange seen with the sulfonamide, meant that coupling could not be 
observed with the protons bonded to the nitrogen atom and neighbouring nuclei 282. 
Furthermore, the JH-H coupling values (J = 8.2 Hz) calculated, were indicative of the 
interaction between the protons present in the aromatic ring, that were ortho to one 
another.  
The mechanistically the amine acts as a nucleophile, and aminolysis is believed to 
proceed via rapid nucleophilic attack of the amine, on the electrophilic sulfonyl centre to 
produce the sulfonamide 283 via a bimolecular SN2-type mechanism, with a linear 
bipyramidal transition state being formed (Figure 5.3) 273. 
 
 
Figure 5.3 SN2 mechanism for the aminolysis reaction with aryl-sulfonyl chlorides and amines 
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5.2.3.1 Examining the scope of the reaction: amine screening 
Following the success of forming the primary sulfonamide with ammonia, it was of 
interest to explore the scope of this methodology by screening various amines with the 
diethyl 4-(chlorosulfonyl)benzylphosphonate, 220, intermediate, in order to determine if 
the aminolysis reaction would be successful.  
In order to examine the versatility and flexibility of this methodology, the amines used in 
the screening were selected to ensure they represented a range of primary, secondary and 
cyclic alkyl amines, as well as aromatic amines. Therefore the amines studied included; 
methylamine, ethylamine, amylamine, dimethylamine, dipropylamine, piperidine, 
morpholine and diphenylamine (Table 5.1).  
The use of primary, secondary and cyclic alkyl amines gave the desired products 
in moderate to high yields and as expected, the nucleophilicity of the amine was found to 
influence the rate of reaction. For instance reactions with primary amines (Table 5.1; 
Entries 1 - 4), and cyclic aliphatic amines (Table 5.1; Entries 7 and 8), although gave 
moderate to high yields, the reaction time was found to be between 12 – 48 h. 
On the other hand, the reaction with diphenylamine (Table 5.1; Entry 9), a relatively 
weak and large nucleophile, was also effective however a longer reaction time of five 
days was required. Nonetheless, the promising results observed with the sulfonyl chloride 
intermediate, 220, and possible use of diverse amines, suggests that this novel approach 
offers an alternative approach towards the synthesis of a wide range of sulfonamide 
analogues. 
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Table 5.1 Summary for the addition-elimination reaction of amines 
 
Entry Compound Amine Condition % Puritya 
(% Yield) 
1 221a ammonia RT / 12 h 90 
2 221b methylamine RT / 24 h 100 (57) 
3 221c ethylamine RT / 48 h 96 (61) 
4 221d amylamine RT / 48 h 60 
5 221e dimethylamine RT / 48 h 98 (68) 
6 221f dipropylamine RT / 48 h 81 
7 221g piperidine RT / 48 h 88 
8 221h morpholine RT / 48 h 82 
9 221i diphenylamine RT / 5 d 83 
a Determined by 1H NMR  
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5.2.4 Synthesis of (E)-4-(3,4-dimethoxystyryl)benzenesulfonamide 
 
The work presented in Chapters 2 to 4, demonstrates the versatility of using the HWE 
condensation reaction in forming the stilbene skeleton, with high selectivity for the 
trans-alkene. In this chapter the same coupling reaction was examined for the 
synthesis of novel stilbenesulfonamides, as the versatile nature of this approach would 
additionally allow the exploration of various heterocyclic aldehydes, in the synthesis 
of the stilbenesulfonamide analogues 9. Furthermore, the mild reaction conditions 
employed would be ideal for the synthesis of stilbenesulfonamides on a larger scale.  
The general reaction involved the coupling of the substituted phosphonate (1 equiv), 
with a benzaldehyde (1 equiv), in the presence of a base (NaOMe or t-BuOK) and a 
solvent (DMF or THF) at room temperature. The aldehydes selected for this study 
(Figure 5.4), were not chosen based on the Hansch method or the                                               
Topliss scheme 79, 284, as examining the versatility of this three step methodology was 
of primary interest. Therefore a variety of aldehydes, possessing the most attractive 
substitutions on the ring were selected based on the literature, specifically the work by 
Yang and co-workers (6), whereby substituents possessing the electron-withdrawing 
group, namely fluorine (F), in addition to substituents comprising of electron-donating 
groups such as dimethylamino (NMe2) and methoxy (OMe) moieties, were reported to 
display significant anti-cancer activity against a number of cancer cell lines, when 
examined in vitro against the NCI-60 human tumour cell line.  
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Figure 5.4 Benzaldehydes selected for HWE coupling 
 
 
The stilbenesulfonamide comprising of the 4-fluoro moiety, was of great interest as 
this analogue was found to display efficacious growth inhibitory activity (GI50 8.93), 
towards the non-small cell lung cancer cell line (A549). A cell line which would be 
used in this study to examine the biological activity of the novel stilbene 
benzenesulfonamides synthesised, therefore it was of interest to synthesise a range of 
analogues, using the various secondary and tertiary benzenesulfonamides available 
from the library. 
The first coupling reaction was explored using the primary sulfonamide, 221a, 
with various aldehydes, in a 1:1 ratio (Table 5.2), the reaction proceeded smoothly 
with over 5 equiv. of the base (NaOMe) and DMF as the solvent. Compared to the six 
step methodology described by Yang et al., 6, this three step methodology proved to 
be successful, when it came to constructing the same analogues (125a, 125b, 125c and 
125g), reported by Yang and co-workers 6. Unfortunately, direct comparisons of the % 
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yields could not be made, as the yields of the stilbenesulfonamide analogues were not 
stated in the literature.  
Nevertheless characterisation by 1H NMR spectra, confirmed that these stilbene 
analogues, all featured an important pair of doublets, corresponding to the alkene 
protons in a trans-configuration at δ ~7.1 ppm and δ ~7.0 ppm. Furthermore the 
calculated J-coupling values (J = 16 - 17 Hz), were distinctly characteristic of the 
proton coupling interactions occurring in a trans-alkene bond. Based on the 1H NMR 
data, the addition of sodium methoxide in excess (> 5 equiv) resulted in a percentage 
purity between 77 – 98 %, although the reaction involving 4-
dimethylaminobenzaldehyde, 231, was found to give the lowest % yield, with the 
stilbene, 231, obtained in a moderate yield of 77 % (Table 5.2; Entry 4). The low yield 
was thought to be due to the phosphonate being added to the reaction mixture in 
excess, which explains why the presence of the starting material, 221a, (23 %) was 
also observed by 1H NMR.  
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Table 5.2 Stilbenesulfonamides via HWE condensation reactions using diethyl 4-
sulfamoylbenzylphosphonate 
 
 
 
Entry Compound R1 R2 Conditions % Puritya 
(%Yield) 
 
 
1 
 
 
232a 
 
 
OMe 
 
 
OMe 
 
NaOMe, DMF 
 
96 (15) 
 
2 
 
232b 
 
H 
 
OMe 
 
NaOMe, DMF 
 
 
88 
 
3 232c OMe H 
 
NaOMe, DMF 98 (7) 
 
4 
 
 
232d 
 
NMe2 
 
H 
 
NaOMe, DMF 
 
77 
a Determined by 1H NMR  
 
Coupling with 4-fluorobenzaldehyde, 230, in the presence of sodium methoxide                         
(> 5 equiv.), gave a mixture of two compounds (Scheme 5.5), characterisation by                   
1H NMR displayed a distinguishable peak at δ 3.83 ppm, indicating the presence of a 
methoxy group, additionally the spectrum featured the important pair of doublets 
corresponding to the alkene (HC=CH) protons at δ 6.97 ppm and δ 7.17 ppm, 
respectively. Furthermore the calculated J-coupling (J = 16.4 Hz), distinctly 
characteristic of the hydrogen coupling interactions occurring in a trans-alkene bond 
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was calculated, therefore confirming the trans-stilbene skeleton had been formed. 
Additionally, the nuclear spin from 19F was observed, due to the strong coupling of the 
fluorine nuclei with the protons, leading to extra splitting in the 1H NMR spectrum 282. 
 
 
Scheme 5.5 Coupling via the Horner-Wadsworth-Emmons reaction using sodium methoxide 
 
 
Based on this characterisation it was likely that the product synthesised, comprised of 
a mixture of compounds possessing a 4-MeO or a 4-fluoro moiety, within the stilbene 
structure. To confirm this, characterisation by LCMS was performed on the mixture, 
the molecular ion peaks of m/z = 275 (C14H12FNO2S requires 277) and m/z = 288 
(C15H15NO3S requires 289), were observed. Additionally calculation of the % purity, 
by 1H NMR identified the presence of compounds 232e and 232c in a 4:1 ratio, which 
suggests that displacement of the para-fluoro moiety on the benzaldehyde, 230, had 
occurred with the nucleophile (MeO) from the base (NaOMe), via nucleophilic 
aromatic substitution (SNAr) (Figure 5.5) 285.  
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Figure 5.5 Nucleophilic aromatic substitution (SNAr) reaction 
 
 
To rule out any postulation of the incorrect aldehyde, 230, being used the experiment 
was repeated, nonetheless the presence of the methoxy moiety was observed again on 
the spectrum. Furthermore comparison of the 1H NMR spectrum of the starting 
material, 230, with the stilbene, 232e, was performed as it was thought that the 
starting material might have some impurities, however the spectral data only 
confirmed the presence of  4-fluorobenzaldehyde 230.  
Based on this discovery, further studies were carried out to investigate the 
influence of NaOMe, in the coupling between 4-fluorobenzaldehyde, 230, and diethyl 
4-sulfamoylbenzylphosphonate, 221a, in order to determine first of all, if the HWE 
reaction was occurring prior to the SNAr, on the fluorine atom. Secondly, to determine 
the influence of the para-sulfonamide moiety, as an electron withdrawing group, and 
the effect it had on the addition-elimination mechanism. 
To examine this, coupling reactions were performed with diethyl benzylphosphonate, 
162, and 4-fluorobenzaldehyde, 230, in the presence of sodium methoxide at 1, 5 and 
10 equivalents, respectively (Table 5.3). The various molar equivalents of the base 
were used in order to determine at which molar equivalent, nucleophilic aromatic 
substitution would occur. The first study, using NaOMe (1 equiv.), was found to 
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produce the 4-fluorostilbenesulfonamide, 236a, in quantitative yield (Entry 1). 
However, characterisation by 1H NMR of the subsequent reactions (5 and 10  equiv of 
NaOMe), indicated the presence of the methoxy moiety, with a distinguishable singlet 
peak at δ ~ 3.8 ppm observed in the spectra, in addition to strong coupling of the 
fluorine nuclei, with the protons. 
 
 
Table 5.3 Synthesis of (E)-1-fluoro-4-styrylbenzene via the Horner-Wadsworth-Emmons 
reaction 
 
Entry Compound Equiv of NaOMe % Puritya  
[Fluoro : OMe] 
 
1 236a 1 
 
> 99 : <1 
2  
3  
236b 
236c 
5 
10 
80  : 20 
53  : 47  
 
a Determined by 1H NMR  
 
The addition of NaOMe (5 equiv.), gave the desired compound, 236a, (80 %) and 
analogue, 236b, (20 %) (Table 5.4; Entry 2), whereas the addition of NaOMe (10 
equiv), considerably increased the yield of the 4-methoxy-stilbenebenzenesulfonamide 
analogue, 236b, up to 47 % (Table 5.4; Entry 3). 
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Next, a reaction using a pure sample of the synthetic stilbene; (E)-1-fluoro-4-
styrylbenzene, 236a, and NaOMe (5 equiv), was carried out in order to determine if 
SNAr would occur in the absence of the electron withdrawing group (SO2NH2). 
Aromatic substitution was believed to occur, with up to 8 times as much of the 4-
fluoro analogue, 236a, identified on the NMR spectrum, compared to the methoxy 
equivalent, 236b, (Table 5.4; Entry 1). This result confirmed that the presence of the 
sulfonamide moiety on the stilbene backbone was not important, and did not have an 
influence on the SNAr reaction observed.  
 
 
Table 5.4 Attempted synthesis of (E)-1-methoxy-4-styrylbenzene 
 
 
Entry Equiv of NaOMe % Puritya  
[Fluoro : OMe] 
 
1 5 82 : 18  
 
a Determined by 1H NMR  
 
 
Next coupling with the primary sulfonamide, 221a, with 4-fluorobenzaldehyde, 230, 
was performed, in order to determine at what equivalent of the base SNAr began to 
occur. As expected substitution did not occur when 1 equiv. of NaOMe was used, and 
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under this reaction condition the condensation reaction proceeded smoothly, to afford 
the desired stilbene, 232e, in excellent yield 98 % (Table 5.5; Entry 1). Notably, in 
contrast with the previous reactions, when > 5 equiv. of NaOMe was used the stilbene, 
232e, was identified as the major product (95 %) on the 1H NMR spectrum, 
additionally a minimal amount of compound, 232c (5 %), was detected. 
 
 
Table 5.5 Synthesis of (E)-4-(4-fluorostyryl)benzenesulfonamide via the Horner-
Wadsworth-Emmons reaction 
 
Entry Equiv of NaOMe % Puritya  (% Yield) 
1 
2 
1 
5 
 
98 (77) 
 
95 (83) 
 
a Determined by 1H NMR  
 
 
Finally, to examine the effect of the presence of sulfonamide moiety on the stilbene 
backbone, NaOMe (1 and 5 equiv, respectively) was added to a pure sample of the 
stilbene sulfonamide, 232e, and stirred in the presence of DMF at room temperature, 
however substitution did not occur, with both equivalents of the base (Table 5.6). 
. 
Chapter 5: Synthesis of resveratrol analogues: Part II 
 
 
159 
 
These results suggest that substitution of the fluorine atom with the methoxy moiety 
only occurs during the HWE reaction when the NaOMe is present in excess (> 5 
equiv.).  
 
Table 5.6 Coupling via the Horner-Wadsworth-Emmons reaction using sodium methoxide 
 
 
Entry Equiv of NaOMe % Puritya (% Yield) 
1 1 
 
100 (57) 
2 5 98 (64) 
 
a Determined by 1H NMR  
 
 
This assumption was proved by the subsequent reactions performed on the remaining 
sulfonamide analogues (221b – 221i), whereby SNAr was believed to occur prior to 
the formation of the stilbene backbone, thereby giving a mixture of products (Figure 
5.6). However, it would be advantageous to perform in-depth NMR studies, and 
observe the kinetics of the reaction, in order to prove this hypothesis and consequently 
determine the rate at which the simultaneous reactions (SNAr and HWE coupling) are 
occurring. 
As an alternative approach the reaction between 4-fluorobenzaldehyde, 230, and the 
primary sulfonamide benzenesulfonamide, 221a, was performed in the presence of           
232e
H2NO2S
F
232e
H2NO2S
F
NaOMe, DMF
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t-BuOK (~ 2 equiv) and THF, this approach was found to proceed smoothly                        
(Figure 5.6), affording the desired stilbenesulfonamide, 232e, in quantitative yield. 
 
Figure 5.6 SNAr Mechanistic in the formation of stilbene sulfonamide analogues 
 
 
Next the coupling with various heterocyclic aldehydes were explored (Figure 5.7), 
these compounds were of interest as the synthesis of novel COX-2 inhibitors, in the 
form of stilbene benzenesulfone and benzenesulfonamide derived styrylheterocycles 
have also been achieved in 4 - 6 steps, by Lim and co-workers 7 .  
 
 
Figure 5.7 Heterocyclic aldehydes selected  
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These analogues, specifically possessing the thiophene functionality (compound 
138c), were reported to show up to 40-fold potency, compared to the lead compound, 
244, (Figure 5.8) 173. It was therefore of interest to examine if the six step 
methodology, described in the literature, could be improved using the three step 
approach developed in this study, in order to synthesise both the compounds reported 
by Lim et al., in addition to other novel benzenesulfonamide derived 
styrylheterocycles for biological screening. 
 
 
Figure 5.8 Benzenesulfone analogue  
 
Following the procedure described in Section 5.2.4, the HWE reaction proceeded in 
the presence of NaOMe (~5 equiv) and DMF, upon occasion when issues with 
solubility were observed, THF was used as an alternative solvent and was found to 
display increased solubility with the heterocyclic aldehydes, compared to DMF (Table 
5.7). Notably, the stilbenesulfonamide analogues 245, 246 and 247 synthesised from 
this three step approach were isolated in higher yields (96 – 100 %), compared to the 
literature (48 – 60 %) 173.  
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Table 5.7 Benzenesulfonamide derived styrylheterocycles formed via the HWE reaction 
using diethyl 4-sulfamoylbenzylphosphonate  
 
Entry Compound Structure Base/Solvent % Puritya        
(% Yield) 
1 245 
 
 
 
NaOMe, DMF  
 
 
100 (30) 
2 246 
 
 
 
NaOMe, THF 
 
98 (94) 
3 247 
 
 
 
NaOMe, DMF 96 (49) 
a Determined by 1H NMR  
 
 
Following the success of the HWE coupling reaction with the various heterocyclic 
aldehydes, the synthesis of other novel benzenesulfonamides were explored, using the 
sulfonamide analogues 221e and 221h. The novel compounds synthesised with diethyl 
4-(N,N-dimethylsulfamoyl)benzylphosphonate, 221e, gave excellent yields with 100 
% purity (Table 5.8). However, the % yields were not comparable when the cyclic 
sulfonamide analogue, 221h, was used, as a moderate yield of 49 % was obtained  
(Table 5.9). 
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Table 5.8 Benzenesulfonamide derived styrylheterocycles formed via the HWE reaction 
using diethyl 4-(N, N-dimethylsulfamoyl)benzylphosphonate 
 
Entry Compound Structure Base/Solvent % Puritya 
(%Yield) 
1 248 
 
 
 
NaOMe, THF 
 
 
100 (59) 
2 249 
 
 
 
NaOMe, THF 
 
98 (100) 
3 250 
 
 
NaOMe, DMF 93 
 
a Determined by 1H NMR  
 
 
 
Table 5.9 Benzenesulfonamide derived styrylheterocycles formed via the HWE reaction 
using diethyl 4-(morpholinosulfonyl)benzylphosphonate 
 
Entry Compound Structure Base/Solvent % Puritya  
1 251 
 
 
 
NaOMe, DMF 
 
 
 
50 
2 
 
252 
 
 
 
NaOMe, DMF 
 
86 
3 253 
 
 
 
NaOMe, DMF 
 
49 
a Determined by 1H NMR  
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Next the versatility of this methodology was explored using the remaining novel 
benzenesulfonamide analogues synthesised in this chapter (Figure 5.9). The secondary 
sulfonamide analogues, 221b - 221h, were additionally coupled with the selected 
benzaldehydes (Figure 5.4), under the same reaction conditions described earlier in 
this chapter (Section 5.2.4).  
 
 
 
Figure 5.9 Structure of benzenesulfonamide analogues used in HWE coupling reactions 
 
 
Compared to the primary sulfonamide, coupling with sulfonamide analogues 221b, 
221c and 221d, gave moderate to excellent yields (61 – 100 %), with the minimal 
yield obtained from the coupling between the secondary sulfonamide, 221b, and                                                         
3-methoxybenzaldehyde 228. Notably, the isolated yields from the coupling between 
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the tertiary sulfonamide, 221f, and the various aldehydes were high (92 – 100 %). On 
the other hand coupling with tertiary cyclic sulfonamides, 221g and 221h, overall 
gave the stilbene benzenesulfonamides in moderate % yields (59 – 77 %), this was 
especially the case when a stoichiometric ratio of the sulfonamide and aldehyde (1:1) 
was used, in the presence of NaOMe (> 6 equiv.). However when the stoichiometric 
ratio was increased, with the addition of the sulfonamide in excess (> 1.2 equiv.), the 
% yields also increased. Additionally, when t-BuOK (~2 equiv.) was used as an 
alternative base, overall excellent % yields (92 – 98 %) were obtained (Table 5.10). 
 
Finally, the HWE coupling of 1°, 2° and 3° benzenesulfonamide analogues with                
4-fluorobenzaldehyde, 230b, was examined, and as expected when NaOMe was used 
a mixture of compounds were observed, due to SNAr taking place in the reaction. 
However, when t-BuOK (~ 2 equiv) was used as an alternative base, in the presence of 
THF the desired product was obtained. The yields obtained from the latter reaction 
gave almost quantitative yields (> 92 %), the high yields were observed with the 
majority of stilbenesulfonamides, apart from compound, 225, which gave an isolated 
yield of 66 % (Table 5.10). The lower yield obtained was likely due to the low equiv. 
of base used in the reaction compared to the other analogues, as the presence of the 
starting materials were also observed on the 1H NMR. It can therefore be postulated 
that if the same equivalent of base was used, complete conversion of the starting 
materials would have been observed. 
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Table 5.10 Synthesis of stilbenesulfonamides via HWE condensation reactions with 4-
fluorobenzaldehyde 
 
Entry Compound Structure % Puritya 
(% Yield) 
1 
 
232e 
 
100 (65) 
2 255 
 
 
66 
3 256 
 
 
98 (39) 
4 257 
 
100 (34) 
5 258 
 
 
98 (40) 
6 259 
 
 
92 
7 260 
 
98 (54) 
a Determined by 1H NMR  
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5.3 Biological testing of analogues  
Lung cancer is said to be the second leading cause of tumour-related deaths, with a 5 
% survival rate, despite only accounting for approximately 20 % of cancer diagnosis. 
In the UK, the non-small cell lung cancer has been reported to account for 87 % of 
lung cancers, with the adenocarcinoma being the most common type of primary lung 
cancer diagnosed 170. For this reason, the non-small cell lung carcinoma cell line, 
A549 was selected for this study, to assess the antitumour activity of the test 
compounds selected as per Section 5.3.1.  
 
5.3.1 Stilbenesulfonamide analogue selection 
 
The present study involved the selection of six compounds from the library of 
analogues synthesised (Table 5.11). These compounds were investigated in vitro for 
their potential activity, with the objective of examining with regards to the SAR, the 
efficacy of the various sulfonamide moieties, compared to the lead compound 
resveratrol, 1, as well as other compounds within the literature. 
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Table 5.11 Stilbenesulfonamide analogues selected for cytotoxicity studies. 
Compound Structure CLogP a 
 
232e 
 
 
 
3.14 
 
255 
 
 
 
 
3.75 
 
257 
 
 
 
 
5.87 
 
258 
 
 
 
259 
 
 
 
 
4.17 
 
5.37 
 
260 
 
 
4.12 
a Calculated LogP (CLogP) obtained from Cambridgesoft ChemBioDraw Ultra software 
v.14.0.0.117.
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The study by Yang et al., 6 identified the stilbene benzenesulfonamide analogue 
comprising of a fluorine moiety, 125a, to be the most selective towards the A459 cell 
line. To ensure consistency with our study, compounds of which possessed a 4-fluoro 
moiety on the aromatic ring were also chosen, as it would allow for the effects of the 
various sulfonamide moieties to be examined, with regards to the inhibition of cell 
proliferation and also allow for comparisons with the stilbene benzenesulfonamide 
analogue, 125a to be made. Furthermore, the bioisosteric replacement of a hydrogen 
atom with a fluorine atom was also considered advantageous, as this would aid in 
improving the pharmacokinetic properties of resveratrol, 1, specifically with regards 
increasing the bioavailability of the lead compound.  
Within the literature, studies have reported the presence of the sulfonamide (p-
SO2NH2) moiety and aromatic ring, to be essential in providing the highest efficacy 
with regards to its anticancer properties. Moreover, the sulfonamide moiety, para-
substituted on the aromatic ring is believed to be preferred 173, 176, as additional 
substitution on the aromatic ring is thought to sterically reduce the activity of the 
compound, due to the presence of a bulky side chain which may hinder the protein 
interaction 286. Based on these assumptions, analogue 255 and 257 (Table 5.11), were 
selected in order to determine the steric effects displayed by these secondary (2°) 
sulfonamide analogues.  
The stilbenesulfonamide, 257, in particular was selected based on the work by Huang 
and co-workers, as the amylamine functional group was reported to be involved in a 
number of anticancer mechanisms, including DNA alkylation 287, and was therefore of 
interest particularly with regards to SAR, and determining if an increase in 
lipophilicity (CLogP 5.87), would lead to an increase in activity. Although it was also 
likely that this compound may be too lipophilic, and as a drug, may result in decreased 
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permeability and in low oral absorption 288. 
The rationale behind the selection of the tertiary (3°) sulfonamide analogue, 
possessing the N,N-dimethylsulfamoyl moiety, 258, was not only to determine the 
steric effects displayed by this analogue, but also to explore the influence of protein 
interactions. As this derivative lacks the hydrogen atoms on the sulfonamide nitrogen, 
it was thought the absence of hydrogen would signify a reduced number of hydrogen 
bond donors (HBD) for protein interactions, and as a result reduce its efficacy. 
Finally, the cyclic sulfonamides, 259 and 260, were selected to examine the steric 
influences displayed by the presence of the morpholine and piperidine functional 
groups, respectively. Additionally, examining the effects of an aromatic sulfonamide, 
such as the N-phenylsulfamoyl, 261, or N,N-diphenylsulfamoyl, 263, derivative          
(Figure 5.10) would have been of great interest in this study, as the presence of an 
additional aromatic group would have given an insight into the electronic effects 
arising from electron rich groups, in relation to their efficacy towards the cancer cell 
line. However, it was also possible that the presence of an additional aromatic group, 
would have decreased the compound’s efficacy, as a result of the electron localisation 
effects 289. Nevertheless neither analogues were available from the library of 
compounds synthesised at the time the study took place, so were not examined in this 
preliminary study.  
 
 
 
Figure 5.10  Structure of N-phenyl stilbenesulfonamide analogues 
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The biological testing of the analogues were performed at the University of 
Hertfordshire, compounds which did not have a % purity of > 98 % when synthesised, 
were recrystallised to ensure that the purity of the compounds used in this study were 
over 98 %. Furthermore the use of a reference anticancer drug and a pure sample of 
resveratrol, 1, were omitted from this study, although it would have been of advantage 
to use either compounds as a reference, this was not considered a major issue at this 
stage of the preliminary study, as direct comparisons of cytotoxicity data could still 
made by referring to the literature, albeit the experimental conditions are known to 
vary. 
 
 
5.3.2 Growth inhibition of A549 cell line 
 
The anti-cancer activity of the six novel stilbenesulfonamides were examined with 
regards to their antiproliferative activity against the A549 cancer cell line, via the use 
of two common cell proliferation assays; trypan blue dye-exclusion and 
Sulforhodamine B protein (SRB) assay, the methods used are described in Appendix 
II. Trypan blue is a stain commonly used in dye exclusion methods in order to assess 
cell viability, this procedure was based on the staining of non-viable (dead) cells with 
compromised membrane integrity, whilst viable (living) cells were unaffected and 
therefore were not stained by the dye 290. The SRB assay was also performed in order 
to determine both growth inhibition as well as cytotoxicity, this assay was based on 
the quantification of cellular protein content in order to determine cell density 291.  
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5.3.2.1 Trypan Blue dye exclusion growth assay 
To determine the effect of the selected compounds (Table 5.11) on cell population 
growth, the A549 cancer cells were treated with two doses of each stilbene 
benzenesulfonamide analogue at concentrations of 50 µM and 5 µM, as presented in 
Figure 5.11 and Figure 5.12, respectively. The number of non-viable cells, which were 
stained with the trypan blue dye, were then counted under the light-microscope at 24, 
48, 72 and 96 h. Analysis of the data from the trypan blue assays clearly indicated that 
analogue, 232e, at a concentration of 50 µM significantly reduced A549 cell growth            
(p < 0.05) compared to the control (1 % DMSO), in a time and dose dependent 
manner. Additionally compound, 255, at the same concentration (50 µM) was found 
to significantly decrease A549 cell growth at 24, 48 and 72 h (p < 0.05) (Figure 5.11). 
 
 
Figure 5.11    Dose and Time dependent responses of A549 of stilbenesulfonamide analogues 
(50µM) 
Relative number of A549 cells counted at 24, 48, 72, and 96 h, after treatment with compounds 232e, 
255, 257, 258, 259 and 260, relative to the control 1 % DMSO. Blue bars indicate 24 h incubation, red 
bars indicate 48 h incubation, green bars indicate 72 h incubation, and purple bars indicate 96 h 
incubation.  * = p <0.05. Bars display number of cells relative to vehicle control. Data shown as mean + 
s.d. n = 6 wells 
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Figure 5.12    Dose and Time dependent responses of A549 of stilbenesulfonamide analogues (5 
µM) 
Relative number of A549 cells counted at 24, 48, 72, and 96 h, after treatment with compounds 232e, 
255, 257, 258, 259 and 260, relative to the control 1 % DMSO. Blue bars indicate 24 h incubation, red 
bars indicate 48 h incubation, green bars indicate 72 h incubation, and purple bars indicate 96 h 
incubation.  * = p <0.05. Bars display number of cells relative to vehicle control. Data shown as mean + 
s.d. n = 6 wells 
 
 
Compounds 257 and 258, at 50 µM also appeared to be effective at reducing A549 
cell growth, however the effect displayed by these compounds were only observed at 
specific times, for instance compound, 257, was found to only significantly reduce 
cell growth (p < 0.05) at 48 and 96 h (compared to the control), but not at 72 h. The 
reasons behind these findings are not clear; it is possible that the variations observed 
here were a result of different opinions as to what was considered viable and non-
viable. Though attempts were made to standardise the cell counting technique, 
ensuring that only viable cells were counted when the distinct colour of the blue dye 
was not observed, it should be considered that the trypan blue assay is a subjective 
procedure, which relies on the subtle colour changes between the cells displayed 
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under a light microscope 292. 
 
Furthermore, no significant effects were observed following the treatments with 259 
and 260, at concentration of both 50 and 5 µM. When considering the effect of the 
other compounds (232e, 255, 257, and 258) at a concentration of 5 µM, it appeared 
that as a general trend, that the stilbenesulfonamide analogues did not have a 
significant effect on cell growth (Figure 5.12). 
 
5.3.2.2 SRB Assay 
 
Next, the cytotoxicity of the selected stilbenesulfonamide analogues (232e, 255, 257, 
258, 259 and 260) against the A549 cancer cell line was determined using the SRB 
assay, according to the National Cancer Institute’s methodology 8. The cells were 
treated at a range of concentrations of the test compounds from 0 to 500µM, for 48 h 
and examined for cellular protein content, in order to calculate the molar 
concentration of each compound resulting in 50 % cell growth inhibition (GI50). Table 
5.12 summarised the GI50 values for each compound tested, and has been ranked from 
the most to the least potent as follows: 255 > 232e > 257 > 260, with compound 258 
and 259 displaying no cytotoxic activity. Notably, compound, 255 (GI50 0.1 µM), was 
found to be the most effective in reducing the cell protein content, when compared to 
the other analogues examined in this study. The second most potent compound was 
232e (GI50 10.4 µM), whereby the GI50 measured, was found to be similar to that 
reported in the study by Yang et al., (GI50 8.9 µM) 6 (Table 5.12). 
 
Chapter 5: Synthesis of resveratrol analogues: Part II 
 
 
175 
 
Table 5.12 Cytotoxicity of trans-stilbenesulfonamide analogues from Sulforhodamine B 
assay 
Compound Structure Cytotoxicity 
(GI50 µM)a 
232e 
 
8.9b 
10.4 
255 
  
 
0.1 
257 
 
 
220 
258 
  
- 
259 
 
 
- 
260 
 
 
>500 
a
The GI50 values are the concentrations relating to 50 % growth inhibition. 
b
Data reported by Yang and co-workers (6). 
 
The results from the SRB assay seem to be in accordance with the trypan blue assay 
data (Section 5.3.2.1), as both assays showed that the compounds with the best 
antitumour activity were 232e and 255. However, based on the high potency (GI50) 
calculated for compound 255 (GI50 0.1 µM) from the SRB assay, an even greater 
inhibition of cell population growth would have been expected, during the study 
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performed using the trypan blue assay (Section 5.3.2.1), when compared to the other 
compounds tested. The reasons for these differences are unclear and require further 
investigation. 
Nevertheless, both analogues, 232e and 255, were found to exhibit increased 
antiproliferative effects when compared to the lead compound, resveratrol 1. Although 
for comparative purposes care must be taken when results come from different in vitro 
studies, the results from the SRB assay performed using resveratrol, 1, as detailed 
from the NCI Developmental Therapeutics Programme database8, reported                 
resveratrol, 1, to have a GI50 of 51.64 µM. By comparison, this means that resveratrol 
is ca. 500-fold less potent than the analogue, 255, (GI50 0.1 µM). Furthermore, 
compound, 255, (GI50 0.1 µM) was also found to be more potent, compared to                        
5-fluorouracil (GI50  0.189µM) 8, a synthetic compound used to treat various forms of 
cancer. 
 
5.3.3 Structure-Activity-Relationship 
 
The SAR of benzenesulfonamide analogues, possessing various functional groups on 
the sulfonamide nitrogen have been explored extensively 293, 294, based on the cell 
viability data in this study, it is not surprising that compound, 232e, displayed 
increased activity against the A549 cancer cell line, as the presence of the sulfonamide                             
(SO2NH2) moiety is known within the literature, to be essential in providing the 
highest efficacy, in relation to anticancer properties 169, 170, 174. Furthermore, the 
promising results observed with compound, 255, indicates that the presence of a HBD 
atom on the sulfonamide moiety and minimal steric effects on the sulfonamide 
nitrogen, may be important for activity. 
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On the other hand, both the increased hydrophobic (π) and steric effects displayed by 
compounds 257, 258, 259 and 260, were found to decrease their activity, which 
suggest that the presence of steric and hydrophobic interactions are not important for 
activity.  
Remarkably, compound 257, which also possesses a HBD atom in the 
sulfonamide moiety was found to display decreased activity, based on this finding it is 
possible that the longer alkyl chain may have moved the hydrogen bonding ability 
within the sulfonamide moiety in compound, 257, further away from the target 
binding pocket it was interacting with. It is also possible that the chain extension, 
resulting from the long alkyl chain may have changed the distances of the 
pharmacophore points in compound, 257 and led to a decrease in activity, however 
this warrants further investigation. 
Based on the growth inhibition studies, it possible that the presence of a HBD 
and minimal steric hindrance are essential for activity, it would be of interest to 
explore the steric and hydrophobic influences displayed by the stilbenesulfonamide 
made from ethylamine, 256, (Figure 5.13) whereby an additional carbon chain is 
added to the sulfonamide nitrogen, in order to determine at what alkyl chain length 
efficacy and potency decreases. 
 
S
O
O
N
H3C
H F
255
S
O
O
N
H3CH2C
H F
256
 
Figure 5.13 Structure of stilbenesulfonamide analogues to be considered for further study 
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Additionally, it would also be of interest to determine the importance of the presence 
of the methyl group on the sulfonamide nitrogen in compound, 255, as the growth 
inhibition studies found compound, 258, of which comprised of two methyl groups, 
each positioned on the sulfonamide nitrogen, to have minimal effect on decreasing 
A549 cell growth. Therefore, by constructing the stilbenesulfonamide, 264, shown in 
Figure 5.14, the presence of the isopropyl moiety on the sulfonamide nitrogen would 
allow us to explore the steric effects of this group, whilst the hydrogen bonding ability 
of the sulfonamide is maintained, and to see if an increase or decrease in activity is 
observed with compound 264. 
 
S
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O
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H3C
CH3
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O
N
H3C
H F
255 264  
Figure 5.14 Structure of stilbenesulfonamide analogues to be considered for further study 
 
 
The presence of the fluorine atom on the aromatic ring, meant that a good level of 
solubility was obtained with the compounds examined. However as the main focus of 
the preliminary study was to solely examine the influence of the groups on the 
sulfonamide moiety, conclusions with regards to the SAR of the functional group 
positioned on the other aromatic ring cannot be fully drawn, but does warrant further 
investigation. 
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5.4 Summary 
 
An alternative approach to the synthesis of trans-stilbenesulfonamides is presented, 
via the coupling of 1,4-disubstituted benzylphosphonate analogue, by means of the 
HWE reaction. The 1,4-disubstituted benzylphosphonate, 220, was prepared via 
chlorosulfonation of the inexpensive and commercially available diethyl 
benzylphosphonate, 162, using chlorosulfonic acid, 219. Subsequent aminolysis of the 
sulfonyl chloride intermediate, 220, with various amines successfully afforded the 
desired primary, secondary, tertiary heterocyclic stilbenesulfonamide analogues, 
221a-221i. Various aldehydes, including heterocyclic aldehydes were found to couple 
with substituted 1,4-disubstituted benzylphosphonate analogues, 221a-221i, via the 
HWE reaction, affording the desired products in moderate to high yields. 
Alternatively, the condensation of 4-fluorobenzaldehyde, 230, with the 1,4-
disubstituted benzylphosphonate, 221a, was found to be successful in the presence of 
potassium-tert-butoxide, as the base. In developing the work, this approach has also 
enabled an inexpensive, short and versatile synthetic route for the synthesis of a 
number of trans-stilbenesulfonamide analogues, previously reported in the literature. 
The growth inhibition studies performed found compound, 255, (GI50 0.1 µM) to be 
increasingly more potent, compared to resveratrol, 1, (GI50 51.64 µM) and other 
current chemotherapeutic drugs in the market, such as 5-fluorouracil (GI50 = 
0.189µM), however further studies are required in order to understand the mechanism 
of action. 
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 Conclusions and Future Work 
 
6.1 Conclusions  
 
The aim of this thesis was to investigate various routes towards the synthesis of                                     
trans-arachidin-1, 2, in addition to resveratrol analogues. We have demonstrated for 
the first time a new methodology for the synthesis of arachidin-1, 2, and resveratrol 
analogues, in the form of stilbene benzenesulfonamides, via the HWE reaction. This 
alkene forming reaction was found to be a favourable approach in the construction of 
the trans-stilbene, whilst affording 100 % E-selectivity. 
 
In the approach designed for the synthesis of arachidin-1, 2, incorporation of the 
prenyl side chain was addressed by examining the regioselective demethoxylation 
reaction with the acetal, 184, whereby the use of iodomethylphosphonate at the 
alkylation step of the reaction, enabled the formation of the desired phosphonate, 190, 
in good yield (86 %). This approach was found to be successful and enabled the 
construction of the 3-methylbut-1-enyl moiety in good yield (71 %), followed by the 
synthesis of the stilbene backbone, 3, via the HWE reaction. The final step involving 
demethylation using BBr3 gave arachidin-1, 2, albeit in poor yield (30 %), however 
optimised studies are required in order to obtain the desired compound in quantitative 
yields. 
Other methodologies designed for the synthesis of arachisin-1,2, were not 
successful, for instance the approach based on the methodology reported by Park and 
co-workers 84, involving the coupling of a silyl ether protected benzaldehyde, 151b, 
with the phosphonate, 153, via the HWE reaction highlighted problems, for instance 
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early cleavage of the silyl ether protecting groups was observed, which meant that this 
approach could not be explored further. However, this might have been prevented by 
the use of a non-silica based stationary phase, during purification via column 
chromatography. 
To overcome this drawback an alternative methodology was designed, this approach 
proceeded by the regioselective demethoxylation of the 3,4,5-trimethoxybenzaldehyde 
dimethyl acetal, 184, followed by alkylation with methyl iodide, and acetal hydrolysis 
to give the desired benzaldehyde, 183. The subsequent HWE coupling of the 
aldehyde, 183, with 3,4-dimethoxy benzylphosphonate, 185, gave the trans-stilbene in 
good yield (86 %). Next the Wohl Ziegler bromination of the stilbene, 182, although 
bromination, using NBS was found to be successful, an interesting observation was 
that the presence of both the radical initiator (AIBN) and incandescent light was not 
required for the required to proceed successfully. Nevertheless the main disadvantage 
of this reaction was the need of a toxic solvent, carbon tetrachloride, in large 
quantities, additionally this approach could not be taken further as a result of steric 
issues, which meant that the formation of the phosphonate was unsuccessful. 
 
Next a study into the synthesis of resveratrol analogues was performed, the formation 
of trans-5-(3,5-dimethoxystyryl)-1,2,3-trimethoxybenzene, 124, was successfully 
achieved via the HWE reaction, albeit in poor yield (39 %), furthermore formylation 
of the substituted stilbene, using dichloromethyl methyl ether and titanium(IV) 
chloride, was found to be unsuccessful. After studies were carried out to optimise 
these conditions, the experimental data suggested that at an elevated temperature of 
above -10 °C, di-formylation on the stilbene skeleton occurs, specifically when the 
Lewis acid is used in excess (> 6 equiv.). 
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Nonetheless studies into the synthesis of resveratrol analogues in the form of trans-
stilbene benzenesulfonamides was successfully demonstrated in Chapter 5, this novel 
and versatile methodology enabled the conversion of various primary, secondary and 
cyclic alkyl amines, as well as aromatic amines into a range of benzenesulfonamide 
analogues, in good to excellent yields (60 – 100%), the design of this methodology 
also enabled a scale up of at least a 15 g scale. Construction of the stilbene backbone 
via the HWE coupling reaction, enabled the formation of a library of stilbene 
benzenesulfonamide analogues, using various substituted aldehydes in addition 
heterocyclic aldehydes, in moderate to high yields (42 – 100 %), with excellent                           
E-selectivity. Although this approach offers the scope of structural variety, the 
compounds synthesised in this phase of work, did not represent this extensively. 
The A459 growth inhibition studies performed on the selected six stilbene 
benzenesulfonamide compounds, demonstrates that with regards to SAR the alkyl 
substitutions on the sulfonamide nitrogen, has an effect of the cytotoxic activity of 
these novel compounds. With the stilbene benzenesulfonamide, 255, made from 
methylamine, exhibiting increased antiproliferative activity compared to the parent 
compound resveratrol, 1, (approximately 500-fold) and other cancer chemotherapeutic 
drugs currently on the market. This analogue will be used as a lead compound, along 
with the ammonia derivative, 232e, in subsequent antiproliferative studies. 
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6.2 Future Work 
 
Synthesis of arachidin-1 
 
The results from this work, offers a promising approach to the total synthesis of the 
natural stilbene phytoalexin arachidin-1, 2, by means of coupling the synthesised            
(E)-3,5-dimethoxy-4-(3-methylbut-1-en-1-yl)benzaldehyde, 192, and diethyl (3,4-                                                                                                                                                                                      
dimethoxybenzyl)phosphonate, 185, via the HWE reaction. Although the present work 
has shown the success of this methodology on a small scale, the next step of this work 
is to synthesise arachidin-1, 2, using the methodology described in Chapter 3; part II, 
on a larger scale. In order to fully characterise the reaction intermediates, as well as 
constructing this peanut phytoalexin in quantitative yield and with increased purity. It 
would also be desirable to extend this methodology to the synthesis of other peanut 
phytoalexins, therefore a second aspect of the future work would be to synthesise 
stilbenes including arachidin-2, 8, and arachidin-3, 9, (Figure 6.1) which belong to the 
arachidin family. 
 
 
Figure 6.1  Structure of known stilbene phytoalexins trans-arachidin-2 (8) and trans-
arachidin-3 (9)  
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Synthesis of resveratrol analogues 
 
 
A successful methodology has been developed for the synthesis of stilbene 
benzenesulfonamides, by the coupling of diethyl 4-sulfamoylbenzylphosphonate, 
221a, with various benzaldehydes, via the HWE condensation reaction. The reaction 
conditions developed have been found to be applicable to a diverse range of primary, 
secondary and cyclic alkyl amines, as well as aromatic amines and as a result, this 
approach has enabled the synthesis of a library of novel stilbene benzenesulfonamides, 
however one aspect of the future work will be to fully characterize these novel 
compounds using other analytical techniques including elemental analysis, in order to 
determine the elemental composition of each analogue and x-ray crystallography, in 
order to identify the arrangement of atoms in three dimensional space.  
The present work has also shown the versatility of this reaction, furthermore based on 
the biological studies performed some interesting findings have emerged. Both 
stilbenesulfonamides made from ammonia and methylamine have displayed potent 
anti-proliferative activity, by decreasing protein density in the SRB study. However, 
these results were obtained from preliminary studies, therefore there is much work to 
be done in examining the activity of these compounds.   
 
As a result the first aspect of the future work would be to investigate and extend the 
work further by examining structural modifications of the stilbene 
benzenesulfonamide analogues, by considering a non-mathematical utilization of the 
Hansch approach to drug design, as recommended by Topliss 79, 284, as they represent 
a range of hydrophobic (π) properties, steric properties and electronic (σ) properties.  
By using the Topliss scheme, it would provide a further understanding of the structure 
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activity relationship of these novel compounds, via an optimization process in order to 
determine which substituents on the aromatic ring will lead to increased potency with 
regards to anti-cancer activity. 
In terms of the study performed by Yang et al., 6, it is not clear if the 
benzenesulfonamide analogues were selected based on a quantitative structure-
activity relationship approach, nevertheless Yang and co-workers reported compound, 
125a, to be the most efficacious against the A549 cell line. Interestingly, the results 
from the growth inhibition studies discussed in Section 5.3.2, indicated an overall 
increase in activity, as the hydrophobicity of the functional group on the sulfonamide 
nitrogen increased, specifically from a hydrogen to a methyl group, with the novel 
analogue compound, 255, found to be increasingly potent. It would therefore be of 
interest to use compound, 255, as a lead compound and optimise the substituents on 
the non-sulfonamide aromatic ring, using the Topliss scheme in order to enhance the 
potency. 
Therefore synthesising and investigating the activity of the unsubstituted 
stilbenesulfonamide, 265, in addition to an analogue possessing a hydrophobic and 
electron withdrawing 4-chloro moiety, 266, (Figure 6.2), would enable the potencies 
of these analogues to be compared, with both analogue, 255, and resveratrol, 1. In 
order to determine if the compound possessing the 4-chloro moiety will display equal, 
less or increased activity compared to the unsubstituted stilbenesulfonamide analogue, 
266. Furthermore, this would help to determine which substituted aldehyde to select 
next, based on the Topliss scheme 295 when synthesising new stilbenesulfonamide 
analogues. 
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Figure 6.2 Structures of stilbenesulfonamide analogues to be examined for biological 
activity 
 
 
Once the optimum substituent on the non sulfonamide aromatic ring, has been 
identified enhancing the groups on the sulfonamide nitrogen would be of interest, as 
previously mentioned in Section 5.3.3, it would give us an understanding of the steric, 
and hydrophobic influences displayed by compounds, 264 and 256, (Figure 6.3), 
compared to compound 255.  
 
 
Figure 6.3 Structure of stilbenesulfonamides to be considered for future work  
 
 
In terms of examining the biological activity of the novel stilbene 
benzenesulfonamides, although the assays performed in this preliminary study show 
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interesting results, in order to understand the activity of these compounds, the next 
aspect of the future work, would be to perform additional studies, using MTS, LDH 
assays in order to determine the mechanism of cell death displayed by these novel 
compounds. Additionally performing studies including flow cytometry to measure 
annexin V and PI in order to determine early-phase apoptosis and/or cell necrosis.  
  One main limitation of this preliminary in vitro study, was that the activity of 
these novel analogues were only examined using one cancer cell line (A549). In order 
to determine the potential anticancer activity and gain a better understanding into the 
efficacy displayed by these novel stilbene benzenesulfonamides, the activity of these 
compounds against the breast cancer carcinoma (IGROV-1) would be of interest to 
investigate next, as a number of the stilbenesulfonamide analogues synthesised by 
Yang et al., have also been reported to be highly selective against this cancer cell 
line6. Furthermore, toxicity studies will need to be performed in vitro, in order to 
determine if these novel stilbene benzenesulfonamide analogues are only selective 
towards cancer cells and not normal mammalian cells. 
 
Within the literature resveratrol, 1, has been reported to exhibit fungicidal effects 
against known human infectious fungi, particularly Saccharomyces cerevisiae whilst 
displaying similar potency to amphotericin B 54. It would therefore be of interest as 
future work to examine the antifungal activity of the stilbene benzenesulfonamides 
against the single-celled eukaryote, Saccharomyces cerevisiae.  
 
Finally, the synthesis of stilbene benzenesulfone derivatives in the form of 
styrylheterocycles, 136(a-d), via the Wittig coupling reaction, has been published by 
Lim et al., 173 with moderate to high yields (70 – 100 %). These analogues are of 
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biological interest, as they have been shown to display high selectivity and potency 
towards the COX-2 protein, therefore another direction would be to explore the scope 
of the three step methodology designed in Chapter 5, and determine whether, this 
approach could be adapted and extended to the synthesis of a methylsulfone (p-
SO2Me) moiety, in order to form stilbene benzenesulfone analogues, with various 
functional groups, in order to explore their selectivity towards COX-2 inhibition 
further (Figure 6.4).  
 
 
 
Figure 6.4 Structure of stilbenebenzenesulfone analogues to be considered for future work  
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Chapter Seven: Experimental 
 
 General Experimental Details 
 
Reaction Conditions 
All moisture or oxygen sensitive reactions were performed under an atmosphere of 
nitrogen, using oven dried glassware, syringes and needles. All transfers were carried 
out using glass or plastic syringes. Stirring was by internal magnetic stirrer unless 
otherwise stated. The organic phases were dried with anhydrous magnesium sulfate or 
sodium sulfate. All reactions were monitored by TLC. 
 
Solvents 
Tetrahydrofuran, dichloromethane and chloroform were dried over molecular sieves 
(4Å). All other solvents were used as supplied from commercial sources. 
 
Reagents and Materials 
The materials and commercial available reagents were used as supplied unless stated 
otherwise.  
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Chromatography 
Thin layer chromatography analysis was carried out using POLYGRAM® SIL 
G/UV254 silica gel with fluorescent plates (Macherey-Nagel); thickness of layer 0.20 
mm. Visualisation by exposure to ultraviolet light (λ =  254 nm / 365 nm) and/or  by 
staining with iodine vapour. Flash column chromatography was carried out using 
Merck silica gel 60 (230- 400 mesh). Samples were applied in a concentrated form; 
using an appropriate solvent.  
 
Physical and analytical measurements 
Melting points were determined using a Griffin melting point apparatus and are 
uncorrected. Infrared spectra were recorded using either a Perkin Elmer FT-IR/FIR 
Spectrometer Frontier, with samples prepared as thin films on the universal ATR 
sampling accessory, or on a Varian FT-IR 800 Scimter series, with samples prepared 
as thin films between either NaCl plates or ATR sampling accessory, or on KBr discs.    
1H NMR and 13C NMR spectra were recorded on one of the following spectrometers: 
a Bruker AM360, operating at 150 MHz, 300 MHz, 500 MHz and 600 MHz and 
JEOL ECA, operating at 400 MHz and 600 MHz for proton (1H) and at 100 MHz and 
150 MHz for carbon (13C). NMR measurements were recorded in either chloroform-d 
(CDCl3) or dimethyl sulfoxide-d6 (DMSO-d6) as solvent, unless otherwise stated. For 
the identification of exchangeable protons, deuterium oxide (D2O) was used. The 
chemical shift values (δH and δC) are quoted as parts per million (ppm) relative to the 
internal standard tetramethylsilane (TMS) and/or the residual proton solvent peak for 
1H NMR spectra, and from the solvent peaks for 13C NMR, using values obtained 
from literature 296. The multiplicity of a 1H NMR signal is designated by the following 
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abbreviation: s = singlet, d = doublet, t = triplet, q = quartet, sep = septet, dd = doublet 
of doublets, dq = doublet of quartets, dsep = doublet of septets, m = multiplet and br = 
broad signal. Multiplets are reported as the mean chemical shift at which they appear. 
The coupling constants (J values) are reported to one decimal place with values in 
hertz (Hz). 1H NMR spectra are reported in the form δH (integration, multiplicity, 
coupling constants, assignment). 13C NMR data are recorded in the form δC 
(assignment). Low-resolution mass spectra, with electrospray ionisation (ESI) were 
recorded on a Varian system with 2 x 210 LC pumps, a 400 auto sampler and a 1200L 
mass spectrometer. 
 
Characterisation 
The structures of compounds synthesised within this experimental chapter were 
analysed and characterised on the basis of, but are not limited to, the following 
spectral data; IR, 1H NMR, 13C NMR and low-resolution mass spectra (ESI). In many 
instances assignment of 13C NMR signals were supported by DEPT experiments. The 
purity of the compounds was determined by NMR analysis, this technique was used to 
confirm the compounds synthesised were ≥ 95 % pure. General structural annotations 
for compounds characterised by 1H and 13C NMR analysis, can be seen in Appendix I. 
Wherever it was not possible to fully characterise a compound, by obtaining all 
required data, reasons for this have been specified in the main section of the thesis. 
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7.1 Experimental for Chapter 2 
 
(E)-(3-methylbut-1-en-1-yl)benzene (157) 
 
 
Triethyl phosphite (7.2 g, 44 mmol) and benzyl bromide (5.04 g, 29 mmol) were 
heated at 150 ºC, whilst stirring under a N2 atmosphere. Once the reaction was 
complete, 20 h, as indicated by TLC [3:1 DCM/cyclohexane], the mixture was cooled 
to room temperature; anhydrous DMF (150 mL). Sodium methoxide (20.99 g, 389 
mmol) was added and the resulting mixture was stirred for 30 min, followed by the 
addition of 2-methylpropanal. (1.98 g, 27 mmol). Upon completion of the reaction (24 
h), the mixture was poured into ice-cold water; the precipitate was filtered off and 
dried, to give the title product as an orange solid 3.23 g. Rf 0.90 [3:1 
DCM/cyclohexane]; υmax (neat)/cm-1 1466, 1620 (C=C), 2977, 3263 (C-H and =CH-); 
δH (400 MHz; CDCl3) 1.04 (6H, d, J = 6 Hz, CH3), 6.18 (1H, d, JAB = 16 Hz, trans-
HC=CH), 6.33 (1H, d, JAB = 15.9 Hz,  trans-HC=CH), 2.45 (1H, sep, J = 6 Hz, CH), 
7.37-7.20 (5H, m, ArH); δC (100 MHz; CDCl3) 22.5, 23.3 (2 x C1), 36.6 (C2), 126.6 
(C4’), 126.8 (C4), 127.7 (C3’ & C5’), 128.5 (C3’ & C6’), 137.4 (C1’), 138.1 (C3). % 
purity determined by 1H NMR (compound, 157, (25 %), compound, 162, (55 %), 
compound, 163, (20 %)). 
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Diethyl 3,5-dimethoxybenzylphosphonate (153) 
 
 
 
Triethyl phosphite (1.55 g, 9.3 mmol) was added to 3,5-dimethoxybenzyl bromide 
(1.43 g, 6.2 mmol). Following the addition, the resulting mixture was heated at 130 
°C, whilst stirring for 24 h under N2. Once the reaction was complete, as indicated by 
TLC  [3:1 DCM/cyclohexane], the reaction mixture was left to cool to room 
temperature, to give the desired product (1.98 g, 100 %) as an orange oil; Rf 0.22 [3:1 
DCM/cyclohexane]; υmax (film)/cm-1 1020 (C-O), 1248 (P=O), 1600 (C=C), 2842, 
2905, 2941, 2987 (C-H and =CH-), 3443 (H2O); δH (400 MHz; CDCl3) 1.22 (6H, dt, J 
= 7.2 Hz, C-CH3), 3.06 (2H, d, J = 21.6 Hz, CH2-P), 3.73 (6H, s, OMe), 3.98 (4H, m, 
O-CH2-C), 6.30 (1H, br, J = 6.1 Hz, ArH4), 6.41 (2H, br, J = 2.4 Hz, ArH 3 & 5); δC 
(100 MHz; CDCl3) 16.2, 16.4 (CH2-CH3), 33.3, 34.7 (CH2-P), 55.3 (OMe), 62.1, 62.2 
(O-CH2-C), 99.1 (C1), 107.8, 107.9 (C2 & C6), 133.6, 133.7 (C1), 160.7 (C3 & C5);  
LCMS (ESI) found m/z [M+H]+: 289, C13H21O5P requires 288.11.  
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3,4-bis((tert-butyldimethylsilyl)oxy)benzaldehyde (151a) 
 
 
 
To a stirred solution of 3,4-dihydroxybenzaldehyde (6.16 g, 44 mmol) in anhydrous 
DCM (120 mL), cooled to the required temperature (0 °C), triethylamine (9.43 g, 93 
mmol) was added, followed by DMAP (1.08 g, 8.8 mmol), in anhydrous DCM (80 
mL). Following the addition, the resulting mixture was stirred at 0 °C for 10 min. tert-
Butyldimethylsilyl chloride (14.1 g, 94 mmol) was added, and the resulting mixture 
warmed to room temperature and stirred for 18 h. Water (100 mL) was added to the 
reaction mixture, the mixture was extracted with dichloromethane (3 x 100 mL); the 
organic phases were combined, dried (Na2SO4), filtered and concentrated in vacuo. 
The crude product was purified by flash chromatography using DCM, to afford the 
title product, 151a, (16.06 g, 98 %), as a pale yellow oil; Rf 0.59 [DCM]; υmax 
(film)/cm-1 1590 (C=C), 1682 (C=O), 2856, 2936, 2959 (C-H and =CH-); δH (600 
MHz; CDCl3) 0.00 (12H, s, Si-CH3), 0.82 (18H, s, C-CH3), 6.90 (1H, d, J = 8.2 Hz, 
ArH5), 7.33 (1H, s, ArH2), 7.37 (1H, d, J = 7.8 Hz, ArH6), 9.75 (1H, s, CHO); δC (150 
MHz; CDCl3) -3.63 (Si-CH3), 17.9 (C-(CH3)3), 25.6 (C-(CH3)3), 108.9 (C2), 110.3 
(C5), 126.8 (C6), 130.0 (C1), 149.5 (C3) 154.4 (C4), 190.9 (CHO); LCMS (ESI) found 
m/z [M+3]+: 369, C19H34O3Si2 requires 366.20. 
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 3,4-bis((triisopropylsilyl)oxy)benzaldehyde (151b) 
 
 
 
To a stirred solution of 3,4-dihydroxybenzaldehyde (5.00 g, 36 mmol) in anhydrous 
DCM (120 mL), cooled to the required temperature (0 °C), triethylamine (7.69 g, 79 
mmol) was added, followed by DMAP (0.88 g, 7.2 mmol), in anhydrous DCM (100 
mL). Following the addition, the resulting mixture was stirred at 0 °C for 10 min. 
Triisopropylsilyl chloride (14.6 g, 76 mmol) was added drop wise, and the resulting 
mixture warmed to room temperature and stirred for 18 h. Water (100 mL) was added 
to the reaction mixture, the mixture was extracted with dichloromethane (3 x 100 mL); 
the organic phases were combined, dried (Na2SO4), filtered and concentrated in vacuo, 
to give the crude compound (15.67 g, 96 %). Purification by flash column 
chromatography [DCM], gave the title compound, 151b, (14.72 g, 90 %), as a yellow 
oil; Rf 0.62 [1:2 DCM/cyclohexane]; υmax (film)/cm-1 1593 (C=C), 1702 (C=O), 2729, 
2865, 2892, 2942 (C-H and =CH-); δH (400 MHz; CDCl3) 1.11 (36H, m, C-CH3), 1.32 
(6H, sep, J = 2.5 Hz, Si-CH), 6.92 (1H, d, J = 8.1 Hz, ArH5’), 7.30 (1H, dd, 4J  = 2.1 
Hz, J = 6.1 Hz, ArH2), 7.35 (1H, d, J = 2.0 Hz, ArH6), 9.77 (1H, s, CHO); δC (100 
MHz; CDCl3) 17.9 (CH-CH3), 26.9 (Si-CH), 118.9 (C2), 119.6 (C5), 125.2 (C6), 130.3 
(C1), 147.8 (C3) 153.4 (C4), 190.7 (CHO); LCMS (ESI) found m/z [M-H]- : 293, 
C16H25O3Si requires 293.16; 450, C25H46O3Si2 requires 450.30. % purity determined 
by 1H NMR (compound, 151b, (86 %), compound, 150, (14 %)). 
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(E)-((4-(3,5-dimethoxystyryl)-1,2-phenylene)bis(oxy))bis(triisopropylsilane) 
(154b) 
 
 
 
To a solution of diethyl 3,5-dimethoxybenzylphosphonate (7.40 g, 25 mmol) and          
3,4-bis((triisopropylsilyl)oxy)benzaldehyde (11 g, 24 mmol) in dry THF (100 mL) at 
0 ºC, under N2 atmosphere. Potassium-tert-butoxide (8.29 g, 113 mmol) was added, 
then the reaction was stirred for 18 h at room temperature, under N2 atmosphere. The 
reaction was monitored by TLC [DCM]. Once the reaction was complete, as indicated 
by TLC, the reaction was quenched by the addition of water (50 mL) and the reaction 
mixture was extracted with ethyl acetate (3 x 100 mL), the organic phases were 
combined, washed with saturated NH4Cl solution (50 mL), followed by water (50 
mL), then brine (50 mL), dried (Na2SO4), filtered and concentrated in vacuo to give 
the impure product (8.04 g, 56 %) as an orange oil. Purification by column 
chromatography on silica gel [1:10 cyclohexane/EtOAc], gave the product as a pale 
yellow oil (3.84 g, 27 %); Rf  0.10, 0.65, 0.73, 0.81, 0.93 [DCM]; υmax (film)/cm-1 1593 
(C=C), 2869, 2892, 2947 (C-H and =CH-); δH (400 MHz; CDCl3) 1.13 (36H, m, C-
CH3), 1.31 (6H, sep, J = 8.0 Hz, Si-CH), 3.82 (6H, s, OMe), 6.36 (1H, d, J = 2.0 Hz, 
ArH4), 6.63 (2H, d, J = 1.0 Hz, ArH2’ & 5’), 6.80 (1H, m, ArH2), 6.79 (1H, m, trans-
HC=CH), 6.94 (1H, d, JAB = 16.3 Hz, trans-HC=CH), 6.96 (1H, dd, 4J = 1.8 Hz, J = 
5.2 Hz, ArH6’), 6.98 (1H, s, ArH6 - overlapping); δC (100 MHz; CDCl3) 12.0, 12.3, 
(CH3), 17.7, 18.0 (Si-CH), 55.3 (OMe), 99.6 (C4), 104.4 (C2 & C6), 117.5 (C2’), 117.7 
(C5’), 124.0 (C6’), 127.1, 127.3 (C7’ & C7), 129.8 (C1’), 142.8 (C1), 147.1 (C4’) 147.2 
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(C3’), 160.9, 161.0 (C3 & C5); LCMS (ESI) found m/z [M+H]+: 427, C25H35O4Si 
requires 427.23, 589, C34H58O4Si2 requires 584.37. 
% purity determined by 1H NMR (compound, 154b, (79 %), compound, 169, (21 %)). 
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7.2 Experimental for Chapter 3 
 
3,5-dimethoxy-4-methylbenzaldehyde (183) 
 
 
 
A solution of 3,4,5-trimethoxybenzaldehyde dimethyl acetal (12.07 g, 50 mmol) in 
anhydrous THF (180 mL), was added dropwise, to a stirring mixture of sodium, 30-35 
wt % dispersion in paraffin, (9.88 g, 429 mmol) in anhydrous THF (60 mL) cooled to  
1 ºC, under an atmosphere of N2. The resulting mixture was stirred for 26 h under an 
atmosphere of N2, at room temperature. Once the reaction was complete, as indicated, 
by TLC [3:1 DCM/cyclohexane], the mixture was cooled to 0 ºC, followed by the 
dropwise addition of iodomethane (7 mL). The resulting mixture was stirred at room 
temperature, under an atmosphere of N2 for 24 h. Once the reaction complete, the 
mixture was added dropwise to water (120 mL) and extracted with ether (2 x 200 mL), 
the organic phases were collected and washed with water (120 mL), and the organic 
phase was separated and dried (MgSO4), filtered and concentrated in vacuo to afford 
the crude acetal. The crude solid was dissolved in a solution of 1M hydrochloric acid 
(200 mL) in THF (200 mL); (1:1) and stirred at room temperature for three days, after 
which the mixture was extracted with diethyl ether (3 x 120 mL), The organic phases 
were then combined and washed with water (2 x 120 mL), the organic phase was 
separated and dried with MgSO4, filtered and concentrated in vacuo. Recrystallization 
(propan-1-ol) gave the title compound, 183 (yield: 8.24 g, 92 %) as a yellow solid; Rf  
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0.59 [3:1 DCM/cyclohexane]; m.p. 86 ºC - 88 ºC (lit m.p. 89 - 90 °C 297); υmax 
(neat)/cm-1 1126, 1239 (C-O), 1391 (CH3), 1462, 1588 (C=C), 1684 (C=O), 2751, 
2797, 2847, 2931, 2973, 3015, 3066, 3112 (C-H and =CH-); δH (100 MHz; CDCl3) 
2.10 (3H, s, C-CH3), 3.88 (6H, s, OMe), 6.98 (2H, s, ArH2 & 6), 9.84 (1H, s, CHO); δC 
(100 MHz; CDCl3) 8.9 (CH3), 55.8 (OMe), 104.6 (C3 & C5), 122.4 (C1), 135.1 (C4), 
158.6 (C2 & C6), 191.9 (CHO); LCMS (ESI) found m/z [M-H]-  : 180, C10H12O3 
requires 180. The data was consistent with literature values 201, 202. 
 
 
4-(Bromomethyl)-1,2-dimethoxybenzene (187) 
 
 
 
Phosphorus tribromide (90 g, 335 mmol), dissolved in anhydrous diethyl ether (160 
mL) was slowly added to a stirred solution of 3,4-dimethoxybenzyl alcohol (47 g, 280 
mmol) in anhydrous diethyl ether (410 mL), at room temperature, under an 
atmosphere of N2, then the reaction was stirred for 22 h. Following the completion of 
the reaction, as indicated by TLC [DCM], the reaction mixture was poured into ice 
cold water (500 mL) and the mixture was neutralised by the addition of sodium 
hydrogen carbonate. The reaction mixture was extracted with dichloromethane (3 x 
200 mL), The organic phases were then combined and dried (MgSO4), filtered and 
concentrated in vacuo to give 4-(bromomethyl)-1,2-dimethoxybenzene, (yield: 65 g, 
101 %), as white crystals; Rf  0.22 [DCM]; m.p. 48 ºC - 51 ºC (lit m.p. 47 - 50 °C 97); 
υmax (KBr)/cm-1 1035 (C-O), 1420 (CH3), 1607, 1523 (C=C), 2839, 2910, 2952, 3005, 
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3014 (C-H and =CH-); δH (75 MHz; CDCl3) 3.73 (3H, s, OMe), 3.75 (3H, s, OMe), 
4.49 (2H, s, CH2), 6.78 (1H, d, J = 9 Hz, ArH3), 6.93 (2H, m, J = 9 Hz, ArH2 & 6); δC 
(100 MHz; CDCl3) 34.5 (CH2-Br), 55.7, 55.8 (2 x OMe), 111.1 (C3), 112.1 (C6), 120 
(C2), 130.8 (C1), 148.6 (C5), 149.2 (C4); LCMS (ESI) found m/z [M + H]+: 230 (79Br), 
C9H11BrO2 requires 229. The data was consistent with literature values 218. % purity 
determined by 1H NMR (compound, 187, (93 %), compound, 186, (7 %)). 
 
 
Diethyl (3,4-dimethoxybenzyl)phosphonate (185) 
 
 
 
Triethyl phosphite (77 g, 0.46 mol) was added to 3,4-dimethoxybenzyl bromide (71 g, 
0.31 mol), then the resulting solution was heated at 151 °C, under an atmosphere of 
N2, for 24 h. The desired product was obtained upon cooling to room temperature 
(yield: 50.60 g, 57 %) as colourless oil. No further work up or additional purification 
was performed. Rf 0.08 [2:1 DCM/cyclohexane]; υmax (neat)/cm-1 1249 (P=O), 2832, 
2907, 2937, 2978 (C-H and =CH-); δH (400 MHz; CDCl3) 1.16 (6H, t, J = 4.1 Hz, C-
CH3), 2.94 (2H, d, J = 21.1 Hz, CH2-P), 3.73 (3H, s, OMe), 3.75 (3H, s, OMe), 3.92 
(4H, m, J = 5.4 Hz, O-CH2-C), 6.78 (1H, d, J = 9 Hz, ArH3), 6.94 (2H, m, J = 9 Hz, 
ArH2 & 6); δC (100 MHz; CDCl3) 16.4 (2 x CH3), 32.4, 33.8 (CH2-P), 55.8 (2 x OMe), 
62.7, 62.0 (2 x OCH2), 111.1 (C3), 112.8 (C6), 121.8 (C2), 123.7 (C4) 147.9 (C5), 148.8 
(C4); LCMS (ESI) found m/z [M + H]+: 289, C13H21O5P requires 288. % purity 
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determined by 1H NMR (compound, 185, (48 %), triethyl phosphite (52 %)). The data 
was consistent with literature values 201, 202. 
 
 (E)-5-(3,4-dimethoxystyryl)-1,3-dimethoxy-2-methylbenzene (182) 
 
 
 
To a stirred mixture of the diethyl (3,4-dimethoxybenzyl)phosphonate (50.60 g, 0.17 
mmol) in anhydrous DMF (210 mL) at room temperature, under an atmosphere of N2, 
sodium methoxide (9.1 g, 0.16 mol) was added. The reaction was stirred for 30 min, 
then 3,5-dimethoxy-4-methylbenzaldehyde (20.24 g, 0.11 mmol) in anhydrous DMF 
(50 mL) was added to the stirred mixture and the reaction mixture was left to stir at 
room temperature. The reaction was monitored by TLC [3:1 DCM/cyclohexane]. 
Once the reaction was complete, as indicated by TLC, the reaction was quenched by 
the addition of ice and stirred. The precipitate was filtered off, washed with cold water 
and air dried to give the crude product; (E)-5-(3,4-dimethoxystyryl)-1,3-dimethoxy-2-
methylbenzene (yield: 12.29 g, 35 %), as a pale yellow solid. Rf 0.48 [3:1 
DCM/cyclohexane]; m.p. 147 ºC - 159 ºC; υmax (KBr)/cm-1 1143 (C-O), 1420 (CH3), 
1462, 1511, 1584 (C=C), 2849, 2917, 2956, 2994, 3002 (C-H and =CH-); δH (400 
MHz; CDCl3) 2.10 (3H, s, CH3), 3.87 (6H, s, OMe), 3.89 (3H, s, OMe), 3.94 (3H, s, 
OMe), 6.68 (2H, s, ArH2 & 6), 6.86 (1H, d, J = 12 Hz, ArH5’), 6.93 (1H, d, JAB = 16.2 
Hz, trans-HC=CH), 7.02 (1H, m, trans-HC=CH), 6.97 (1H, m, ArH2’), 7.27 (1H, d, J 
= 6 Hz, ArH6’); δC (100 MHz; CDCl3) 8.93 (CH3), 55.8, 55.9 (OMe), 101.8 (C2 & C6), 
108.7 (C2’), 111.3 (C5’), 114.2 (C4), 119.8 (C6’), 127.4, 127.7 (C7 & C7’), 130.5 (C1’), 
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136.0 (C1), 148.9 (C4’), 149.2 (C3’), 158.5 (C3 & C5); LCMS (ESI) found m/z [M + 
H]+: 315, C19H22O4 requires 314. % purity determined by 1H NMR (compound, 182, 
(86 %), compound, 183, (14 %)). 
 
 
Attempted Synthesis of (E)-2-(bromomethyl)-5-(3,4-dimethoxystyryl)-1,3-
dimethoxybenzene (181b) 
 
 
To the crude (E)-5-(3,4-dimethoxystyryl)-1,3-dimethoxy-2-methylbenzene (0.92 g, 
2.9 mmol) dissolved in carbon tetrachloride (70 mL), N-bromosuccinimide (2.08 g, 12 
mmol) followed by 2,2′-azobis(2-methylpropionitrile) (0.032 mg, 1.9 x 10-5 mmol) 
was added, then the mixture was heated under reflux at 78 °C, whilst stirring for 24 h. 
The reaction was monitored by TLC [3:1 DCM/cyclohexane], once the reaction was 
complete, the mixture was cooled and filtered using a sintered funnel, to collect the 
succinimide solid. The organic solvent was washed with water (3 x 100 mL) dried 
(Na2SO4), filtered and concentrated in vacuo. Petroleum ether, 40 – 60 % (50 mL) was 
added and the precipitate was filtered under vacuum, to afford a beige solid. Yield:    
0.22 g, 19 %;  Rf 0.55 [2:1 EtOAc/cyclohexane]; m.p. 98 - 110 ºC; υmax (neat)/cm-1 
1167 (C-O), 1514, 1589 (C=C), 2843, 2948, 3014 (C-H and =CH-); δH (400 MHz; 
CDCl3) 3.88 (6H, s, OMe), 3.90 (3H, s, OMe), 3.93 (3H, s, OMe), 4.58 (2H, q, J = 
3.12 Hz, CH2-Br), 6.85 (2H, s, ArH2 & 6), 6.89 (1H, m, trans-HC=CH), 6.92 (1H, m, 
ArH5’), 6.99 (1H, d, JAB = 16.0 Hz, trans-HC=CH), 7.32 (1H, m, ArH2’), 7.53 (1H, m, 
ArH6’); LCMS (ESI) found m/z [M+H]+: 393, C19H21BrO4 requires 392. 
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Diethyl (4-(dimethoxymethyl)-2,6-dimethoxybenzyl)phosphonate (190) 
 
 
 
A solution of 3,4,5-trimethoxybenzaldehyde dimethyl acetal (3.23 g, 13 mmol) in 
anhydrous THF (30 mL), was added dropwise, to a stirring mixture of sodium, 30-35 
wt % dispersion in paraffin (2.8 g, 121 mmol) in anhydrous THF (110 mL) cooled to 0 
ºC, under an atmosphere of N2. The resulting mixture was stirred for 24 h under an 
atmosphere of N2, at room temperature. Once the reaction complete, as indicated by 
TLC [3:1 DCM/cyclohexane], the mixture was cooled to 0 ºC and diethyl  
iodomethylphosphonate (5.0 g, 18 mmol) was added drop wise. The resulting mixture 
was stirred at room temperature, under N2 for 24 h. The reaction was quenched by the 
addition of water (20 mL) and extracted with ether (3 x 30 mL), the organic phases 
were collected and washed with water (20 mL), and then brine (20 mL), and the 
organic phases were collected, dried (MgSO4), filtered and concentrated in vacuo to 
afford the crude acetal, as a fluffy orange solid. The crude acetal was immediately 
used for the next reaction. Yield: 6.92 g. Rf 0.06 [3:1 DCM/cyclohexane]; υmax 
(neat)/cm-1 1118, 1204 (C-O), 1462, 1595 (C=C), 2847, 2915, 2953 (C-H and =CH-); 
δH (400 MHz; CDCl3) 1.24 (6H, t - broad,  C-CH3), 3.32 (2H, d - broad, CH2-P), 3.47 
(6H, m - broad, OMe), 3.84 (6H, m - broad, OMe), 3.95 (4H, m, O-CH2-C), 6.38 (1H, 
s, CH), 6.50 (2H, s - broad, ArH2 & 6); LCMS (ESI) found m/z = 361, C16H27O7P 
requires 362. Broad peak signals were observed in the NMR spectrum, therefore the 
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product could not be fully characterised by NMR analysis. % purity determined by 1H 
NMR (compound, 190, (86 %), compound, 184, (14 %)). 
 
 
(E)-5-(dimethoxymethyl)-1,3-dimethoxy-2-(3-methylbut-1-en-1-yl)benzene (191) 
 
 
 
Crude diethyl (4-(dimethoxymethyl)-2,6-dimethoxybenzyl)phosphonate (6.70 g, 18 
mmol) was stirred in anhydrous THF (30 mL) at room temperature, under an 
atmosphere of N2. t-BuOK (8.61 g, 77 mmol) was added and the resulting mixture 
was stirred for 15 min; 2-methylpropanal (1.58 g, 22 mmol) was added to the stirred 
mixture and left to stir at room temperature. The reaction was monitored by TLC [3:1 
DCM/cyclohexane], once the reaction was complete, the reaction was quenched by 
the addition of ice and the resulting mixture was extracted with ether (3 x 150 mL), 
the organic phases were collected and washed with water (50 mL), then brine (50 
mL). The organic phases were collected, dried (MgSO4), filtered and concentrated in 
vacuo to afford an orange solid. The crude product, was immediately used for the next 
reaction. Yield: 8.14 g, 157 %. Rf  0.16  [3:1 DCM/cyclohexane]; υmax (neat)/cm-1 
1119, 1204   (C-O), 1462, 1596 (C=C), 2848, 2915, 2956 (C-H and =CH-); δH (400 
MHz; CDCl3) 0.94 (6H, d, J = 6.7 Hz, C-(CH3)2), 1.92 (1H, dsep, CH-(CH3)2), 3.46 
(6H, s, OMe), 3.78 (6H, s, OMe), 6.35 (1H, dd, J = 16.0 Hz, J = 2.3 Hz, trans-
CH=CH), 6.52 (1H, d, JAB = 15.9 Hz, trans-CH=CH), 6.67 (2H, d, J = 2.2 Hz, ArH2 & 
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6), 6.75 (1H, s, CH); LCMS (ESI) found m/z [M-H]- : 279, C16H24O4 requires 280. % 
purity determined by 1H NMR (compound, 190, (71 %), compound, 191, (29 %)). 
 
 
(E)-3,5-dimethoxy-4-(3-methylbut-1-en-1-yl)benzaldehyde (192) 
 
 
 
The crude acetal (8.04 g, 29 mmol) was dissolved in a solution of 1M HCl : THF (75 
mL : 75 mL) and stirred at room temperature for 48 h, after which the mixture was 
extracted with diethyl ether (3 x 150 mL), the organic phases were then combined and 
washed with water (50 mL), the organic phase were collected, dried (MgSO4), filtered 
and concentrated in vacuo, to give the crude yellow fluffy solid. The crude product, 
was immediately used for the next reaction. Yield: 6.56 g, 98 %. Rf 0.36 [3:1 
DCM/cyclohexane]; υmax (neat)/cm-1 1072 (C-O), 1472 (C=C), 1706 (C=O), 2848, 
2915, 2956 (C-H and =CH-); δH (400 MHz; CDCl3) 0.96 (6H, d, J = 6.9 Hz, C-
(CH3)2), 1.91 (1H, dsep,  J = 4.0 Hz, CH-(CH3)2), 3.77 (6H, s, OMe), 6.47 (1H, dd, 
JAB = 16.0 Hz, JAB = 2.4 Hz, trans-CH=CH), 6.54 (1H, d, JAB =15.9 Hz, trans-
CH=CH), 6.66 (2H, d, J = 2.2 Hz, ArH2 & 6), 9.82 (1H, s, CHO); LCMS (ESI) found 
m/z [M-H]- : 233, C14H18O3 requires 234. % purity determined by 1H NMR 
(compound, 192, (52 %), compound, 191, (48 %)). 
 
Chapter 7: Experimental 
 
 
206 
 
5-((E)-3,4-dimethoxystyryl)-1,3-dimethoxy-2-((E)-3-methylbut-1-en-1-yl)benzene 
(3) 
 
 
 
To a stirred mixture of the benzylphosphonate (5.23 g, 18 mmol) in THF (40 mL) at 
room temperature, t-BuOK (6.02 g, 54 mmol) was added and the resulting mixture 
was stirred. (E)-3,5-Dimethoxy-4-(3-methylbut-1-en-1-yl)benzaldehyde (6.53 g, 18 
mmol) was added and the reaction mixture was left to stir at room temperature. The 
reaction was monitored by TLC [3:1 dichloromethane/cyclohexane]. Once the 
reaction was complete (24 h), the reaction was quenched by the addition of water (50 
mL) and extracted with ether (3 x 100 mL); the organic phases were collected and 
washed with water (50 mL), and the organic phase was separated, dried (MgSO4), 
filtered and concentrated in vacuo to afford the product, as a golden yellow oil (yield: 
3.09 g, 30 %). Trituration of the crude product [diethyl ether/cyclohexane], gave the 
titled product, 3, as an orange solid. Yield 30 %; Rf 0.67 [3:1 DCM/cyclohexane]; 
m.p. 78 - 89 ºC; υmax (neat)/cm-1 1205 (C-O), 1377, 1515 (CH3), 1462, 1597 (C=C), 
2848, 2915, 2955 (C-H and =CH-); δH (400 MHz; CDCl3) 0.95 (6H, d, J = 6.8 Hz, C-
(CH3)2), 1.92 (1H, dsep, CH-(CH3)2), 3.77 (3H, s, OMe), 3.79 (3H, s, OMe), 3.87 (6H, 
s, OMe), 6.47 (1H, d, JAB = 16.0 Hz, trans-CH=CH), 6.55 (1H, d, JAB = 16.0 Hz, 
trans-CH=CH), 6.67 (2H, d, J = 2.4 Hz, ArH2 & 6), 6.79 (1H, d, JAB = 16.0 Hz, trans-
HC=CH stilbene), 6.85 (1H, m, trans-HC=CH stilbene), 6.82 (1H, m, ArH6’ - overlapping), 
6.89 (1H, d, J = 2.5 Hz, ArH2’), 6.98 (1H, m, ArH6’); LCMS (ESI) found m/z [M-H]- : 
367, C23H28O4 requires 368. 
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 Model reaction: Demethylation with boron tribromide (202a) 
 
 
To a solution of (E)-1,2-dimethoxy-4-(4-methylstyryl)benzene (0.5 g, 1.9 mmol) 
dissolved in dry DCM (45 mL), cooled to -20 ºC, whilst stirring under an atmosphere 
of N2, boron tribromide (1.97 g, 7.9 mmol) was added dropwise. Following the 
addition, the round bottom flask was allowed to warm up to room temperature, whilst 
stirring. Once the reaction was complete (4 h), as indicated by TLC [1:2 
EtOAc/DCM], the reaction mixture was added dropwise into a saturated solution of 
NaHCO3 (40 mL), whilst stirring, then the DCM solvent was removed. The resulting 
aqueous solution was extracted with ethyl acetate (3 x 100 mL), the organic phases 
were collected, dried (Na2SO4), filtered and concentrated in vacuo. Yield of crude 
product: 0.34 g, 76 %, as a yellow oily solid. Trituration of the crude product [diethyl 
ether / cyclohexane], gave the pure product (0.20 g, 44 %), as a pale yellow solid. Rf  
0.75 [1:5 EtOAc/DCM]; m.p. 140 °C – 143 °C; υmax (neat)/cm-1 1439, 1516, 1597 
(C=C), 2855, 2913, 3023 (C-H and =CH-), 3344 (OH); δH (400 MHz; CDCl3) 2.34 
(3H, s, CH3), 4.82 (2H, s - broad, OH), 6.83 (1H, d, J 8.0 Hz, ArH5’), 6.89 (1H, d, JAB 
= 16.0 Hz, trans-HC=CH), 6.94 (1H, d, JAB = 16.0 Hz, trans- HC=CH), 6.94 (1H, dd, 
J = 2.3 Hz, J  = 8.0 Hz, ArH6’), 7.05 (1H, d, J = 2.0 Hz, ArH2’), 7.14 (2H, d, J = 8.0 
Hz, ArH3 & 5), 7.36 (2H, d, J = 8.0 Hz, ArH2 & 6); δC (100 MHz; CDCl3) 21.0 (CH3), 
116.1 (C2’), 119.5 (C5’), 125.0 (C6’), 132.8 (C7 & C7’), 133.8, 133.9 (C2 & C6), 136.7 
(C3 & C5), 139.2 (C1), 143.4 (C1), 146.5 (C4), 154.10 (C3’), 154.63 (C4’); LCMS (ESI) 
found m/z [M-H]- : 225, C15H14O2 requires 226. 
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Model reaction: Attempted demethylation with pyridine hydrochloride (202b) 
 
 
(E)-1,2-Dimethoxy-4-(4-methylstyryl)benzene (0.74 g, 2.9 mmol) and excess molten 
pyridine hydrochloride (5.42 g, 47 mmol) were mixed and heated (141 ºC), whilst 
stirring for 1 h. Once the reaction was complete, as indicated by TLC [2:1 
DCM/cyclohexane], the reaction mixture was poured into 2N HCl (50 mL) and the 
resulting mixture was extracted with ethyl acetate (3 x 100 mL), dried over Na2SO4, 
filtered and concentrated in vacuo to yield the impure product. Purification by 
trituration with ether : cyclohexane (3:1), gave the pure product (0.17 g, 26 %), as a 
deep orange solid. Rf  0.08 [3:1 DCM/cyclohexane]; υmax (neat)/cm-1 1515, 1601 
(C=C), 2856, 2911, 3025 (C-H and =CH-), 3405 (OH); δH (600 MHz; CDCl3) 2.33 
(3H, s, CH3), 5.12 (2H, s, OH), 6.82 (1H, d, J = 8.2 Hz, ArH5’), 6.90 (1H, m, trans-
HC=CH), 6.94 (1H, m, trans-HC=CH), 9.40 (1H, dd, J = 2.4 Hz, J = 7.8 Hz, ArH6’), 
7.04 (1H, d, J = 2.0 Hz, ArH2’), 7.12 (2H, d, J = 7.8 Hz, ArH3 & 5), 7.35 (2H, d, J = 
7.8 Hz, ArH2 & 6); δC (100 MHz; CDCl3) 21.2 (CH3), 112.8 (C2’), 115.5 (C5’), 120.0 
(C6’), 126.2 (C7 & C7’), 127.0 (C2 & C6), 129.3 (C3 & C5), 131.3 (C1’), 134.6 (C1), 
137.1 (C4) 143.1 (C3’), 143.5 (C4’); LCMS (ESI) found m/z [M-H]- : 225, C15H14O2 
requires 226. % purity determined by 1H NMR (compound, 202b, (38 %), ethyl 
acetate (44 %), compound, 199, (18 %)). 
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7.3 Experimental for Chapter 4 
 
5-(Bromomethyl)-1,2,3-trimethoxybenzene (208) 
 
 
To a solution of 3,4,5-trimethoxybenzyl alcohol (37 g, 187 mmol) in anhydrous 
dichloromethane (535 mL), cooled to -5 °C, whilst stirring, phosphorus tribromide (35 
g, 144 mmol) was added dropwise and the resulting mixture was stirred for 4 h at -5 
°C. Once the reaction was complete, as indicated by TLC [3:1 DCM/cyclohexane], the 
reaction mixture was added slowly to ice whilst stirring and neutralised with sodium 
hydrogen carbonate. The mixture was extracted with dichloromethane (3 x 120 mL); 
the organic phases were combined and dried (Na2SO4) filtered and concentrated in 
vacuo to afford the crude title compound, 208, (yield: 38.60 g), as a pale pink solid; Rf 
0.24 [3:1 DCM/cyclohexane]; υmax (neat)/cm-1 668 (C-Br), 1125 (C-O), 1469, 1592 
(C=C), 22836, 2940, 2969, 2994, 3077 (C-H and =CH-); δH (400 MHz; CDCl3) 3.79 
(3H, s, OMe), 3.81 (6H, s, OMe), 4.41 (2H, s, CH2), 6.57 (2H, s, ArH2 & 6); δC (100 
MHz; CDCl3) 34.5 (CH2), 56.1 (2 x OMe - meta), 60.9 (OMe), 106.1 (C2 & C6), 133.2 
(C1), 138.0 (C4), 153.3 (C3 & C5). LCMS (ESI) found m/z [M-H]-  : 259, C10H13BrO3 
requires 260.00. 
 
 
 
 
Chapter 7: Experimental 
 
 
210 
 
Diethyl 3,4,5-trimethoxybenzylphosphonate (209) 
 
 
 
The diethyl benzylphosphonate derivative was prepared according to the procedure 
reported by Azzena et al., 222. Triethyl phosphite (37.46 g, 225 mmol) and 5-
(bromomethyl)-1,2,3-trimethoxybenzene (38.60 g, 148 mmol), were heated under 
reflux at 151 °C under an atmosphere of N2, for 24 h. Following completion, as 
indicated by TLC [3:1 DCM/cyclohexane], the reaction mixture was left to cool to 
room temperature, yielding the desired product (yield: 61.16 g, 130 %), as a pale 
yellow viscous oil; Rf 0.09 [3:1 DCM/cyclohexane]; υmax (neat)/cm-1 1247 (P=O), 
1462, 1590 (C=C),  2839, 2913, 2940, 2986 (C-H and =CH-); δH (400 MHz; CDCl3) 
0.89 (6H, t,           J = 7.0 Hz, C-CH3), 2.70 (2H, d, J = 21.4 Hz, CH2-P), 3.42 (3H, s, 
OMe), 3.46 (6H, s, OMe), 3.66 (4H, dq, J = 7.0 Hz, O-CH2), 6.18 (2H, d, J = 2.5 Hz, 
ArH2 & 6); δC (100 MHz; CDCl3) 16.0, 16.1 (2 x CH3), 32.7, 34.1 (CH2-P), 55.7 (2 x 
OMe - meta), 60.3 (OMe), 61.7, 61.8 (2 x O-CH2), 106.6, 106.7 (C2 & C6), 126.8 (C1), 
136.7 (C4), 152.8 (C3 & C5); LCMS (ESI) found m/z [M + H]+: 319, C14H23O6P 
requires 318. % purity determined by 1H NMR (compound, 208, (90 %), triethyl 
phosphite (10 %)). 
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3,5-dimethoxybenzaldehyde (211) 
 
 
 
To a solution of anhydrous tetrahydrofuran (360 mL) and sodium metal, 30-35 wt. % 
dispersion in wax (5.79 g, 84 mmol), cooled to -5 °C,  3,4,5-
trimethoxybenzylaldehyde dimethyl acetal (26.17 g, 108 mmol) dissolved in 
anhydrous tetrahydrofuran (144 mL) was added drop wise, under an atmosphere of 
N2, and the resulting mixture was stirred for 3 days at room temperature. Once the 
reaction was complete, as indicated by TLC, the reaction mixture was quenched by 
the dropwise addition of water (480 mL). The mixture was extracted with diethyl ether 
(3 x 360 mL); the organic phases were combined and washed with brine, then dried 
(Na2SO4), filtered and concentrated in vacuo to afford the crude acetal. The crude 
acetal (29.2 g) was dissolved in THF (395 mL): 1M HCl (395 mL), the reaction 
mixture was stirred for 48 h at room temperature. Once the reaction was complete, as 
indicated by TLC, the reaction mixture was extracted with diethyl ether (4 x 360 mL); 
the organic phases were combined and washed with water (4 x 360 mL), then brine 
(20 mL), then dried (MgSO4), filtered and concentrated in vacuo to afford the afford 
the title compound, 211, (yield: 18.02 g, 100 %), as a yellow solid; m.p. 45 - 48 ºC 
(Lit. m.p. 46 – 48 ºC 202); Rf 0.74 [3:1 DCM/cyclohexane]; υmax (KBr)/cm-1 1129, 
1234 (C-O), 1463, 1592 (C=C), 1695 (C=O), 2755, 2850 (CHO), 2921, 3010, 3092 
(C-H and =CH-); δH (400 MHz; CDCl3) 3.74 (3H, s, OMe), 3.75 (3H, s, OMe), 6.60 
(1H, m, ArH4), 6.91 (2H, m, ArH2 & 6), 9.80 (1H, s, CHO); δC (100 MHz; CDCl3) 55.5 
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(OMe), 107.0 (C2 & C6), 138.4 (C1 & C4), 139.4 (C3 & C5), 191.8 (CHO); LCMS 
(ESI) found m/z [M-H]- : 165, C9H10O3 requires 166. The data was consistent with 
literature values 202. 
 
 
(E)-5-(3,5-dimethoxystyryl)-1,2,3-trimethoxybenzene (124) 
 
 
To a stirred mixture of 3,5-dimethoxybenzaldehyde (18.02 g, 108 mmol) in DMF (270 
mL) at room temperature, under N2, diethyl (3,4,5-trimethoxybenzyl)phosphonate 
(33.06 g, 104 mmol), followed by sodium methoxide (28.5 g, 528 mmol) was added. 
The reaction was stirred at room temperature, under an atmosphere of N2. Once the 
reaction was complete, as indicated by TLC [3:1 DCM/cyclohexane], the reaction was 
quenched by the addition of ice and stirred. The precipitate formed was filtered off, 
washed with cold water and air dried to give the impure product as a pale brown solid 
(72 %). Purification by recrystallization (ethanol) afforded the desired product, 124, as 
a white crystals. Yield: 13.39 g, 39 %; m.p. 128 - 132 ºC (Lit. m.p. 135 ºC 298; Rf 0.27 
[3:1 DCM/cyclohexane]; υmax (KBr)/cm-1 1511, 1589 (C=C), 2835, 2849, 2918, 2976, 
3005, 3034 (C-H and =CH-); δH (400 MHz; CDCl3) 3.85 (6H, s, OMe), 3.89 (3H, s, 
OMe), 3.93 (6H, s, OMe), 6.41 (1H, t, J = 2.2 Hz, ArH4), 6.68 (2H, d, J = 2.2 Hz, 
ArH2& 6), 6.75 (2H, s, ArH2’ & 6’), 6.95 (1H, d, JAB = 16.1 Hz, trans-HC=CH), 7.03 
(1H, d, JAB = 16.5 Hz, trans-HC=CH); δC (75 MHz; CDCl3) 55.4, 56.2, 61.0 (OMe), 
100.0 (C4), 103.7 (C2’ & C6’), 104.5 (C2 & C6), 128.2, 129.2 (C7 & C7’), 132.9 (C1’), 
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138.1 (C4’), 139.3 (C6’'), 153.4 (C3’ & C6’), 161.0 (C3 & C5); LCMS (ESI) found m/z 
[M + H]+: 331, C19H22O5 requires 330. 
 
Pentyltriphenylphosphonium bromide (215)  
 
 
To a stirred solution of 1-bromopentane (9.99 g, 66 mmol) in toluene (50 mL),  
triphenylphosphine (4.32 g, 16 mmol), was added, the mixture was refluxed 18 h. 
Following completion, as indicated by TLC [3:1 cyclohexane/DCM], the reaction 
mixture was left to cool to room temperature and the mixture was poured into ice, 
filtered and washed with cold diethyl ether, to afford the crude product as a white 
solid. Yield: 1.42 g, 21 %;  Rf 0.08 [3:1 cyclohexane/DCM]; m.p. 150 - 153 °C (Lit 
m.p. 167 – 168 °C 299); υmax (KBr)/cm-1 1436, 1585 (C=C), 2793, 2859, 2956, 3055 
(C-H and =CH-); δH (400 MHz; CDCl3) 0.69 (3H, t, J = 7.3 Hz, C-CH3), 1.18 (2H, q, 
J = 7.2 Hz, CH2), 1.51 (4H, m, CH2), 3.57 (2H, t, J = 3.3 Hz, CH2-P), 7.61 (6H, m, 
ArH2), 7.71 (9H, m, ArH4 & 3); δC (100 MHz; CDCl3) 13.6 (CH3), 22.1, 22.5, 23.0 
(CH2), 32.3, 32.4 (CH2-P), 130.5, 130.6 (C1), 133.5, 133.6 (C3 & C2), 135.1 (C1); 
LCMS (ESI) found m/z [M-H ]: 332 C23H26P+ requires 333. 
 The data was consistent with literature values 105.
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7.4 Experimental for Chapter 5 
 
Diethyl benzylphosphonate (162)  
 
 
 
Triethyl phosphite (210 g, 1.26 mol) and benzyl bromide (179 g, 1.05 mol), were 
heated at 160 °C, under an atmosphere of N2, for 48 h. The reaction was monitored by 
TLC [2:1 EtOAc/cyclohexane]. Following completion, as indicated by TLC, the 
reaction mixture was left to cool to room temperature affording the desired product 
(yield: 116.5 g, 48 %) as pale yellow oil; Rf  0.45 [2:1 EtOAc/cyclohexane]; υmax 
(NaCl)/cm-1 1250 (P=O), 2908, 2933, 2982, 3034, 3063, 3090 (C-H and =CH-); δH 
(600 MHz; CDCl3) 1.16 (6H, t, J = 7.3 Hz, C-CH3), 3.09 (2H, d, J = 21.9  Hz, CH2-
P), 3.95 (4H, m, O-CH2-C), 7.18 - 7.24 (5H, m, ArH); δC (100 MHz; CDCl3) 16.74 (2 
x CH3), 33.1, 34.5 (CH2-P), 62.1, 62.2 (2 x O-CH2), 126.9 (C1), 128.5 (C3 & C5), 
129.8 (C2 & C6), 131.6, 131.7 (C4); LCMS (ESI) found m/z [M + H]+: 229, C11H17O3P 
requires 228. 
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Diethyl 4-(chlorosulfonyl)benzylphosphonate (220)  
 
 
Diethyl 4-(chlorosulfonyl)benzylphosphonate was prepared according to the 
procedure reported by Herweh 275.  Chlorosulfonic acid (152 g, 1.31 mol) was cooled 
to 0 °C. Diethyl benzylphosphonate (30 g, 131 mmol) was added dropwise and the 
resulting mixture was stirred for 24 h at room temperature. Once the reaction was 
complete, as indicated by TLC [4:1 EtOAc/cyclohexane], the reaction mixture was 
added slowly to ice whilst stirring. The mixture was extracted with dichloromethane 
(4 x 150 mL); the organic phases were combined and washed with 10 % aqueous 
sodium hydrogen carbonate solution (3 x 50 mL). The organic phases were then 
combined and washed with brine (50 mL), the organic phase was separated and dried 
(Na2SO4), filtered and concentrated in vacuo (yield: 38.83 g, 90 %),  to give the 
product as a viscous pale yellow oil; Rf 0.22 [4:1 EtOAc/cyclohexane]; υmax 
(NaCl)/cm-1 1246 (P=O), 1173, 1369 (S=O), 1592 (C=C), 2911, 2932, 2984, 3051, 
3091 (C-H and =CH-); δH (600 MHz; CDCl3) 1.21 (6H, t, J = 7.3 Hz, C-CH3), 3.20 
(2H, d, J = 22.0 Hz, CH2-P), 4.01 (4H, m, OCH2-C), 7.49 (2H, dd, J = 8.2 Hz, J = 2.0 
Hz, ArH3 & 5), 7.90 (2H, d, J = 8.2 Hz, ArH2 & 6); δC (150 MHz; CDCl3) 16.2 (2 x 
CH3), 33.2, 34.1 (CH2-P), 62.3 (2 x O-CH2), 126.9 (C2 & C6), 130.8 (C3 & C5), 140.5 
(C4), 142.6 (C1); LCMS (ESI) found m/z [M + H]+: 327 (35Cl), 329 (37Cl), 328 (35Cl 
and 13C), C11H16ClO5PS requires 326. % purity determined by 1H NMR (compound, 
220, (82 %), compound, 162, (18%)).
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Diethyl 4-sulfamoylbenzylphosphonate (221a) 
 
 
 
Method A: A solution of ammonia solution in 2M EtOH (16 mL) in ethanol (20 mL), 
was added slowly to a stirred solution of diethyl 4-(chlorosulfonyl)benzylphosphonate 
(18.28 g, 56 mmol), cooled to the required temperature (< 10 ºC). Following the 
addition, the resulting mixture was stirred at room temperature. Once the reaction was 
complete, as indicated by TLC [1:4 cyclohexane/EtOAc], the mixture was poured into 
a minimal amount of ice and filtered to afford a solid product (yield: 13.41 g, 78 %) as 
a white solid. Rf 0.16 [EtOAc]; m.p. 145-149 °C; υmax (NaCl)/cm-1 1234 (P=O), 1156, 
1337 (S=O), 1604 (C=C), 2921, 2995, 3058, 3141 (C-H and =CH-), 3200, 3298 (N-
H); δH (600 MHz; CDCl3) 1.25 (6H, t, J = 7.8 Hz, C-CH3), 3.19 (2H, d, J = 22.0 Hz, 
CH2-P), 4.03 (4H, m, OCH2), 4.99 (2H, s, NH2), 7.42 (2H, dd, J = 8.2 Hz,  J = 1.9 
Hz, ArH 3 & 5), 7.85 (2H, d, J = 8.2 Hz, ArH 2 & 6); δC (150 MHz; CDCl3) 16.3  (2 x 
CH3), 33.2, 34.1 (CH2-P), 62.4 (2 x O-CH2), 126.6 (C2 & C6), 129.2 (C3 & C5), 130.4 
(C4), 137.0 (C1); LCMS (ESI) found m/z [M-H]- : 305,  [M+H]+: 308, C11H18NO5PS 
requires 307. % purity determined by 1H NMR (compound, 221a, (90 %), compound, 
220,(10%)).
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Diethyl 4-(N-methylsulfamoyl)benzylphosphonate (221b) 
 
 
 
According to method A; the reaction with diethyl 4-
(chlorosulfonyl)benzylphosphonate (4.04 g,  12 mmol) and methylamine solution 40 
wt % in H2O (2.4 mL) gave the desired product, 221b (yield: 2.25 g, 57 %) as a white 
solid; Rf  0.11 [1:4 cyclohexane/EtOAc]; m.p. 112-115 °C; υmax (NaCl)/cm-1  1242 
(P=O), 1159, 1311 (S=O), 2866, 2910, 2989, 3097 (C-H and =CH-), 3313 (N-H); δH 
(600 MHz; CDCl3) 1.23 (6H, t, J = 7.8 Hz, C-CH3), 2.62 (3H, d, J = 5.5 Hz, N-CH3), 
3.19 (2H, d, J = 22.4 Hz, CH2-P), 4.02 (4H, m, O-CH2), 4.68 (1H, q, J = 5.0 Hz, N-
H), 7.43 (2H, dd, J = 8.2 Hz, J = 1.9 Hz, ArH 3 & 5), 7.78 (2H, d, J = 8.2 Hz, ArH 2 & 
6); δC (150 MHz; CDCl3) 16.3 (2 x CH3), 29.1 (N-CH3), 33.4, 34.3 (CH2-P), 62.4 (2 x 
O-CH2), 127.4 (C2 & C6), 130.5 (C3 & C5), 137.2 (C4), 137.6 (C1); LCMS (ESI) found 
m/z [M-H]- : 320, [M+H]+: 322, C12H20NO5PS requires 321.  
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Diethyl 4-(N-ethylsulfamoyl)benzylphosphonate (221c) 
 
 
 
According to method A; the reaction with diethyl 4-
(chlorosulfonyl)benzylphosphonate (4.27 g, 13 mmol) and ethylamine solution 40 wt 
% in H2O (1.5 mL) gave the desired product, 221c (yield: 2.69 g, 61 %) as a white 
solid; Rf  0.13 [1:4 cyclohexane/EtOAc]; m.p. 129-132 °C; υmax (film)/cm-1 1233 
(P=O), 1159, 1311 (S=O), 2885, 2984, 3097 (C-H and =CH-); δH (600 MHz; CDCl3) 
1.07 (3H, t, J = 7.2 Hz, N-C-CH3), 1.23 (6H, t, J = 7.2 Hz, O-C-CH3), 2.96 (2H, m, 
N-CH2), 3.18 (2H, d, J = 22.0 Hz, CH2-P), 4.00- 4.03 (4H, m, O-CH2), 4.59 (1H, t, N-
H), 7.42 (2H, dd, J = 8.2 Hz, J = 2.8 Hz, ArH3 & 5), 7.80 (2H, d, J = 8.2  Hz, ArH2 & 
6); δC (150 MHz; CDCl3) 15.2 (N-C-CH3), 16.3 (2 x CH3), 33.3, 34.2 (CH2-P), 38.2 
(N-CH2), 62.3 (2 x O-CH2), 127.2 (C2 & C6), 130.4 (C3 & C5), 137.1 (C4), 138.6 (C1); 
LCMS (ESI) found m/z [M-H]- : 334, C13H22NO5PS requires 335.  
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Diethyl 4-(N-pentylsulfamoyl)benzylphosphonate (221d) 
 
 
 
Method B: A solution of amylamine (19 mL) in ethanol (20 mL), was added slowly 
to a stirred solution of diethyl 4-(chlorosulfonyl)benzylphosphonate (24.3 g, 75 
mmol), cooled to the required temperature (< 10 ºC). Following the addition, the 
resulting mixture was stirred at room temperature. Once the reaction was complete, as 
indicated by TLC [1:4 cyclohexane/EtOAc], the mixture was poured into a minimal 
amount of ice and stirred. When a solid precipitate was not formed, during aqueous 
work up, the mixture was extracted with dichloromethane (3 x 50 - 100 mL); the 
organic phases were combined, dried (Na2SO4), filtered and concentrated in vacuo, to 
afford the product (yield: 27.62 g) as a golden yellow oil; Rf 0.71[EtOAc]; υmax 
(NaCl)/cm-1 1230 (P=O), 1160, 1330 (S=O), 2859, 2929, 2963, 3154 (C-H and =CH-), 
3276 (N-H); δH (600 MHz; CDCl3) 0.76 (3H, t, J = 7.2 Hz, C-CH3), 1.16 - 1.20 (6H, 
m, O-C-CH3),  1.26 - 1.39 (6H, m, C-CH2), 2.83 (2H, t, J = 7.2 Hz, N-CH2-C),  3.17 
(2H, d, J = 22.2 Hz, CH2-P), 3.96-4.06 (4H, m, O-CH2), 5.38 (1H, s, NH), 7.38 (2H, 
dd, J = 8.4 Hz, J = 2.4 Hz, ArH3 & 5), 7.75 (2H, d, J = 9 Hz, ArH2 & 6); δC (150 MHz; 
CDCl3) 13.8 (CH3 sulfonamide), 16.3 (CH3 phosphonate), 22.0 (CH2-CH3), 28.6, 29.1 (2 x 
CH2), 32.7, 34.0 (CH2-P), 43.1 (N-CH2), 62.4 (2 x O-CH2), 127.1 (C2 & C6), 130.2 (C3 
& C5), 136.4 (C4), 138.9 (C1); LCMS (ESI) found m/z [M + H]+: 378, C16H28NO5PS 
requires 377. % purity determined by 1H NMR (compound, 221d, (60 %), compound, 
220,(40%)).
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Diethyl 4-(N,N-dimethylsulfamoyl)benzylphosphonate (221e) 
 
 
 
According to method A; the reaction with diethyl 4-
(chlorosulfonyl)benzylphosphonate (6.1 g, 19 mmol) and dimethylamine (5 mL) gave 
the titled product, 221e (yield:                     4.18 g, 68 %) as a white solid; Rf 0.17 [1:3 
cyclohexane/EtOAc]; m.p. 129 – 133 °C; υmax (NaCl)/cm-1 1257 (P=O), 1163, 1338 
(S=O), 2915, 2982, 3028, 3090 (C-H and =CH-); δH (400 MHz; CDCl3) 1.20 (6H, t, J 
= 7.0 Hz, C-CH3), 2.65 (6H, s, N-CH3), 3.17 (2H, d,  J = 22.1 Hz, CH2-P), 4.00 (4H, 
m, O-CH2), 7.44 (2H, dd, J = 8.5 Hz, J = 2.5 Hz, ArH 3 & 5), 7.67 (2H, d, J = 7.7 Hz, 
ArH 2 & 6); δC (100 MHz; CDCl3) 16.4 (CH3 phosphonate), 33.1, 34.5 (CH2-P), 33.1, 34.5 
(N-CH3), 62.3, 62.4 (CH2-CH3), 128.0 (C2 & C6), 130.4 (C3 & C5), 134.0 (C4), 137.4 
(C1); LCMS (ESI) found m/z [M + H]+: 336, C13H22NO5PS requires 335. 
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Diethyl 4-(N,N-dipropylsulfamoyl)benzylphosphonate (221f) 
 
 
 
According to method B; the reaction with diethyl 4-
(chlorosulfonyl)benzylphosphonate (3.14 g, 9.6 mmol) and dipropylamine (15 mL) 
gave the product (yield: 1.79 g, 48 %) as an orange oil; Rf 0.5 [3:1 
cyclohexane/EtOAc]; υmax (film)/cm-1 1253 (P=O), 1160, 1336 (S=O), 1600 (C=C), 
2884, 2930, 2977 (C-H and =CH-); δH (400 MHz; CDCl3) 0.80 (6H, t, J = 7.4 Hz, 
CH3 sulfonamide), 1.18 (6H, t, J = 6.9 Hz, CH3 phosphonate), 1.49 (4H, q, J = 7.6 Hz, CH2- 
CH3), 3.01 (4H, t, J = 7.5 Hz, N-CH2), 3.14 (2H, d,  J = 22.0 Hz, P-CH2), 3.99 - 3.95 
(4H, m, O-CH2), 7.41 (2H, dd, J = 8.1 Hz, J = 1.8 Hz, ArH 3& 5), 7.69 (2H, d, J = 8.2 
Hz, ArH 2 & 6); δC (100 MHz; CDCl3) 11.2 (CH3 sulfonamide), 16.1, 16.4 (CH3 phosphonate), 
22.0 (CH2-CH3), 33.1, 34.5 (CH2-P), 50.0 (N-CH2), 62.4 (O-CH2), 127.2 (C2 & C6), 
130.4 (C3 & C5), 136.6 (C4), 138.8 (C1); LCMS (ESI) found m/z [M + H]+:  392, 
C17H30NO5PS requires 391. % purity determined by 1H NMR (compound, 221f, (81 
%), compound, 220, (19 %)). 
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Diethyl 4-(piperidine-1-ylsulfonyl)benzylphosphonate (221g) 
 
 
 
According to method B; the reaction with diethyl 4-
(chlorosulfonyl)benzylphosphonate (6 g, 18 mmol) and piperidine (3.8 mL) gave the 
product (yield: 5.57 g, 81 %) as pale yellow/colourless needles; Rf 0.25 [DCM]; υmax 
(film)/cm-1 1257 (P=O), 1163, 1338 (S=O), 2915, 2982, 3028, 3090 (C- and =CH-); δH 
(600 MHz; CDCl3) 1.22 (6H, dt, J = 3 Hz, C-CH3), 2.67 (6H, s, N-CH2), 3.19 (2H, d, 
J = 22.2 Hz, P-CH2), 4.00 (4H, m, OCH2), 7.45 (2H, dd, J = 8.4 Hz, J = 2.4 Hz, ArH 
3 & 5), 7.67 (2H, d, J = 8.2, ArH2 & 6); δC (100 MHz; DMSO-d6) 16.7 (2 x CH3), 23.4, 
25.1 (2 x CH2 sulfonamide), 32.1 (CH2-P), 47.1 (N-CH2), 62.1 (2 x O-CH2), 127.9 (C2 & 
C6), 131.2 (C3 & C5), 134.2 (C4), 138.6 (C1); LCMS (ESI) found m/z [M + H]+: 376, 
C16H26NO5PS requires 375. % purity determined by 1H NMR (compound, 221g, (88 
%), compound, 220, (12 %). 
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Diethyl 4-(morpholinosulfonyl)benzylphosphonate (221h) 
 
 
 
According to method B; the reaction with diethyl 4-
(chlorosulfonyl)benzylphosphonate (24 g, 74 mmol) and morpholine (14 mL) gave the 
product (yield: 21.41 g, 88 %) as opaque/colourless oil; Rf 0.40 [EtOAc]; υmax 
(film)/cm-1 1243 (P=O), 1160, 1347 (S=O), 2868, 2907, 2929, 2989, 3094 (C-H and 
=CH-); δH (600 MHz; CDCl3) 1.20 (6H, t, J = 7.0 Hz, C-CH3), 2.86 - 2.96 (4H, m, N-
CH2), 3.16 (2H, d, J = 22.2 Hz, P-CH2), 4.00-4.01 (4H, m, OCH2), 7.45 (2H, dd, J = 
8.4 Hz, J = 2.5 Hz, ArH 3 &5), 7.66 (2H, d, J = 8.4 Hz, ArH 2 & 6); δC (100 MHz; 
CDCl3) 16.4 (2 x CH3), 33.2, 34.6 (CH2-P), 46.0 (N-CH2), 62.4 (O-CH2- phosphonate), 
66.1 (O-CH2- morpholine), 128.1 (C2 & C6), 130.6 (C3 & C5), 133.7 (C4), 137.9 (C1); 
LCMS (ESI) found m/z [M + H]+: 378, C15H24NO6PS requires 377. % purity 
determined by 1H NMR (compound, 221h, (82 %), compound, 220, (18 %)). 
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Diethyl 4-(N,N-diphenylsulfamoyl)benzylphosphonate (221i) 
  
 
 
According to method B; the reaction with diethyl 4-
(chlorosulfonyl)benzylphosphonate (6.04 g, 19 mmol) and diphenylamine (5 mL) 
gave the product (yield: 7.79 g, 92 %) as a green oil; Rf 0.87 [3:1 
cyclohexane/EtOAc]; υmax (film)/cm-1 1244 (P=O), 1175, 1312 (S=O), 2911, 2941, 
2980, 3044, 3132, 3205, 3308 3386, (C-H and =CH-); δH (400 MHz; CDCl3) 1.16 
(6H, t, J = 7.5 Hz, C-CH3), 3.43 (2H, d, J = 22.2 Hz, P-CH2), 3.95-3.97 (4H, m, 
OCH2), 6.83 (6H, t, J = 7.3 Hz, ArH), 7.08 (2H, d, ArH 10), 7.22 (4H, t, ArH 7,9, 11 & 
12), 7.58 (2H, dd, J = 8.4 Hz,  J = 2.4 Hz, ArH 2 & 6), 7.86 (2H, d, J = 7.8 Hz, ArH 3 & 
5); δC (100 MHz; DMSO-d6) 16.7 (2 x CH3), 31.0, 31.9 (CH2-P), 62.1 (2 x O-CH), 
117.2 (C8 & C12), 120.1 (C10), 128.0 (C3 & C5), 129.7 (C10), 131.6 (C2 & C6, C9 & C11), 
132.4 (C1), 140.0 (C4), 140.9 (C7); LCMS (ESI) found m/z [M+H]+: 460, 
C23H26NO5PS requires 459.  
% purity determined by 1H NMR (compound, 221i, (83 %), compound, 220, (17 %)). 
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(E)-4-(3,4-dimethoxystyryl)benzenesulfonamide (232a) 
 
 
Method C:  
To a stirred mixture of diethyl 4-sulfamoylbenzylphosphonate (2.00 g, 6.5 mmol) in 
DMF (10 mL) at room temperature, under N2 atmosphere, sodium methoxide (5.27 g, 
97 mmol) was added. The reaction was stirred for 30 min and 3,4-
dimethoxybenzaldeyde (1.06 g, 6.4 mmol) dissolved in DMF (10 mL) was added to 
the stirred mixture and the reaction mixture was left to stir at room temperature. The 
reaction was monitored by TLC [1:4 cyclohexane/EtOAc]. Once the reaction was 
complete, as indicated by TLC, the reaction was quenched by the addition of ice, 
filtered, washed with cold water and air dried to give the impure product as a golden 
yellow solid. Purification by recrystallization (absolute ethanol 99%) gave the titled 
product, 232a, as a pale yellow solid (yield: 0.31 g, 15 %); Rf 0.86 [EtOAc]; m.p. 221 
- 227 °C; υmax (film)/cm-1 1156, 1329 (S=O), 1516, 1591 (C=C), 2839, 2945, 2972, 
3004 (C-H and =CH), 3250, 3340 (N-H); δH (400 MHz; DMSO-d6) 3.80 (6H, s, 
OMe), 6.98 (1H, d, J = 8.4 Hz, ArH 5), 7.14 (1H, dd, J = 8.4 Hz, J = 1.9 Hz, ArH 6), 
7.22 (1H, d, JAB = 16.4 Hz, trans-HC=CH), 7.29 (1H, d, J = 1.8 Hz, ArH 2), 7.34 (1H, 
d, JAB = 16.0 Hz, trans-HC=CH), 7.32 (2H, s, NH2), 7.59 (2H, d, J = 8.6 Hz, ArH 3’ & 
2’), 7.79 (2H, d, J = 8.5 Hz, ArH 5’ & 6’); δC (150 MHz; DMSO-d6) 56.0, 56.6 (OMe), 
109.9 (C2), 112.3 (C5), 121.1 (C6), 125.3 (C2’ & C6’), 126.6 (C3’ & C5’), 126.8 (C7 & 
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C7’), 131.7 (C1), 141.5 (C1’), 142.8 (C4’), 149.5 (C4), 149.7 (C3); LCMS (ESI) found 
m/z [M-H]- : 318, C18H17NO4S requires 319. 
 
 
(E)-4-(4-methoxystyryl)benzenesulfonamide (232b) 
 
 
 
According to method C; the reaction with diethyl 4-sulfamoylbenzylphosphonate 
(0.99 g, 3.2 mmol) and 4-methoxybenzaldeyde (0.44 g, 3.2 mmol) provided the 
impure product as a beige solid (yield: 0.34 g, 36 %). Purification by recrystallization 
(diethyl ether) gave the desired product as a beige solid (yield: 0.31 g, 33 %); Rf 0.78 
[1:3 cyclohexane/EtOAc]; m.p. 259 - 262 °C; υmax (film)/cm-1 1164, 1308 (S=O), 
1513, 1592 (C=C), 2946, 2983, 3020, 3062 (C-H and =CH-), 3262, 3351 (N-H); δH 
(400 MHz; DMSO-d6) 3.37 (2H, s, NH2), 3.78 (3H, s, OMe), 6.97 (2H, d, J 8.8 Hz, 
ArH 11 & 13), 7.17 (1H, d, JAB = 16.4 Hz, trans-HC=CH), 7.36 (1H, d, JAB = 16.4 Hz, 
trans-HC=CH), 7.58 (2H, d, J = 8.8 Hz, ArH 10 & 14), 7.73 (2H, d, J = 8.5 Hz, ArH 2 & 
3), 7.79 (2H, d, J = 8.5 Hz, ArH 5 & 6); δC (150 MHz; DMSO-d6) 55.7 (OMe), 114.8 
(C11 & C13), 125.1 (C3 & C5), 126.6 (C2 & C6), 126.8 (C7 & C8), 128.7 (C9), 131.3 (C10 
& C14), 141.4 (C4), 142.3 (C1), 159.9 (C12); LCMS (ESI) found m/z [M-H]- : 288 
C15H15NO3S requires 289. % purity determined by 1H NMR (compound, 232b, (88 
%), compound, 228, (12 %)). 
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(E)-4-(3-methoxystyryl)benzenesulfonamide (232c) 
 
 
According to method C; the reaction with diethyl 4-sulfamoylbenzylphosphonate 
(2.00 g, 6.5 mmol) and 3-methoxybenzaldeyde (0.89 g, 6.6 mmol) provided the 
impure product as a brown solid. Purification by recrystallization (absolute ethanol 99 
%) gave the titled product, 232c, as a beige solid (yield: 0.14 g, 7 %); Rf 0.88 
[EtOAc]; m.p. 149 - 151 °C; υmax (film)/cm-1 1156, 1321 (S=O), 1577, 1608 (C=C), 
2842, 2950, 2976, 3020, 3072 (C-H and =CH-), 3237, 3320 (N-H); δH (600 MHz; 
CDCl3) 3.84 (3H, s, OMe), 4.74 (2H, s, NH2), 6.86 (1H, dd, J = 8.2 Hz, J = 1.2 Hz, 
ArH 4), 7.04 (1H, broad, ArH 6), 7.05 (1H, d, JAB = 16.5 Hz, HC=CH), 7.11 (2H, d, J 
= 7.8 Hz, ArH 2), 7.18 (1H, d, JAB = 16.5 Hz, HC=CH), 7.28 (1H, t, J = 7.8 Hz, ArH 
5), 7.61 (2H, d, J = 8.7 Hz, ArH 3’ & 2’), 7.88 (2H, d, J = 8.2 Hz, ArH 5’ & 6’); δC (100 
MHz; CDCl3) 55.3 (OMe), 112.1 (C2), 114.1 (C4), 119.5 (C6), 126.7 (C3’, C5’, C2’, & 
C6’), 126.9 (C7 & C7’), 129.8 (C5), 132.0 (C1), 138.0 (C1’), 141.8 (C4’), 159.9 (C3); 
LCMS (ESI) found m/z [M-H]-  : 287, C15H15NO3S requires 289. 
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 (E)-4-(4-fluorostyryl)benzenesulfonamide (232e) 
 
 
 
Method F: 
To a stirred mixture of diethyl 4-sulfamoylbenzylphosphonate (1.00 g, 3.3 mmol) in 
THF (18 mL) at room temperature, under N2, potassium tert-butoxide (0.73 g, 6.5 
mmol) was added. The reaction was stirred for 5 minutes and 4-fluorobenzaldehyde 
(0.43 g, 3.5 mmol) was added to the stirred mixture and the reaction mixture was left 
to stir at room temperature for 4 h. Once the reaction was complete, as indicated by 
TLC [3:1 EtOAc/cyclohexane], the reaction was quenched by the addition of ice, 
filtered, washed with cold water and air dried. When a solid precipitate was not 
formed, the reaction mixture was extracted with DCM (3 x 50 mL), the organic phases 
were combined, dried (Na2SO4), filtered and concentrated in vacuo to give the product 
as a white solid (yield: 0.59 g, 65 %). Purification by washing (diethyl ether and 
cyclohexane) afforded the titled product, 232e, as a white solid (yield: 0.46 g, 51 %); 
Rf 0.84 [1:3 cyclohexane/EtOAc]; m.p. 189 - 194 °C; υmax (film)/cm-1 1163, 1324 
(S=O), 1512, 1590 (C=C), 3018, 3049, 3067 (C-H and =CH-), 3268, 3367 (N-H); δH 
(600 MHz; CDCl3) 4.78 (2H, s, NH2), 7.07 (2H, t, J = 8.5 Hz, ArH 3 & 5), 7.02 (1H, d, 
JAB= 16.1 Hz, trans-HC=CH), 7.17 (1H, d, JAB = 16.4 Hz, trans-HC=CH), 7.50 (2H, 
q, J = 8.8 Hz, ArH 2 & 6), 7.61 (2H, d, J = 8.3 Hz, ArH 3’ & 2’), 7.89 (2H, d, J = 8.4 Hz, 
ArH 5’ & 6’); δC (150 MHz; DMSO-d6) 116.1, 116.3 (C3 & C5), 126.7 (C2’ & C6’), 127.2 
(C3' & C5’), 129.2, 129.3 (C7 & C7’), 130.4 (C2 & C6), 133.7 (C1), 140.9 (C1’), 143.2 
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(C4’), 161.3, 163.7 (C4); LCMS (ESI) found m/z [M-H]-  : 276, C14H12FO2S requires 
277. 
 
 
(E)-4-(4-(dimethylamino)styryl)benzenesulfonamide (232d) 
 
 
 
According to method C; the reaction with diethyl 4-sulfamoylbenzylphosphonate 
(0.76 g, 2.5 mmol) and 4-(dimethylamino)benzaldehyde (0.35 g, 2.3 mmol) provided 
the impure product as a bright yellow solid (yield: 0.61 g, 86 %). Purification by 
recrystallization  (diethyl ether) afforded the desired product as an orange solid (yield: 
0.2 g, 28 %); Rf 0.83 [1:3 cyclohexane/EtOAc]; m.p. 254 °C - decomposed; υmax 
(film)/cm-1 1154, 1303 (S=O), 1592 (C=C), 2811, 2909, 2992, 3076 (C-H and =CH-), 
3253, 3351 (N-H); δH (400 MHz; DMSO-d6) 2.94 (6H, s, N-CH3), 6.73 (2H, d, J = 8.7 
Hz, ArH 11 & 13), 7.03 (1H, d, JAB = 16.4 Hz, trans-HC=CH), 7.29 (1H, m, trans-
HC=CH), 7.31 (1H, s, NH2), 7.47 (2H, d, J = 8.6 Hz, ArH 2 & 6), 7.68 (2H, d, J = 8.4 
Hz, ArH 3’&2’), 7.75 (2H, d, J = 8.4 Hz, ArH 6’& 5’); δC (100 MHz; DMSO-d6) 40.2 (N-
CH3), 112.7 (C3 & C5), 122.4 (C1), 126.4 (C2 & C6), 126.6 (C2’ & C6’), 128.5 (C3’ & 
C5’) 132.0 (C7 & C7’), 143.1 (C1’), 142.1 (C4’), 150.9 (C4); LCMS (ESI) found m/z [M-
H]-  : 301, C16H18N2O2S requires 302. % purity determined by 1H NMR (compound, 
232d, (77 %), compound, 231, (23 %)). 
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 (E)-4-(2-(furan-2-yl)vinyl)benzenesulfonamide (245) 
 
 
 
To a stirred mixture of diethyl 4-sulfamoylbenzylphosphonate (1.02 g, 3.3 mmol.) in 
DMF (16 mL) at room temperature, under an atmosphere of N2, sodium methoxide 
(7.55 g, 139 mmol) was added. The reaction was stirred for 30 min then furan-2-
carboxaldehyde (0.31 g, 3.2 mmol) was added to the stirred mixture and the reaction 
mixture was left to stir at room temperature. The reaction was monitored by TLC [1:3 
cyclohexane/EtOAc]. Once the reaction was complete, as indicated by TLC, the 
reaction was quenched by the addition of ice, filtered, washed with cold water and air 
dried to give the impure product as a pale yellow solid (yield: 0.24 g, 30 %). 
Purification by recrystallization (diethyl ether) gave the titled product, 245, as a pale 
yellow solid (yield: 0.17 g, 21 %); Rf  0.75 [3:1 EtOAc/cyclohexane]; m.p. 234 - 236 
°C; υmax (film)/cm-1 1159, 1294 (S=O), 1536 (C=C), 2871, 3067, 3155 (C-H and 
=CH), 3253, 3346 (N-H); δH (400 MHz; DMSO-d6) 6.58 (1H, dd, J = 3.0 Hz, =CH 3), 
6.64 (1H, d, J = 3.2 Hz, =CH 2), 7.04 (1H, d, JAB = 16.4 Hz, trans-HC=CH), 7.28 
(1H, d, JAB = 16.3 Hz, trans-HC=CH), 7.34 (2H, s, NH2), 7.73 (1H, m, =CH 4), 7.76 
(4H, q, J = 9.0 Hz, ArH 3’& 2’, ArH 5 & 6); δC (100 MHz; DMSO-d6) 111.4 (C2), 112.8 
(C3), 119 (C5), 125.1 (C7), 126.7 (C2’ & C6’), 127.0 (C3’ & C5’), 140.6 (C1’), 142.7 
(C4’), 144.1 (C4), 152.7 (C1); LCMS (ESI) found m/z [M-H]-  : 248, C12H12NO3S 
requires 249. 
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 (E)-4-(2-(thiophen-2-yl)vinyl)benzenesulfonamide (247) 
 
 
To a stirred mixture of diethyl 4-sulfamoylbenzylphosphonate (1.04 g, 3.4 mmol.) in 
DMF (16 mL) at room temperature, under an atmosphere of N2, sodium methoxide 
(6.25 g, 116 mmol) was added. The reaction was stirred for 30 min, 2-
thiophenecarboxaldehyde (0.33 g, 2.9 mmol) was added to the stirred mixture and the 
reaction mixture was left to stir at room temperature under an atmosphere of N2. The 
reaction was monitored by TLC [1:3 cyclohexane/EtOAc]. Once the reaction was 
complete, as indicated by TLC, the reaction was quenched by the addition of ice, 
filtered, washed with cold water and air dried to give the titled product, 247, as a 
golden yellow solid (yield: 0.38 g, 49 %). Purification not performed, as the 
compound was considered to be of adequate purity, following analysis by 1H NMR. Rf 
0.87 [3:1 EtOAc/cyclohexane]; m.p. 254 – 259 °C; υmax (film)/cm-1 1160, 1289 (S=O), 
1596 (C=C), 3013, 3069, 3102 (C-H and =CH), 3263, 3348 (N-H); δH (400 MHz; 
DMSO-d6) 7.01 (1H, d, JAB = 16.3 Hz, trans-HC=CH), 7.09 (1H, t, J = 3.5 Hz, =CH 
3), 7.28 (1H, d, =CH 2 overlapping), 7.32 (2H, s, NH2 - overlapping), 7.53 (1H, d, J = 
4.6 Hz,          =CH 4), 7.61 (1H, d, JAB = 16.1 Hz, trans-HC=CH), 7.76 (4H, d, J =  9.9 
Hz, ArH3’ & 2’, ArH 6’ & 5’); δC (100 MHz; DMSO-d6) 125.0 (C2’& C6’), 126.6 (C3’ & 
C5’), 126.8 (C3), 127.0 (C2), 128.3 (C7 & C4), 128.6 (C7), 140.6 (C1’), 142.3 (C1), 
143.1 (C4’); LCMS (ESI) found m/z [M-H]-  : 265, C12H11NO2S2 requires 265. 
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(E)-4-(3,4-dimethoxystyryl)-N-methylbenzenesulfonamide (260) 
 
 
 
According to method C; the reaction with diethyl 4-(N-
methylsulfamoyl)benzylphosphonate (1.43 g, 4.5 mmol) and 3,4-
dimethoxybenzaldeyde (0.76 g, 4.6 mmol) provided the product as a cream solid 
(yield: 0.95 g, 64 %); Purification by recrystallization (absolute ethanol) gave the 
desired product as a fluffy cream solid (yield: 0.53 g, 36 %); Rf 0.52 [2:1 
EtOAc/cyclohexane]; m.p. 164 - 169 °C; υmax (film)/cm-1 1138, 1318 (S=O), 1517, 
1591 (C=C), 2845, 2942, 2965, 3007, 3081 (C-H and =CH-), 3271 (N-H); δH (400 
MHz; CDCl3) 2.65 (3H, d, J = 5.2 Hz, N-CH3), 3.86 (3H, s, OMe), 3.92 (3H, s, OMe), 
4.71 (1H, q, J = 5.2 Hz,          N-H), 6.85 (1H, d, J = 8.8 Hz, ArH 5), 6.96 (1H, d, JAB 
= 16.2 Hz, trans-HC=CH), 7.05 (1H, d, J = 6.4 Hz, ArH 6), 7.06 (1H, d, J = 6.6 Hz, 
ArH 2), 7.14 (1H, d, JAB = 16.2 Hz, trans-HC=CH), 7.58 (2H, d, J = 8.5 Hz, ArH 3’ & 
2’), 7.80 (2H, d, J = 8.4 Hz, ArH 5’& 6’); δC (100 MHz; CDCl3) 29.3 (N-CH3), 56.0 (2 x 
OMe), 108.9 (C2), 111.2 (C5), 120.7 (C6), 126.6 (C2’ & C6’), 127.8 (C3’ & C5’), 129.5 
(C7 & C7’), 131.9 (C1), 136.6 (C1’), 142.1 (C4’), 149.2 (C4), 149.6 (C3); LCMS (ESI) 
found m/z [M-H]-  : 332, C17H19NO4S requires 333. % purity determined by 1H NMR 
(compound, 260, (90 %), ethyl acetate (10 %)). 
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(E)-4-(4-methoxystyryl)-N-methylbenzenesulfonamide (261) 
 
 
 
According to method C; the reaction with diethyl 4-(N-
methylsulfamoyl)benzylphosphonate (1.45 g, 4.5 mmol) and p-anisaldehyde (0.61 g, 
4.5 mmol) provided the product as an orange solid (yield: 1.21 g, 88 %). Purification 
by recrystallization (absolute ethanol) gave the desired product as a fluffy pale orange 
solid (yield: 0.57 g, 42 %); Rf 0.59 [3:1 EtOAc/cyclohexane]; m.p. 203 - 208 °C; υmax 
(film)/cm-1 1154, 1317 (S=O), 1517, 1592 (C=C), 2843, 2909, 2955, 2983, 3020 (C-H 
and =CH-), 3281 (N-H); δH (400 MHz; CDCl3) 2.67 (3H, d, N-CH3), 3.83 (3H, s, 
OMe), 4.32 (1H, q, J = 5.4 Hz, N-H), 6.91 (2H, d, J = 8.8 Hz, ArH 3 & 5), 6.97 (1H, d, 
JAB = 16.3 Hz, trans-HC=CH), 7.17 (1H, d, JAB= 16.3 Hz, trans-HC=CH), 7.47 (2H, 
d, J = 8.7 Hz, ArH 2 & 6), 7.59 (2H, d, J = 8.5 Hz, ArH 3’ & 2’), 7.80 (2H, d, J = 8.5 Hz, 
ArH 6’ & 5’); δC (100 MHz; CDCl3) 31.8 (N-CH3), 57.9 (OMe), 116.8 (C3 & C5), 129.1 
(C2’ & C6’), 130.2 (C3’ & C5’), 130.2 (C7 & C7’), 130.7 (C1), 134.2 (C2 & C6), 139.0 
(C1’), 144.8 (C4’), 162.5 (C4); LCMS (ESI) found m/z [M-H]-  : 302, C16H17NO3S 
requires 303. % purity determined by 1H NMR (compound, 261, (61 %), ethanol            
(39 %)). 
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 (E)-4-(3-methoxystyryl)-N-methylbenzenesulfonamide (262) 
 
 
 
According to method C; the reaction with diethyl 4-(N-
methylsulfamoyl)benzylphosphonate (1.80 g, 5.6 mmol) and 3-methoxybenzaldehyde 
(0.76 g, 5.9 mmol) provided the product as a yellow solid. Purification by 
recrystallization (absolute ethanol  99 %) gave the titled product, 262, as a pale yellow 
solid (yield: 0.09 g, 5 %); Rf 0.82 [EtOAc]; m.p. 85 - 89 °C; υmax (film)/cm-1 1160, 
1312 (S=O), 1582 (C=C), 2937, 2963, 3011, 3024, (C-H and =CH-), 3263 (N-H); δH 
(600 MHz; CDCl3) 2.67 (3H, d, J = 5.4 Hz, N-CH3), 3.84 (3H, s, OMe), 4.28 (1H, q, J 
= 5.2, N-H), 6.86 (1H, m, ArH 4), 7.05 (1H, d, J = 7.3 Hz, ArH 6), 7.08 (1H, d, JAB = 
16.5 Hz, trans-HC=CH), 7.12 (1H, d, J = 7.3 Hz, ArH 2), 7.17 (1H, d, JAB = 16.0 Hz, 
trans-HC=CH), 7.29 (1H, t, J = 8.2 Hz, ArH 5), 7.61 (2H, d, J = 8.7 Hz, ArH 3’ & 2’) 
7.82 (2H, d, J = 9 Hz, ArH 5’ & 6’); δC (150 MHz; CDCl3  and DMSO-d6) 27.9 (N-CH3), 
54.4 (OMe), 111.1 (C2), 113.2 (C4), 118.6 (C6), 125.9 (C3’, C5’), 126.3 (C2’, & C6’), 
126.6 (C7 & C7’), 128.9 (C5), 130.6 (C1), 137.0 (C1’), 140.2 (C4’), 158.9 (C3); LCMS 
(ESI) found m/z [M-H]-  : 301, C16H17NO3S requires 303. 
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 (E)-4-(4-fluorostyryl)-N-methylbenzenesulfonamide (255) 
 
 
 
According to method F; the reaction with diethyl 4-(N-
methylsulfamoyl)benzylphosphonate (1.00 g, 3.1 mmol) and 4-fluorobenzaldehyde 
(0.39 g, 3.1 mmol) provided the product as a pale cream solid (yield: 0.90 g, 99 %). 
Purification by washing  (diethyl ether and cyclohexane) afforded the desired product 
as a white crystalline solid (yield: 0.62 g, 68 %); Rf 0.75 [3:1 EtOAc/cyclohexane]; 
m.p. 163 - 167 °C; υmax (film)/cm-1 1152, 1314 (S=O), 1512, 1590 (C=C), 2830, 3023, 
3049, 3075 (C-H and =CH-), 3273 (N-H); δH (400 MHz; CDCl3) 2.68 (3H, d, J = 5.4 
Hz, CH3), 4.42 (1H, q, J = 5.4 Hz, N-H), 7.02 (1H, m, trans-HC=CH), 7.07 (2H, t, J 
= 8.6 Hz, ArH 3 & 5), 7.17 (1H, d, JAB = 16.4 Hz, trans-HC=CH), 7.50 (2H, q, J = 8.7 
Hz, ArH 2 & 6), 7.61 (2H, d, J = 8.6 Hz, ArH 3’ & 2’), 7.83 (2H, d, J = 8.5 Hz, ArH 6’ & 
5’); δC (100 MHz; CDCl3) 29.4 (N-CH3), 115.8, 116.0 (C3 & C5), 126.5, 126.9 (C2’ & 
C6’), 127.8 (C3’ & C5’) 128.5 (C7 & C7’), 130.9 (C2 & C6), 132.7 (C1), 137.2 (C1’), 
141.7 (C4’), 161.4, 164.1 (C4); LCMS (ESI) found m/z [M-H]-  : 290, C15H14FNO2S 
requires 291. % purity determined by 1H NMR (compound, 255, (66 %), diethyl ether 
(34 %)). 
 
 
 
 
Chapter 7: Experimental 
 
 
236 
 
(E)-4-(4-(dimethylamino)styryl)-N-methylbenzenesulfonamide (263) 
 
 
 
According to method C; the reaction with diethyl 4-(N-
methylsulfamoyl)benzylphosphonate (1.03 g, 3.2 mmol) and 4-
(dimethylamino)benzaldehyde (0.50 g, 3.4 mmol) provided the product as a 
fluorescent yellow solid (yield: 0.6 g, 59 %). Purification by recrystallization (diethyl 
ether) afforded the desired product as a fluorescent yellow solid (yield: 0.49 g, 48 %); 
Rf 0.90 [3:1 EtOAc/cyclohexane]; m.p. 131 - 134 °C; υmax (film)/cm-11145, 1294 
(S=O), 2815, 2862, 2895, 2950, 2983, 3025 (C-H and =CH-), 3262 (N-H); δH (400 
MHz; DMSO-d6) 2.41 (3H, s, N-CH3), 2.95 (6H, s, N-CH3), 6.73 (2H, d, J = 8.8 Hz, 
ArH 3 & 5), 7.04 (1H, d, JAB = 16.3 Hz, trans-HC=CH), 7.30 (2H, d, JAB = 16.3 Hz, J = 
16.3 Hz, trans-HC=CH), 7.47 (2H, d, J = 8.8 Hz, ArH 2 & 6), 7.69 (4H, d, ArH 3’ & 2’ & 
ArH 6’ & 5’), 7.71 (1H, s, NH2 - overlap); δC (100 MHz; DMSO-d6) 29.2 (NH-CH3), 
40.3, 40.4 (N-CH3), 112.5, 112.6 (C3 & C5), 122.2 (C1), 126.6 (C2 & C6), 126.8 (C2’ & 
C6’), 127.6 (C3’ & C5’) 128.6 (C7 & C7’), 132.4 (C1’), 141.0 (C4’), 150.5 (C4); LCMS 
(ESI) found m/z [M + H]+: 317, C17H20N2O2S requires 316. % purity determined by 1H 
NMR (compound, 263, (90 %), compound, 221b, (10 %)). 
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(E)-N-Ethyl-4-(3-methoxystyryl)benzenesulfonamide (264) 
 
 
 
According to method C; the reaction with diethyl 4-(N-
ethylsulfamoyl)benzylphosphonate (0.54 g, 1.6 mmol) and m-anisaldehyde (0.22 g, 
1.6 mmol) gave the product as a golden yellow solid (yield: 0.059 g, 12 %). 
Purification by recrystallization (diethyl ether) afforded the titled product as a pale 
yellow solid (yield: 0.05 g, 10 %). Rf 0.92 [3:1 EtOAc/cyclohexane]; m.p. 92 - 96 °C; 
υmax (film)/cm-1 1156, 1316 (S=O), 1582 (C=C), 2842, 2948, 2989 (C-H and =CH-), 
3269 (N-H); δH (400 MHz; CDCl3) 1.10 (3H, t, J = 5.2 Hz, N-CH3), 3.03 (3H, q, J = 
6.0 Hz, CH2-CH3), 3.84 (3H, s, OMe), 4.55 (1H, t, N-H), 6.86 (1H, dd, J = 8.2 Hz, J 
= 2.3  Hz, ArH 4), 7.05 (1H, d, J = 1.2 Hz, ArH 6), 7.09 (1H, d, JAB = 16.4 Hz, trans-
HC=CH), 7.18 (1H, d,  JAB = 16.3 Hz, trans-HC=CH), 7.13 (1H, s, ArH 2), 7.29 (1H, 
t, J = 7.8 Hz, ArH 5), 7.60 (2H, d, J = 8.6 Hz, ArH 3’ & 2’), 7.83 (2H, d, J = 8.5 Hz, 
ArH 5’& 6’); δC (100 MHz; CDCl3) 15.2 (CH3), 38.3 (NH-CH2), 55.3 (OMe), 112.2 
(C2), 114.2 (C4), 119.6 (C6), 126.9 (C3’, C5’), 127.1 (C2’, & C6’), 127.6 (C7 & C7’), 
129.9 (C5), 132.0 (C1), 137.9 (C1’), 138.4 (C4’), 160.0 (C3); LCMS (ESI) found m/z 
[M-H]-  : 316, C17H19NO3S requires 317. % purity determined by 1H NMR 
(compound, 264, (83 %), diethyl ether (17 %)).  
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(E)-N-Ethyl-4-(4-fluorostyryl)benzenesulfonamide (256) 
 
 
 
According to method F; the reaction with diethyl 4-(N-
ethylsulfamoyl)benzylphosphonate (0.85 g, 2.5 mmol) and 4-fluorobenzaldehyde            
(0.31 g, 2.5 mmol) gave the product as a white solid (yield: 0.60 g, 78 %). Purification 
by washing (diethyl ether and cyclohexane) afforded the desired product as a white 
crystalline solid (yield: 0.30 g, 39 %); Rf 0.84 [3:1 EtOAc/cyclohexane]; m.p. 149 - 
153 °C; υmax (film)/cm-1 1158, 1319 (S=O), 1507, 1595 (C=C), 2882, 2945, 2997, 
3059        (C-H and =CH-), 3299 (N-H); δH (400 MHz; CDCl3) 1.10 (3H, t, J = 7.2 
Hz, CH3), 3.02 (2H, q, J = 6.1 Hz, CH2), 4.67 (1H, t, J = 5.9 Hz, N-H), 7.01 (1H, d, 
JAB = 16.5 Hz, trans-HC=CH), 7.06 (2H, t, J = 8.6 Hz, ArH 3 & 5), 7.16 (1H, d, JAB = 
16.2 Hz, trans-HC=CH), 7.49 (2H, d, J = 8.8 Hz, ArH 2 & 6), 7.60 (2H, d, J = 8.6 Hz, 
ArH 3’ & 2’), 7.84 (2H, d, J = 8.3 Hz, ArH 6’ & 5’); δC (100 MHz; CDCl3) 15.1 (CH2-
CH3), 38.3 (CH2), 115.8, 116.0 (C3 & C5), 126.6, 126.9 (C2’ & C6’), 127.6 (C3’ & C5’), 
128.5 (C7 & C7’), 130.8 (C2 & C6), 132.7 (C1), 138.4 (C1’), 141.6 (C4’), 161.6 (C4); 
LCMS (ESI) found m/z [M-H]-  : 304, C16H16FNO2S requires 305. 
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(E)-4-(4-(Dimethylamino)styryl)-N-ethylbenzenesulfonamide (265) 
 
 
 
According to method C; the reaction with diethyl 4-(N-
ethylsulfamoyl)benzylphosphonate (0.60 g, 1.8 mmol) and 4-
(dimethylamino)benzaldehyde (0.30 g, 2.0 mmol) gave the product as a brown solid 
(yield: 0.15 g, 25 %). Purification by recrystallization (ethanol) afforded the desired 
product as a light brown solid (yield: 0.09 g, 15 %); Rf 0.91 [3:1 EtOAc/cyclohexane]; 
m.p. 207 - 210 °C; υmax (film)/cm-1 1155, 1312 (S=O), 1602 (C=C), 2816, 2885, 2945, 
2987, 3028 (C-H and =CH-), 3291 (N-H); δH (400 MHz; CDCl3) 1.10 (3H, t,                        
J = 7.2 Hz, CH3 sulfonamide), 3.01 (6H, s, N-CH3), 4.51 (2H, t, J = 6.0 Hz, N-CH2), 6.70 
(2H, d, J = 8.8 Hz, ArH 3 & 5), 6.89 (1H, d, JAB = 16.2 Hz, trans-HC=CH), 7.14 (1H, d, 
JAB = 16.2 Hz, trans-HC=CH), 7.41 (2H, d, J = 8.6 Hz, ArH 2 & 6), 7.55 (2H, d, J = 
8.4 Hz, ArH 3’ & 2’), 7.84 (2H, d, J = 8.3 Hz, ArH 5’ & 6’); δC (100 MHz; CDCl3) 15.1 
(CH2-CH3), 38.3 (N-CH2), 40.2 (N-CH3), 112.3 (C3 & C5), 122.1 (C1), 124.6 (C2 & 
C6), 126.2 (C2’ & C6’), 127.5 (C3’ & C5’), 128.2 (C7 & C7’), 137.0 (C1’), 142.8 (C4’), 
150.7 (C4); LCMS (ESI) found m/z [M-H]-  : 331, C18H22N2O2S requires 330. 
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 (E)-4-(3,4-Dimethoxystyryl)-N-pentylbenzenesulfonamide (266) 
 
 
 
According to method C;  the reaction with diethyl 4-(N-
pentylsulfamoyl)benzylphosphonate (1.10 g, 2.9 mmol) and 3,4-
dimethoxybenzaldehyde (0.47 g, 2.8  mmol)  gave the product as an orange oil (yield: 
0.87 g, 77 %); Rf 0.90 [2:1 EtOAc/cyclohexane]; υmax (film)/cm-1 1160, 1330 (S=O), 
1519, 1529 (C=C), 2847, 2863, 2932, 2952, 3069 (C-H and =CH-), 3255 (N-H); δH 
(400 MHz; DMSO-d6) 0.79 (3H, t, J = 6.7 Hz, C-CH3), 1.18 (4H, m, C-CH2), 1.35 
(2H, m, C-CH2), 2.72 (2H, q, J = 6.6 Hz,  N-CH2), 3.78 (3H, s, OMe), 3.82 (3H, s, 
OMe), 4.32 (1H, t, J = 5.6 Hz, NH2), 6.87 (2H, d, J = 8.5 Hz, ArH 5 & 6), 6.97 (1H, d, 
JAB = 16.2 Hz, trans-HC=CH), 7.07 (1H, m, ArH 2), 7.15 (1H, d, JAB = 16.4 Hz, 
trans-HC=CH), 7.75 (2H, d, J = 8.4 Hz ArH 3’ & 2’); 7.59 (2H, d, J = 8.6 Hz, ArH 5’ & 
6’), δC (100 MHz; CDCl3) 13.9 (CH3), 22.2 (CH2-CH3), 28.7, 29.4 (2 x CH2), 43.3 
(NH-CH2), 56.0 (OMe), 109.0 (C2), 111.3 (C5), 120.6 (C6), 126.6 (C2’ & C6’), 127.6 
(C3’ & C5’), 132.2 (C7 & C7’), 131.9 (C1), 136.6 (C1’), 142.1 (C4’), 149.2 (C4), 149.6 
(C3); LCMS (ESI) found m/z [M-H]-  : 388, C21H27NO4S requires 389. 
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 (E)-4-(3-Mmethoxystyryl)-N-pentylbenzenesulfonamide (267) 
 
 
According to method C; the reaction with diethyl 4-(N-
pentylsulfamoyl)benzylphosphonate (1.10 g, 2.9 mmol) and m-anisaldehyde (0.45 g, 
3.3  mmol) afforded the product as an orange oil, purification not performed (yield: 
0.87 g, 83 %); Rf 0.89 [3:1 EtOAc/cyclohexane]; υmax (film)/cm-1 1152, 1320 (S=O), 
1516 (C=C), 2866, 2938, 2966 (C-H and =CH-), 3270 (N-H); δH (400 MHz; CDCl3) 
0.79 (3H, t, J = 6.8 Hz, CH3), 1.15 (4H, m, C-CH2), 1.40 (2H, m, C-CH2), 2.86 (2H, q, 
J = 6.6 Hz,  N-CH2), 3.78 (3H, s, OMe), 5.76 (2H, t, J = 6.0 Hz, N-H), 6.79 (1H, dd, J 
= 5.7 Hz, J = 1.8 Hz, ArH 6), 7.00 (1H, d, JAB = 16.3 Hz, trans-HC=CH ), 7.07 (1H, 
m, trans-HC=CH), 7.05 (2H, m, J = 7.9 Hz ArH 2), 7.23 (1H, t, J = 7.9 Hz, ArH 13), 
7.54 (2H, d, J = 8.3 Hz, ArH 3’& 2’), 7.82 (2H, d, J = 8.4 Hz, ArH 5’ & 6’); δC (100 MHz; 
DMSO-d6) 14.3 (CH3), 22.1 (CH2-CH3), 28.7, 29.2 (CH2-CH2), 43.3 (N-CH2), 55.6 
(OMe), 112.3 (C2), 114.6 (C4), 120.0 (C6), 127.4 (C3’, C5’), 127.5 (C2’, & C6’), 130.3 
(C7 & C7’), 131.8 (C5), 138.5 (C1), 139.6 (C1’), 141.4 (C4’), 160.1 (C3); LCMS (ESI) 
found m/z [M-H]-  : 358, C20H25NO3S requires 359. % purity determined by 1H NMR 
(compound, 267, (86 %), compound, 221d, (8 %), compound, 228, (6 %)). 
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(E)-4-(4-Methoxystyryl)-N-pentylbenzenesulfonamide (268) 
 
 
 
According to method C; the reaction with diethyl 4-(N-
pentylsulfamoyl)benzylphosphonate (2.08 g, 5.5 mmol) and p-anisaldehyde (yield: 
0.78 g, 5.7 mmol) afforded the product as an orange solid. Purification by 
recrystallization (diethyl ether) gave the desired product as an orange solid (yield: 
0.28 g, 14 %); Rf 0.93 [3:1 EtOAc/cyclohexane]; m.p. 154 - 155 °C; υmax (film)/cm-1 
1148, 1325 (S=O), 1592 (C=C), 2858, 2940, 2966, 3017 (C-H and =CH-), 3272 (N-
H); δH (400 MHz; DMSO-d6) 0.79 (3H, m, C-CH3), 1.18 (4H, m, C-CH2), 1.35 (2H, q, 
J = 6.0 Hz, C-CH2), 2.72 (2H, q, J = 6.5 Hz, N-CH2), 3.78 (3H, s, OMe), 6.97 (2H, d, 
J = 8.5 Hz, ArH3 & 5), 7.17 (1H, d, JAB = 16.4 Hz, trans-HC=CH), 7.36 (1H, d, JAB = 
16.4 Hz, trans-HC=CH), 7.53 (1H, s, NH), 7.58 (2H, d, J = 8.3 Hz, ArH2 & 6), 7.74 
(4H, s, ArH 3’ & 2’ & ArH 6’ & 5’); δC (100 MHz; CDCl3)  13.9 (CH3), 22.2 (CH2-CH3), 
28.7, 29.3 (CH2-CH2), 43.3 (N-CH2), 55.4 (OMe), 114.3 (C3 & C5), 124.6 (C2’ & C6’), 
126.6 (C3’ & C5’), 128.2 (C7 & C7’), 129.3 (C1), 129.3 (C2 & C6), 137.9 (C1’), 142.1 
(C4’), 160.0 (C4); LCMS (ESI) found m/z [M-H]-  : 358, C20H25NO3S requires 359. % 
purity determined by 1H NMR (compound, 268, (92 %), compound, 221d, (8 %), 
compound, 229, (6 %)). 
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(E)-4-(4-Fluorostyryl)-N-pentylbenzenesulfonamide (257) 
 
 
 
According to method F; the reaction with diethyl 4-(N-
pentylsulfamoyl)benzylphosphonate (1.6 g, 4.2 mmol) and 4-fluorobenzaldehyde 
(0.53 g, 4.3 mmol) gave the product as an orange crystalline solid. Purification by 
washing (diethyl ether and cyclohexane) afforded the desired product as a white 
crystalline solid (yield: 0.5 g, 34 %); Rf 0.95 [3:1 EtOAc/cyclohexane]; m.p.            
133 - 135 °C; υmax (film)/cm-1 1158, 1324 (S=O), 1512, 1590 (C=C), 2866, 2934, 
2960, 3023, 3059 (C-H and =CH-), 3278 (N-H); δH (400 MHz; CDCl3) 0.83 (3H, t, J 
= 6.2 Hz, CH3), 1.23 (2H, q, J = 7.2 Hz, CH2-CH3), 1.47 (2H, q, J = 7.0 Hz, N-CH2-
CH2),  2.96 (2H, q, J = 6.8 Hz, N-CH2-CH2), 4.59 (1H, t, J = 6.0 Hz, N-H), 7.01 (1H, 
d, JAB = 16.4 Hz, HC=CH), 7.06 (2H, m, ArH 3 & 5), 7.16 (1H, m, HC=CH), 7.49 (2H, 
q, J = 5.4 Hz, ArH 2 & 6), 7.59 (2H, d, J = 8.6 Hz, ArH 3’ & 6’), 7.83 (2H, d, J = 8.3 Hz, 
ArH 5’ & 6’); δC (100 MHz; CDCl3) 13.9 (CH3), 22.2 (CH2-CH3), 28.7, 29.3 (CH2-CH2), 
43.3 (N-CH2), 115.8, 116.0 (C3 & C5), 126.5, 126.8 (C2’ & C6'), 127.6 (C3’ & C5’), 
128.4, 128.5 (C7 & C7’), 130.8 (C2 & C6), 132.7 (C1), 138.4 (C1’), 141.5 (C4’), 161.6 
(C4); LCMS (ESI) found m/z [M-H]-  : 346, C19H22FNO2S requires 347. 
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 (E)-4-(4-(Dimethylamino)styryl)-N-pentylbenzenesulfonamide (269) 
 
 
 
According to method C; the reaction with diethyl 4-(N-
pentylsulfamoyl)benzylphosphonate (2.02 g, 5.4 mmol) and 4-
(dimethylamino)benzaldehyde (0.88 g, 5.9  mmol) gave the product as a waxy orange 
solid (yield: 0.43 g, 20 %). Purification by recrystallization (diethyl ether) afforded the 
desired product as a dark orange solid (yield: 0.22 g, 11 %); Rf 0.93 [3:1 
EtOAc/cyclohexane]; m.p. 165 - 240 °C; υmax (film)/cm-1 1153, 1317 (S=O), 1593 
(C=C), 2802, 2862, 2931, 2961, 3030 (C-H and =CH-), 3268 (N-H); δH (400 MHz; 
DMSO-d6) 0.79 (3H, t, J = 6.6 Hz, C-CH3), 1.86 (4H, m, C-CH2), 1.35 (2H, q, J = 6.7 
Hz, C-CH2), 2.72 (2H, q, J = 7.0 Hz, N-CH2), 2.94 (6H, s, N-CH3), 3.36 (1H, s, NH – 
overlapping with H2O peak), 6.72 (2H, d, J = 8.8 Hz, ArH 3 & 5), 7.03 (1H, d, JAB = 
16.4 Hz, trans-HC=CH), 7.29 (1H, d, JAB = 16.4 Hz, trans-HC=CH), 7.46 (2H, d, J = 
8.7 Hz, ArH 2 & 6), 7.71 (4H, s, ArH 3’ & 2’ & ArH 5’& 6’); δC (100 MHz; DMSO-d6) 14.3                     
(CH3), 22.2 (CH2 ), 28.7, 29.1 (CH2 ), 40.02 (N-CH3), 43.0 (NH-CH2), 112.6 (C3 & 
C5), 122.3 (C1), 127.4 (C2 & C6), 127.4 (C2’ & C6’) 128.6 (C3’ & C5’), 132.3 (C7 & C7’), 
138.4 (C1’), 142.4 (C4’), 150.9 (C4); LCMS (ESI) found m/z [M-H]-  : 371, 
C21H28N2O2S requires 372. 
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 (E)-4-(3,5-Dimethoxystyryl)-N,N-dimethylbenzenesulfonamide (270) 
 
 
According to method C; the reaction with diethyl 4-(N,N-
dimethylsulfamoyl)benzylphosphonate (2.02 g, 6.0 mmol) and 3,4-
dimethoxybenzaldehyde (1.00 g, 6.0 mmol) afforded the titled product, 270, as a 
golden solid (yield: 1.95 g, 93 %). Purification by recrystallization (diethyl ether) 
afforded the product as a pale golden solid (yield: 1.69 g, 81 %); Rf 0.78 [2:1 
EtOAc/cyclohexane]; m.p. 154 - 158 °C; υmax (film)/cm-1 1155, 1335 (S=O), 1589 
(C=C), 2848, 2881, 2913, 2936 (C-H and =CH-); δH (400 MHz; CDCl3) 2.71 (6H, d, J 
5.7 Hz, N-CH3), 3.90 (3H, s, OMe), 3.94 (3H, s, OMe), 6.86 (1H, d, J = 7.8 Hz, ArH 
5), 6.97 (1H, d, JAB= 16.2 Hz, trans-HC=CH), 7.07 (2H, m, ArH 2 & 6), 7.16 (1H, d, 
JAB = 16.2 Hz, trans-HC=CH), 7.61 (2H, d, J = 8.2 Hz, ArH 3’ & 2’), 7.73 (2H, d, J = 
8.4 Hz, ArH 5’ & 6’); δC (100 MHz; CDCl3) 38.0 (N-CH3), 56.0 (OMe), 109.0 (C2), 
111.3 (C5), 120.7 (C6), 124.8 (C2’ & C6’), 126.5 (C3’& C5’), 128.3 (C7 & C7’), 132.0 
(C1), 133.4 (C1’), 142.1 (C4’), 149.3 (C4), 149.7 (C3); LCMS (ESI) found m/z [M+H]+: 
348, C18H21NO4S requires 347. 
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(E)-4-(4-Methoxystyryl)-N,N-dimethylbenzenesulfonamide (271) 
 
 
According to method C; the reaction with diethyl 4-(N,N-
dimethylsulfamoyl)benzylphosphonate (2.0 g, 6.0 mmol) and p-anisaldehyde (0.81 g, 
6.0 mmol) gave the crude product as a pale yellow solid (yield: 2.77 g, 146 %). 
Purification by recrystallization (diethyl ether) afforded the titled product, 271, as a 
pale yellow solid (yield: 1.64 g, 87 %); Rf 0.89 [3:1 EtOAc/cyclohexane]; m.p.                                   
210 - 216 °C;  υmax (film)/cm-1 1155, 1335 (S=O), 1515, 1593 (C=C), 2839, 2945, 
2973, 3028 (C-H and =CH-); δH (400 MHz; CDCl3) 2.71 (6H, s, N-CH3), 3.83 (3H, s, 
OMe), 6.91 (2H, d, J = 8.8 Hz, ArH 5), 6.97 (1H, d, JAB = 16.3 Hz, trans-HC=CH), 
7.17 (1H, d, JAB = 16.4 Hz, trans-HC=CH), 7.47 (2H, d, J = 8.5 Hz, ArH 2 & 6), 7.60 
(2H, d, J = 8.2 Hz, ArH 3’ & 2’), 7.72 (2H, d, J = 8.4 Hz, ArH5’ & 6’); δC (100 MHz; 
CDCl3) 38.0 (N-CH3), 55.4 (OMe), 112.6 (C3 & C5), 124.6 (C1), 126.5 (C2 & C6), 
128.2 (C2’ & C6’), 129.3 (C3’ & C5’), 131.7 (C7 & C7’), 133.4 (C1’), 142.2 (C4’), 160.8 
(C4); LCMS (ESI) found m/z [M+H]+: 317, C17H19NO3S requires 317. % purity 
determined by 1H NMR (compound, 271, (92 %), compound, 221e, (8 %)).  
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(E)-4-(3-Methoxystyryl)-N,N-dimethylbenzenesulfonamide (272) 
 
 
According to method C; the reaction with diethyl 4-(N,N-
dimethylsulfamoyl)benzylphosphonate (2.08 g, 6.2 mmol) and 3-
methoxybenzaldehyde (0.82 g, 6.0 mmol) gave the impure product as beige solid 
(yield: 1.65 g, 84 %). Purification by recrystallization (absolute ethanol) afforded the 
titled product, 272, as a pale beige solid (yield: 1.26 g, 64 %); Rf 0.78 [EtOAc]; m.p. 
131 - 135 °C; υmax (KBr)/cm-1 1047, 1256 (C-O), 1582 (C=C), 1156.2, 1330 (S=O), 
2807, 2837, 2889, 2933, 2959, 3007, 3059 cm-1 (C-H and =CH-); δH (600 MHz; 
CDCl3) 2.70 (6H, s, N-CH3), 3.84 (3H, s, OMe), 6.85 (1H, dd, J = 8.2 Hz, J = 1.5 Hz, 
ArH4), 7.05 (1H, m, ArH6), 7.10 (1H, d, JAB = 16.5 Hz, trans-HC=CH), 7.12 (1H, d, J 
= 9.1 Hz, ArH2), 7.18 (1H, m, trans-HC=CH), 7.28 (1H, t, J = 8.2, ArH5), 7.63 (2H, 
d, J = 8.2 Hz, ArH3’& 2’), 7.74 (2H, d, J = 8.2 Hz, ArH5’ & 6’); δC (100 MHz; CDCl3) 
38.0 (N-CH3), 55.3 (OMe), 112.2 (C2), 114.2 (C4), 119.6 (C6), 126.9, 127.1, (C3’, C5’), 
127.2 (C2’, & C6’), 128.2 (C7 & C7’), 132.9 (C5), 133.9 (C1), 137.9 (C1’), 141.7 (C4’), 
160.0 (C3); LCMS (ESI) found m/z [M+H]+: 318, C17H19NO3S requires 317. 
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 (E)-4-(4-Fluorostyryl)-N,N-dimethylbenzenesulfonamide (258) 
 
 
According to the method F; the reaction with diethyl 4-(N,N-
dimethylsulfamoyl)benzylphosphonate (1.06 g, 3.1 mmol) and 4-fluorobenzaldehyde 
(0.39 g, 3.1 mmol) afforded the product as beige solid (yield: 0.58 g, 60 %). 
Purification by washing (diethyl ether and cyclohexane) afforded the desired product 
as a pale cream solid (yield: 0.39 g, 40 %); Rf 0.84 [2:1 EtOAc/cyclohexane]; m.p. 
193 - 197 °C; υmax (film)/cm-1 1158, 1329 (S=O), 1512, 1595 (C=C), 2814, 2872, 
2976, 3085 (C-H and =CH-); δH (400 MHz; CDCl3) 2.72 (6H, t, J = 5.1 Hz, CH3), 
7.02 (1H, d, JAB = 16.2 Hz, trans-HC=CH),7.06 (2H, m, ArH3 & 5), 7.17 (1H, m, 
trans-HC=CH), 7.49 (2H, dd, J = 5.4 Hz, ArH 2 & 6), 7.62 (2H, d, J = 8.3 Hz, ArH3’ & 
6’), 7.74 (2H, d, J = 8.2 Hz, ArH5’ & 6); δC (100 MHz; CDCl3) 38.0 (N-CH3), 115.8, 
116.0 (C3 & C5), 126.6, 126.7 (C2’ & C6'), 127.2 (C3’ & C5’), 128.3, 128.5 (C7 & C7’), 
130.9 (C2 & C6), 132.7 (C1), 134.0 (C1’), 141.7 (C4’), 161.6 (C4); LCMS (ESI) found 
m/z [M+H]+: 306, C16H16FNO2S requires 305. 
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(E)-4-(4-(Dimethylamino)styryl)-N,N-dimethylbenzenesulfonamide (273) 
 
 
According to method C; the reaction with diethyl 4-(N,N-
dimethylsulfamoyl)benzylphosphonate (2.01 g, 6.0 mmol) and 4-
(dimethylamino)benzaldehyde (0.89 g, 6.0 mmol) afforded the impure product as a 
golden yellow solid (yield: 1.56 g, 79 %). Purification by recrystallization (diethyl 
ether) afforded the titled product, 273, as a golden yellow solid (yield: 1.19 g, 60 %); 
Rf 0.97 [EtOAc]; m.p. 210 - 215 °C; υmax (film)/cm-1 1157, 1331 (S=O), 1588 (C=C), 
2809, 2914, 3024 (C-H and =CH-); δH (400 MHz; CDCl3) 2.71 (6H, s, CH3), 2.99 
(6H, s, CH3), 6.50 (2H, d, J = 8.4 Hz, ArH 3 & 5), 6.90 (1H, d, JAB = 16.3 Hz, trans-
HC=CH), 7.15 (1H, d, JAB = 16.2 Hz, trans-HC=CH), 7.42 (2H, d, J = 8.4 Hz, ArH 2 & 
6), 7.57 (2H, d, J = 8.2 Hz, ArH 3’ & 2’), 7.79 (2H, d, J = 7.9 Hz, ArH 5’& 6’); δC (100 
MHz; CDCl3) 38.0 (N-CH3), 40.4 (N-CH3), 112.3 (C3 & C5), 122.1 (C1), 124.6 (C2 & 
C6), 126.1 (C2’ & C6’), 128.2 (C3’ & C5’), 128.3 (C7 & C7’), 132.5 (C1’), 142.9 (C4’), 
150.7 (C4); LCMS (ESI) found m/z [M+H]+: 331, C18H22N2O2S requires 330. 
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 (E)-1-((4-(3-Methoxystyryl)phenyl)sulfonyl)piperidine (274) 
 
 
 
According to method C; the reaction with diethyl 4-(piperidine-1-
ylsulfonyl)benzylphosphonate (1.54 g, 4.1 mmol) and m-anisaldehyde (0.55 g, 4.1 
mmol) gave the product as a brown solid (yield: 0.87 g, 59 %). Purification by 
recrystallization (diethyl ether) afforded the desired product as a pale orange solid 
(yield: 0.47 g, 32 %); Rf 0.86 [3:1 EtOAc/cyclohexane]; m.p. 144 - 146 °C, υmax 
(film)/cm-1 1157, 1325 (S=O), 1580 (C=C), 2862, 2948, 3005 (C-H and =CH-); δH 
(400 MHz; DMSO-d6) 1.35 (2H, m, C-CH2), 1.52 (4H, m, C-CH2), 2.89 (4H, t, J = 
5.3 Hz, N-CH2), 3.80 (3H, s, OMe), 6.90 (1H, dd, J = 8.3 Hz, J = 2.4  Hz, ArH 4), 
7.22 (2H, d, J = 7.8 Hz, ArH 6), 7.23 (1H, s, ArH 2), 7.32 (1H, t, J = 8.2 Hz, ArH 5), 
7.38 (1H, d, JAB = 16.5 Hz, trans-HC=CH, 7.43 (1H, d, JAB = 16.5 Hz, trans-
HC=CH), 7.70 (2H, d, J = 8.4 Hz, ArH 3’ & 2’), 7.83 (2H, d, J = 8.4 Hz, ArH 5’ & 6’); δC 
(100 MHz; DMSO-d6) 23.4, 25.2 (3 x CH2), 47.1 (N-CH2), 55.6 (OMe), 112.5 (C2), 
114.71 (C4), 120.1 (C6), 127.5 (C3’, C5’), 128.4 (C2’, & C6’), 130.3 (C7 & C7’), 132.3 
(C5), 134.5 (C1), 138.4 (C1’), 142.1 (C4’), 160.1 (C3); LCMS (ESI) found m/z [M + 
H]+: 358, C20H23NO3S requires 357. % purity determined by 1H NMR (compound, 
274, (94 %), diethyl ether (6 %)). 
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(E)-1-((4-(4-Fluorostyryl)phenyl)sulfonyl)piperidine (259) 
 
 
 
According to method F; the reaction with diethyl 4-(piperidine-1-
ylsulfonyl)benzylphosphonate (1.51 g, 4.0 mmol) and 4-fluorobenzaldehyde (0.46 g, 
3.7 mmol) gave the product as a beige solid (yield: 0.95 g, 68 %). Purification by 
recrystallization (diethyl ether and cyclohexane) afforded the product as a light brown 
solid (yield: 0.71 g, 51 %); Rf 0.86 [3:1 EtOAc/cyclohexane]; m.p. 208 - 213 °C; υmax 
(film)/cm-1 1158, 1340 (S=O), 1512, 1590 (C=C), 2846, 2934, 2960, 2991, 3023, 3080 
(C-H and =CH-); δH (400 MHz; DMSO-d6) 1.35 (2H, m, C-CH2), 1.53 (4H, m, C-
CH2), 2.88 (4H, t, J = 5.8 Hz, N-CH2), 6.97 (2H, d, J = 8.4 Hz, ArH 3 & 5), 7.20 (1H, d, 
JAB = 16.5 Hz, trans-HC=CH), 7.60 (1H, d, JAB = 16.5 Hz, trans-HC=CH), 7.60 (2H, 
d, J = 8.5 Hz, ArH 2 & 6), 7.68 (2H, d, J = 8.1 Hz, ArH 3’ & 2’), 7.79 (2H, d, J = 8.1 Hz, 
ArH 5’ & 6’); δC (100 MHz; DMSO-d6) 23.4, 25.2 (3 x CH2), 47.1 (N-CH2), 114.8, 
115.2 (C3 & C5), 127.1 (C2’ & C6’), 128.4 (C3’ & C5’), 128.9 (C7 & C7’), 129.6 (C2 & 
C6), 132.1 (C1), 142.5 (C1’ & C4’), 160.1 (C4); LCMS (ESI) found m/z [M + H]+: 346, 
C19H20FNO2S requires 345. % purity determined by 1H NMR (compound, 259, (92 
%), compound, 221g, (8 %)). 
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 (E)-4-((4-(3-Methoxystyryl)phenyl)sulfonyl)morpholine (275) 
 
 
 
According to method C; the reaction with diethyl 4-
(morpholinosulfonyl)benzylphosphonate (1.0 g, 2.6 mmol) and m-anisaldehyde (0.36 
g, 2.6 mmol) gave  the impure product as white solid (yield: 0.67 g, 70 %). 
Purification by recrystallization (ethanol) afforded the desired product as a fine white 
solid (yield: 0.33 g, 35 %); Rf 0.64 [DCM]; m.p. 163 - 165 ˚C; υmax (film)/cm-1 1164, 
1327 (S=O), 1592 (C=C), 2857, 2932, 3002 (C-H and =CH-); δH (600 MHz; CDCl3) 
3.01 (4H, t, J = 4.8 Hz, , N-CH2), 3.73 (4H, t, J = 3.6 Hz, O-CH2), 3.84 (3H, s, OMe), 
6.85 (1H, dd, J = 8.4 Hz, J = 2.4 Hz, ArH 4), 7.05 (1H, m, ArH 6), 7.09 (1H, d, JAB = 
15.6 Hz, trans-HC=CH), 7.12 (1H, d, J = 8.4 Hz, ArH2), 7.19 (1H, d, JAB = 16.2 Hz, 
trans-HC=CH), 7.29 (1H, t, J = 7.8 Hz, ArH 5), 7.63 (2H, d, J = 8.4 Hz, ArH 3’ & 2’), 
7.71 (2H, d, J = 8.4 Hz, ArH 5’ & 6’); δC (150 MHz; CDCl3) 46.0 (N-CH2), 55.3 (OMe), 
66.1 (O-CH2), 112.1 (C2), 114.1 (C4), 119.5 (C6), 126.7 (C3’, C5’), 126.8 (C2’ & C6’), 
128.3 (C7 & C7’), 130.0 (C5), 132.3 (C1), 139.8 (C1’), 141.3 (C4’), 159.8 (C3); LCMS 
(ESI) found m/z [M + H]+: 360, C19H21NO4S requires 359. % purity determined by 1H 
NMR (compound, 275, (77 %), compound, 221h, (23 %)). 
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 (E)-4-((4-(4-Fluorostyryl)phenyl)sulfonyl)morpholine (260) 
 
 
 
According to method F; the reaction with diethyl 4-
(morpholinosulfonyl)benzylphosphonate (1.58 g, 4.2 mmol) and 4-
fluorobenzaldehyde (0.52 g, 4.2 mmol) afforded the impure product as white solid 
(yield: 1.39 g, 96 %). Purification by washing (diethyl ether and cyclohexane) 
afforded the desired product as a pale cream solid (yield: 0.79 g, 54 %); Rf 0.92 [3:1 
EtOAc/cyclohexane]; m.p. 210 - 215 °C; υmax (film)/cm-1 1163, 1350 (S=O), 1507, 
1595 (C=C), 2866, 2898, 2934, 2971, 3070 (C-H and =CH-); δH (400 MHz; CDCl3) 
3.00 (4H, t, J = 4.5 Hz, N-CH2), 3.73 (4H, t, J = 4.7 Hz, O-CH2), 7.02 (1H, m, trans-
HC=CH), 7.06 (2H, t, J = 8.7 Hz, ArH 3 & 5), 7.18 (1H, d, JAB = 16.3 Hz, trans-
HC=CH), 7.50 (2H, d, J = 5.4 Hz, ArH 2 & 6), 7.62 (2H, d, J = 8.6 Hz, ArH 3’ & 2’), 7.71 
(2H, d, J = 8.4 Hz, ArH 6’& 5’); δC (100 MHz; CDCl3) 46.0 (N-CH2), 66.1 (O-CH2), 
115.8, 116.0 (C3 & C5), 126.4, 126.8 (C2’ & C6’), 128.4 (C3’ & C5’), 128.5, 128.6 (C7 & 
C7’), 131.2 (C2 & C6), 132.6 (C1), 133.5 (C1’), 142.1 (C4’), 161.7 (C4); LCMS (ESI) 
found m/z [M+H]+: 348, C18H18FNO3S requires 347
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Appendix A1 The annotated reference for general compounds characterised by 1H and 13C 
NMR analysis 
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Appendix II 
 
Appendix A2 List of reagents, assay kits used for biological testing 
 
 
Reagent 
 
Company Serial 
Number 
Concentration 
A549 cell line University of 
Nottingham 
- - 
Dulbecco’s Modified Eagle 
Medium (DMEM) 
Gibco® Life 
Technologies 
31885-023 1x (w/v) 
Penicillin/Streptomycin Sigma PO781 10,000 units/mL 
(w/v)/10 mg/mL 
(w/v) 
L-glutamine Gibco® Life 
Technologies 
25030-024 200 mM 
Dulbecco’s phosphate 
buffered saline (DPBS/PBS) 
 
Diluted to X1 in deionized 
water to make PBS 
Gibco® Life 
Technologies 
14200-067 10x (w/v) 
Trypsin/EDTA Sigma T4174 0.5 % (w/v) /             
0.5 % (w/v) 
Trypan Blue Sigma (Life 
Science) 
T8154 0.4 % (w/v) 
Cell Titer 96 Aqueous One 
Solution Cell Proliferation 
Assay 
ProMega G3580 - 
Dimethyl sulfoxide Sigma D2650  Neat 
Foetal Bovine Serum (FBS) Gibco 10500-064 - 
Trichloroacetic acid European 
Pharmacopeia 
1092501 Neat 
Sulforhodamine B Sigma 230162-5G - 
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Cell culture 
The non-small cell lung carcinoma cancer cell line, A549 was grown in the 
Dulbecco's Modified Eagle medium, supplemented with 10% heat-inactivated fetal 
bovine serum, 100 u/mL penicillin, 100 µg/ml streptomycin and 2 mM (w/v) L-
glutamine solution.  
Trypan blue dye exclusion growth assay 
 
The A549 cells were plated out into 96-well plates and incubated at 37 °C overnight to 
allow for cell attachment. Each stilbene benzenesulfonamide analogue was then 
dissolved in dimethyl sulfoxide (DMSO), mixed with fresh medium and added to each 
plate at the desired concentration (5.0 and 50 µM). The final DMSO concentration in 
all cultures was 1.0 % v/v. This concentration of DMSO did not alter cell-growth 
when compared with the vehicle free medium (no drug).  
Following each of the selected treatment period (24, 48, 72 and 96 h), the cells were 
harvested by trypsinization and centrifuged. The cell pellet was resuspended in 2 mL 
of fresh media and the cells were stained with trypan blue dye. The number of non-
viable (dead) and viable cells was counted using a haemocytometer. Growth inhibition 
by the stilbene benzenesulfonamide analogues was expressed as a percentage of the 
control (cells treated with the vehicle). 
 
Sulforhodamine B assay (SRB) 
 
Cells (A549) were plated out in 96-well plates on day 0 and then treated on day 1 with 
concentrations of each tested compound at 0 to 500 µM (dissolved in DMSO and 
fresh media as described above) for 48 h.  
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At completion of the experiment, the cells were fixed by adding trichloroacetic acid to 
a final concentration of 5 % (v/v). After 1 h at 4 °C, plates were washed four times 
with deionised water, dried, and stained for 30 min with 50 µL sulforhodamine B in 
PBS (0.4 %, w/v). Following three wash steps with 1 % acetic acid, 150 µL Tris (10 
mM/L) was added to dissolve the staining. The plates were then read at 492 nm using 
a spectrophotometer. After correction for medium-only and no-drug controls, the GI50 
values were calculated from the growth inhibition curves generated by fitting 
sigmoidal curves to the data using nonlinear least square regression analysis. 
 
Statistical analysis 
 
Descriptive statistics were performed using Microsoft Excel 2010, including Q-tests 
for outliers. Tests for normality were performed using Shapiro-Wilks test, and tests for 
significance were carried out using One-Way ANOVA and Tukey or Games-Howell 
post-hoc tests, using IBM SPSS Statistics 22. The chosen level of significance was            
p < 0.05. 
